Clinical Aspects of Pregnancy-induced Amelioration of Rheumatoid Arthritis: PARA-study by Man, Y.A. (Yael) de
C
LIN
IC
A
L A
SPEC
TS O
F PR
EG
N
A
N
C
Y-IN
D
U
C
ED
 A
M
ELIO
R
A
TIO
N
 O
F R
H
EU
M
A
TO
ID
 A
R
TH
R
ITIS PA
R
A
-STU
D
Y
  Ya
ë
l A
. d
e
 M
a
n
In this PhD thesis, embedded 
in the PARA-study, several 
clinical aspects of the 
spontaneously occurring 
pregnancy-induced 
improvement of rheumatoid 
arthritis (RA) are addressed. 
An overview is given of all 
rheumatic diseases and the 
current knowledge about 
their disease courses and 
treatment options during 
pregnancy and postpartum. 
This thesis focuses fi rstly on 
the description of tools to 
objectively measure the 
disease activity and function-
ality of RA before, during, and 
after pregnancy. Associations 
with the disease course and 
patient’s characteristics are 
subsequently made. 
The infl uence on the 
pregnancy outcome of both 
disease activity and treatment 
of RA with prednisone, are 
assessed regarding pregnancy 
duration and birth weight. 
Postpartum however RA tends 
to fl are again. The problems 
which patients with RA will 
encounter in parental 
function, while nursing their 
babies, are addressed.
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“Kon ik maar altijd zwanger zijn!” 
 
citaat 80-jarige patiënte met reumatoïde artritis 
 
 
“If only I could have been pregnant forever!” This is a quote from an 80-year-old 
lady with rheumatoid arthritis (RA), who developed RA before the discovery of 
cortisone in 1950, which was the primary treatment for RA. Female patients 
suffering from rheumatoid arthritis (RA) reported in those days that only 
pregnancy induced a spontaneous and considerable improvement of their 
disease. Outside pregnancy no other situation could relieve their pain and the 
swelling of their disabling joint disease. Postpartum, however, almost all 
patients reported a flare of their disease again. 
 
Rheumatoid arthritis is a chronic, systemic, inflammatory autoimmune disease 
leading to destructive arthropathy, which can be accompanied by extra-articular 
manifestations (1). Fortunately, in recent decades the pharmacological 
treatment of RA has improved considerably. The reduction of inflammation and 
destruction by treatment has contributed to the preservation of functionality in 
RA patients nowadays (2). One can imagine that because of these 
achievements in treatment, RA patients with a wish to conceive now face other 
questions: first about the possibilities of using current pharmacological 
treatment before and during pregnancy, especially regarding outcome of 
pregnancy, and secondly what they can expect regarding their parenting 
function postpartum if the disease may flare (3, 4). 
 
As early as in 1938, Hench was the first physician to describe the phenomenon 
of spontaneous improvement of disease activity among his patients (5). Up to 
now several attempts have been made to reveal the pathogenesis of the 
improvement, however, it has still not been elucidated (6). Even the hormonal 
changes as explanation have not yet been proven (7), despite the fact that the 
risk of RA developing in women who had been pregnant or had used or were 
still using oral contraceptives, decreases (8, 9). In order to elucidate the 
mechanism it is important to study immunological, biochemical, and hormonal 
changes in time combined with objective disease activity scores, preferably 
collected prospectively, in order to avoid selection bias. Only with accurately 
collected data on several time points from before pregnancy, during pregnancy 
and postpartum, might one get insight into changes and associate these with 
the favourable course of the disease during pregnancy, but also with the 
disease flare in the postpartum period. 
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Despite a considerable number of previous studies conducted in the field of 
pregnancy and RA, a large prospective study from preconception or early 
pregnancy onwards was lacking. For that reason a nationwide prospective 
cohort study on pregnancy and RA was conducted (the PARA-study, acronym 
for Pregnancy-induced Amelioration of Rheumatoid Arthritis-study) in the 
Netherlands between 2002 and 2009. This study aims to describe the clinical 
course before, during and after pregnancy for patients and health professionals 
in rheumatology, and strives to study the pathogenesis of the improvement 
during pregnancy and flare postpartum. Such a prospective design of the study 
will give a high level of evidence examining causal relations between the 
improvement of RA during pregnancy and the deterioration of RA postpartum. 
 
The work presented in this thesis aims (I) to prospectively study disease activity 
of rheumatoid arthritis (RA) before, during and after pregnancy, (II) to explore  
associations of the pregnancy-induced amelioration of RA between the clinical 
characteristics and immunological changes in autoantibodies, (III) to determine 
the influence of disease activity and medication use on pregnancy outcome, 
and, finally, (IV) to address clinical aspects in parenting function postpartum. 
 
In this chapter, firstly an introduction on pregnancy and rheumatic diseases is 
given, including an extensive review on the clinical course of RA during and 
after pregnancy, and on pregnancy outcome in RA women (section 1.1); and 
secondly, antirheumatic treatment during pregnancy and postpartum is 
discussed in detail (section 1.2). 
 
In chapter two after a brief outline of the PARA-study, objective and validated 
disease activity scores for RA (Disease Activity Score of 28 joints) and 
functionality scores (Health Assessment Questionnaire) for use during 
pregnancy will be defined. Up to now no validated measurement tools for 
functionality and disease activity during pregnancy have been defined, and 
previous studies used all kinds of scoring methods (10, 11). 
 
In chapter three, the course of disease activity of RA during pregnancy and 
postpartum will be determined with defined and validated measurement tools in 
an era of new treatment options (section 3.1). Subsequently, pregnancy-
induced changes in autoantibody levels will be determined, and patients’ 
characteristics (presence or absence of autoantibodies) will be associated with 
the course of disease activity of RA during pregnancy and postpartum (section 
3.2). 
 
In chapter four disease activity of RA and prednisone use during pregnancy and 
its influences on birth weight and other pregnancy outcomes will be addressed, 
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since unfavourable pregnancy outcomes were previously demonstrated in 
rheumatic diseases (6, 12, 13). 
 
In chapter five parental function expressed in parenting disability scores will be 
for the first time described postpartum and it will be associated with patients’ 
characteristics in order to find (modifiable) factors for better parental function 
postpartum (3). 
 
Finally, in chapter six all the results described in this thesis will be discussed in 
a broader context. Some methodological considerations, implications for clinical 
practice, and recommendations for future research regarding pregnancy and 
RA will be put forward. 
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INTRODUCTION 
Pregnancy has an important impact on many rheumatic diseases. This may be 
either a dramatic improvement like in rheumatoid arthritis (RA) or a deterioration 
as in systemic lupus erythematosus (SLE). In addition, the disease may 
influence the outcome of the pregnancy by causing recurrent spontaneous 
abortions, still birth, or congenital abnormalities. The changes in the course of 
rheumatic diseases during pregnancy can be explained by the major changes in 
the immune system of the mother in order to enable her to maintain the partially 
non-self foetus. The immunological phenomena that are part of the rheumatic 
diseases may influence the pregnancy itself and the health of the foetus. 
 
As soon as a patient indicates that she wants to become pregnant, the 
physician needs to pay extra attention. The medication has to be changed often 
and the physician should be alert to potential decreased fertility or frequent 
early miscarriages. Sometimes the gynaecologist has to be consulted at an 
early stage. Depending on the underlying disease, the frequency of the clinic 
visits has to be increased to monitor the woman and foetus in close cooperation 
with a specialized obstetrician. The delivery can cause problems either for the 
mother or for the child and needs specialist supervision. After delivery, 
breastfeeding and the risk of a flare in some of the rheumatic diseases require 
adjustments of the medication. Additional non-medical measures might be 
needed to lighten the physical task of the mother in caring for her baby. This 
chapter deals with the influence of pregnancy on the course and outcome of the 
rheumatic diseases, the effect of the rheumatic diseases on the course and 
outcome of the pregnancy for mother (obstetric complications), and child, 
fertility and disease management before, during, and after pregnancy. 
RHEUMATOID ARTHRITIS 
Effect of pregnancy on maternal disease 
Amelioration of signs and symptoms of RA during pregnancy is a consistent 
finding throughout the RA literature, starting with the classical observation by 
Hench in 1938 (1). The improvement of RA occurs in about 75 percent of the 
patients. In retrospective studies, improvement of the arthritis is reported in 54-
83 percent (2), in prospective studies in 66-86 percent (2, 3). The most recent 
and largest study showed widespread variability of disease response during 
pregnancy with 16 percent of the patients experiencing a complete remission 
(3) in contrast to the high remission rate of 53 percent reported previously (2). 
The reported amelioration of RA in pregnancy is probably an underestimation of 
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the favourable effect of pregnancy as patients will diminish or stop their 
antirheumatic medication during gestation. The improvement of RA starts in the 
first trimester of the pregnancy to reach its peak in the second and third 
trimesters. 
 
RA typically deteriorates after delivery starting in the first month postpartum. 
After 3-4 months postpartum, most women will experience disease recurrence. 
Up to 90 percent of the women will get active disease after childbirth, 
irrespective of whether they had a remission during pregnancy or not (2). 
Prediction of the pregnancy effect on RA  
The disease response during previous pregnancies is predictive for the disease 
response in subsequent pregnancies (2, 3). The postpartum flare - or the 
absence of a postpartum flare - cannot be predicted. Presence of rheumatoid 
factor, age, disease duration, functional class, or parity have no influence on the 
RA response during or after pregnancy. 
Pregnancy in relation to onset and outcome of RA 
RA onset 
Women who never had children have an approximately two-fold risk of 
developing RA compared to women who have children (2, 4, 5). This conclusion 
can also be reversed by stating that women who have been pregnant have an 
approximately two-fold reduced risk of developing RA compared to nulliparous 
women. Notably, one hardly sees women develop RA during pregnancy, but the 
onset of RA in the postpartum period is a well-known phenomenon. This has 
been confirmed in several studies showing a reduced risk of onset during 
pregnancy, odds ratios between 0.2 and 0.6, and an increased risk of onset in 
the 3-month postpartum period, odds ratios between 3.4 and 5.6 (2, 6, 7). 
Breastfeeding, in particular after the first pregnancy, has been implicated as 
being responsible for the increased risk of RA onset after pregnancy or for the 
postpartum flare in established RA (8, 9). Whether pregnancy really reduces the 
risk of RA or just delays the onset of symptoms through its ameliorating effect 
on the disease is still debated, though the latter explanation appears the most 
acceptable. There are some studies that question a reduced lifetime risk of RA 
due to pregnancy or breastfeeding (10, 11). 
Outcome of RA 
Patients often ask whether pregnancy will affect the ultimate outcome of their 
disease. The amelioration during pregnancy and postpartum flare appear to 
have no net effect on the prognosis of RA (2). In the only prospective study 
trying to answer this question, a trend was found to a more favourable outcome 
14
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in patients who had ever been pregnant compared to women who were never 
pregnant; this trend was, however, not significant (12). Table 1.1.1 summarizes 
the clinical observations in relation to RA and pregnancy. 
Table 1.1.1: Clinical observations in relation to RA and pregnancy 
Issues Clinical observation 
During pregnancy  
 Disease activity Amelioration or remission in about 75% (peak 
third trimester) 
 Onset RA A two- to five-fold decreased risk to develop RA 
during pregnancy in healthy women 
 Obstetric problems (pre-eclampsia) None, or probably none 
 Foetal outcome No significant differences compared to healthy 
women and their babies 
Delivery No problems, unless severe hip arthritis 
Postpartum  
 Disease activity Flare in 90% of patients within 6 months 
 Breastfeeding Breastfeeding may increase the risk to develop 
(two- to five-fold) or deteriorate RA postpartum 
 Maternal care Need for extra assistance for mother and child 
Long-term (>10 years) No adverse effect but also no apparent 
favourable effect 
Fertility Equal to healthy women 
Fecundity Possibly decreased 
Mechanisms explaining the favourable effect of pregnancy 
The possible mechanisms by which pregnancy decreases disease activity in RA 
have intrigued doctors and scientists for many decades with no conclusive 
explanation till now. Doctors have tried to copy the favourable effect by treating 
patients with blood, placental products, or serum from pregnant women without 
much success. The hormonal, immunological, and biochemical changes during 
pregnancy have all been considered as possible causes of the pregnancy-
induced remission and postpartum flare in RA (2, 13-16). Increased serum 
cortisol concentrations did not explain the amelioration of RA probably because 
the concomitant elevation of steroid binding globulin. The elevated levels of sex 
hormones also could not satisfactorily explain the pregnancy-induced remission 
in RA. Treatment with female hormones exerts no or only a modest effect on 
disease activity in RA (13). Many other hormones are increased during 
pregnancy. The hormonal shifts are associated with shifts in cytokine profiles. 
Pregnancy is characterized by a decreased production of T-helper 1 (Th1) cell 
associated cytokines (like IL-1 and interferon-gamma), an increased production 
of Th2 cell associated cytokines (like IL-4 and IL-10) and decreased production 
of pro-inflammatory cytokines (TNF-alpha, IL-12) (13, 17, 18). Since RA is 
marked by a Th1 cytokine profile, a shift towards a Th2 cytokine profile during 
15
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pregnancy is an attractive explanation for a pregnancy-induced remission in RA, 
however conflicting results are reported (17). Exposure of foetal (paternal) non-
self HLA antigens to the mother is also implicated in the causation of pregnancy 
induced amelioration of RA. Disparity of maternal-foetal HLA-DR and 
particularly HLA-DQ correlated with amelioration of the arthritis during 
pregnancy (2). These findings fit well with the fact that not all patients will 
improve during pregnancy and that a favourable response in a previous 
pregnancy will predict a similar response in a subsequent pregnancy. The 
studies till now are, however, not conclusive (19, 20). 
 
Changes in the levels of Į-2 pregnancy-associated protein (PAG) parallel the 
timing of arthritis amelioration during, and return after, pregnancy and are 
therefore also indicated as a possible explanation for the pregnancy-induced 
changes in RA. The studies on this topic are also not conclusive (2). Recently, a 
correlation was found between the increase during pregnancy and decrease 
postpartum of glycosylation of IgG and the clinical course of RA in that period 
(21), though the significance of this finding is still not clear. Table 1.1.2 
summarizes the possible mechanisms that account for the pregnancy effect on 
disease activity of RA. 
Fertility 
Women with RA were found to have smaller family sizes than controls, which 
could not be attributed to lower fertility (2). Women with RA appear to need a 
longer time to conceive (lower fecundity). Many possible explanations have 
been put forward such as ovulatory dysfunction, tubal abnormalities, antibodies 
to spermatozoa, and hormonal disturbances. Another reason for delayed 
conception could be a decrease in the frequency of intercourse owing to pain 
from the arthritis. The physician should be aware of the potential increased time 
to conception because of pain or low fecundity in order to timely discuss the 
issue with the woman and, if necessary, refer her to a gynaecologist. Patients 
often stop or lower their antirheumatic medication the moment they seriously 
make efforts to get pregnant. When it takes a long time before the woman 
conceives—or knows she cannot conceive—she is also without adequate 
antirheumatic medication for an unnecessarily long time, a situation that should 
be avoided. 
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Table 1.1.2: Possible mechanisms that account for the pregnancy effect on disease activity of 
RA  
Mechanisms  Account for amelioration of RA  
Hormonal   
 Cortisol  Probably not; serum levels rise along with 
steroid binding globulin  
 Female sex hormones  Explain insufficiently the amelioration of RA 
and when given as a treatment it has at the 
most a modest effect on disease activity  
Immunological   
 Cytokines   
  Shift in Th1 (IL1 and INF-Ȗ) and Th2 
(IL-4 and IL-10) cytokine profiles  
Possible; not yet determined for well-defined 
RA patients, but there are conflicting results 
in literature 
  Decreased pro-inflammatory (TNF-Į, 
IL-12)  
Possible; not yet determined for well-defined 
RA patients  
 Regulatory T-cells Possibly beneficial effect of Treg on disease 
activity, not yet determined in high number of 
RA patients 
 Increased phagocyte and recurring 
lymphocyte gene activity, molecular 
activation of monocytes 
Possibly associated with postpartum flare; not 
yet determined in high numbers of RA 
patients 
 Maternal–foetal HLA disparity HLA–DR, 
HLA–DQ  
Possible HLA–DQ correlates, but there are 
conflicting results in literature  
Biochemical   
 Increased Į-2 pregnancy-associated 
protein (PAG) levels  
Possible; changes in PAG parallels the timing 
of amelioration and deterioration of RA during 
pregnancy  
 Increased glycosylation of IgG  Possible; levels change along with the clinical 
course  
Obstetric problems and foetal outcome  
Labour and delivery are usually uneventful in women with RA and there is no 
increased risk of foetal loss. There are few studies showing a increased risks for 
pre-eclampsia, caesarean delivery, prematurity, lower birth weight (however, 
not small for gestational age (SGA)) and longer hospitalization at birth among 
infants born to women with rheumatoid arthritis compared to the general 
population (22-25). In those studies, the case groups did not only include well-
defined RA but also ankylosing spondylitis (AS), juvenile idiopathic arthritis 
(JIA), and inflammatory arthritis, which prohibits specific conclusions for RA. An 
influence of disease activity of RA during pregnancy on birth weight was 
suggested, however, could not be discriminated from the influence of 
medication use during pregnancy (22). In rare cases, a normal vaginal delivery 
is not possible because of severe hip arthritis. If a caesarean section under 
general anaesthesia is required, special precaution has to be taken in case of 
atlanto-axial subluxation of the spine. 
17
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ANKYLOSING SPONDYLITIS 
Effect of pregnancy on maternal disease  
Unlike the pregnancy effects in RA, disease activity in AS does not substantially 
change during pregnancy. Amelioration of the disease is found in 20-31 
percent, aggravation in 28-33 percent, and no change in 33-60 percent. A 
postpartum aggravation of AS is seen in 45-87 percent of the women depending 
on whether women were studied retrospectively or prospectively (26-29). In 
retrospect, women tend to forget their postpartum deterioration. The differences 
in the percentages are due to the heterogeneity of the studied populations. In 
general, spinal disease remains unchanged during pregnancy while peripheral 
arthritis and uveitis are suppressed during gestation and tend to exacerbate 
after delivery. The postpartum flare correlates with the disease activity during 
conception (28). 
Prediction of pregnancy effect on AS  
Improvement of AS activity during pregnancy - if any - is predicted by a history 
of peripheral arthritis. Women carrying a female foetus appear to fare better 
than women pregnant with a male foetus (28). This effect may be attributed to 
hormonal differences in pregnancies of a male or female child. Patients who get 
pregnant during active disease tend to have active disease in the postpartum 
period and - in case of spinal disease - will also experience many problems 
during pregnancy because of unchanged or even aggravated disease activity. 
Patients with predominantly spinal disease are therefore advised not to get 
pregnant during a very active period of their disease. Postpartum flares in AS 
have no relation with breastfeeding or the return of menses after delivery (26). 
Pregnancy in relation to the onset of AS  
The onset of AS symptoms typically occurs at the childbearing age. 
Consequently, the onset of AS around pregnancy would not be rare. Ostensen 
and Ostensen (1998) found a pregnancy-related onset of AS in 21 percent of 
939 studied patients (28). For AS not associated with psoriasis or inflammatory 
bowel disease, the onset of AS seems to be slightly more often in the post-
partum period than during pregnancy. This slightly increased onset postpartum 
can be explained in several ways: (i) high physical demands on the mother in 
caring for her new-born; (ii) a methodological flaw, comparing the 9 months risk 
of onset during pregnancy with the 6 months postpartum risk; (iii) a real 
increased postpartum risk of onset of AS. The risk of pregnancy-related onset of 
AS - if any - appears to be low. 
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Fertility 
In a large multinational study, women with AS had 2.4 pregnancies per woman, 
with an average of two children per woman (28). These figures do not differ 
from the situation in the general population of those countries, indicating that 
there is no decreased fertility in AS.  
Obstetric problems and foetal outcome  
Foetal outcome is not compromised in AS (27, 28). Women with AS have no 
increased risk for foetal loss, prematurity, or low birth weight. Delivery may be a 
problem in advanced hip disease. This is, however, rarely the case in this age 
group and a normal vaginal delivery can be expected. Caesarean section was 
reported more frequently in AS women (28 percent) than expected from the 
figures reported for healthy women in North America and Europe (28). In 58 
percent, AS was mentioned as the reason for the caesarean section. The 
decision to perform a caesarean section may be influenced by the inclination of 
the obstetrician to choose primary surgical delivery for women with 
inflammatory joint disease of the pelvic region and not by actual peri-partum 
problems.  
JUVENILE IDIOPATHIC ARTHRITIS  
The onset of JIA is by definition before the childbearing age, so all patients will 
be confronted with the possible effects of their disease on reproduction and 
fertility. In a recent study, at least one-third of female JIA patients were advised 
against having children, in particular by doctors (30). There are no good 
reasons for such negative advice, however, since the outcome of pregnancy in 
JIA is good. 
Effect of pregnancy on maternal disease  
The effect of pregnancy on disease activity in JIA is very similar to that in RA 
(30-32). About 60 percent of the patients will experience amelioration and 10–
20 percent an aggravation. The favourable effect of pregnancy on disease 
activity is pre-eminently seen in patients with polyarticular disease, although 
patients with pauciarticular disease also showed a high remission rate of the 
disease during pregnancy (32). The remission rate during pregnancy of 
systemic disease is generally much lower than the remission rate of the other 
forms of JIA. 
 
Postpartum flares are common, even in women who did not have a change in 
their disease activity during pregnancy. In about 60 percent, the disease will 
flare in the postpartum period, mostly in the first 6 months after delivery. In the 
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study of pauciarticular JIA the postpartum flare seemed to be predicted by 
active disease before pregnancy and by breastfeeding (32). The flare related to 
breastfeeding occurred only when the breastfeeding was stopped. Analogous to 
RA, the experience of previous pregnancies appears to predict the response of 
the disease to subsequent pregnancies.  
Pregnancy complications and foetal outcome  
Pregnancy generally passes without much extra problems. Consequences of 
the JIA influence the mode of delivery; severe hip involvement may prevent 
normal vaginal delivery. This problem is probably encountered more often in JIA 
than in RA because of the relative long duration of the disease in JIA. Similarly, 
patients with JIA may have more problems in caring for their babies than RA 
patients because of the more extensive joint impairments. 
 
Early case series showed no evidence of adverse foetal outcome in terms of 
increased abortion rate, still birth, pre-term birth, or intrauterine growth 
retardation. In a recent controlled study, however, a significantly higher rate of 
miscarriages was seen in JIA patients than in healthy controls, 20.8 and 9.5 
percent, respectively (30). 
Fertility 
Fertility appears to be normal in JIA, but patients report more difficulties in 
getting pregnant during 1 year of unprotected intercourse than healthy controls 
(30).The lower chance to conceive (fecundity) may be due to the higher 
frequency of gynaecological problems that were also found more often in the 
JIA patients than in the healthy controls. Ultimately, the number of pregnancies 
was similar for JIA and healthy controls with an average of 2.3 pregnancy per 
woman. 
SYSTEMIC LUPUS ERYTHEMATOSUS 
In pregnancies associated with SLE both maternal and foetal problems are 
common. Adolescents with SLE should preferably be given special attention 
regarding fertility and pregnancy in a translation clinic (33). Maternal disease 
outcome and maternal obstetric complications will be discussed separately from 
foetal and neonatal outcome (Table 1.1.3a and b). 
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Table 1.1.3a: Consequences of pregnancy in SLE, maternal perspective 
Consequences  Risk factors  
Maternal perspective   
Effect of pregnancy on SLE flares   
  More than two-fold risk of flares Active disease before conception  
   No time preference of flares  
   Flares not more severe than outside pregnancy  
Effect of SLE on pregnancy: obstetric complications   
  Hypertension Renal flare, prednisone  
  Pre-eclampsia  Renal flare, prednisone  
  Thrombosis  
  - deep venous thrombosis  Antiphospholipid syndrome  
  - stroke  Antiphospholipid syndrome  
  Diabetes mellitus Prednisone  
  Hyperglycaemia  Prednisone  
  Bladder infections  Medications?  
  Premature rupture of membranes Probably multifactorial  
  More frequent caesarean section  Multifactorial  
  Rare obstetric complications (uterine rupture, 
bilateral retinal detachment during labour, 
severe retinopathy, HELLP) 
Renal flare, APLS, and medication 
The maternal perspective  
Effect of pregnancy on maternal disease: lupus flare  
Despite all the conflicting results in the literature, there is some agreement that 
the frequency of flares is higher in pregnant than in non-pregnant SLE patients 
(34-36). Considering the often heterogeneous patient populations studied and 
the very different ways flares were assessed, the similarity of the results in the 
different studies support the clinical impression that SLE patients tend to flare 
during pregnancy. In nearly all studies the frequencies of flares during 
pregnancy were higher than 57 percent, with flare rates ranging from 0.06 to 
0.136 per patient-month, compared to very consistent flare rates in control 
groups of 0.039–0.054 per patient-month. The flares during pregnancy are not 
more severe than outside pregnancy and they mostly affect the skin and the 
joints (34, 36), though others found less musculoskeletal flares and more renal 
and haematologic flares (35). One should realize that the frequency, nature, 
and severity of the flares are not only determined by pregnancy itself but also by 
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the change in medication because of the pregnancy. Monitoring disease activity 
of SLE during pregnancy can be performed with the lupus activity index during 
pregnancy (37). The disease manifestations, the pregnancy, and the medication 
together will determine the morbidity of mother and child. Hypertension 
develops frequently during pregnancy as well as mild oedema and proteinuria 
and may progress into (pre)eclampsia mimicking a flare of the disease. In 
general, pregnancy does not lead to worsening of renal function in patients with 
previous lupus nephritis, but the combination of pre-eclampsia and renal 
disease may rapidly lead to serious morbidity requiring clear differentiation 
between a renal flare and (pre)eclampsia and subsequent adequate therapy; 
high dose immunosuppression or delivery, respectively. 
Prediction of lupus flare  
A flare can occur at any time during pregnancy or the puerperium (38). There is 
no specific postpartum risk of a flare. It is not possible to predict when or if an 
individual patient will flare and what the nature of the flare will be, though 
quiescent disease in the year prior to conception seems to be associated with 
fewer disease flares during pregnancy (39). Low-dose prednisone (10 mg/day) 
does not prevent flares occurring. Close monitoring of the patient during the 
whole pregnancy and the puerperium is necessary, since most patients can or 
will not plan their pregnancy exclusively after a year without disease activity. 
Mechanisms explaining pregnancy flares 
During pregnancy, strong hormonal and immunologic changes are required to 
permit the woman to carry a child that is partly non-self. SLE is strongly 
associated with female sex hormones since the female to male ratio of SLE is 
about 10:1. In particular, female sex hormones will rise during pregnancy, which 
in turn stimulate prolactin production. Prolactin is known to be an 
immunomodulator with multiple effects on the immune system. Prolactin 
receptors are expressed in a number of cells, including T- and B-lymphocytes, 
and belong to the family of cytokine receptors. Prolactin levels were found to be 
associated with SLE activity in some studies, but not in others (34, 35, 40, 41). 
Use of bromocriptine during pregnancy was tested in SLE patients and 
suggests that it possibly reduces unfavourable pregnancy outcome, however, 
this have to be confirmed in a randomised clinical trial (41, 42). 
 
In contrast with the possibly favourable effect in RA, the shift from Th1 to Th2 
cytokines in pregnancy may be deleterious in SLE. The Th2 cytokines are 
responsible for the humoral immunity and a shift towards a Th2 cytokine profile 
may therefore worsen an antibody-mediated disease like SLE (18). 
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Table 1.1.3b: Consequences of pregnancy in SLE, foetal perspective 
Consequences  Risk factors  
Foetal perspective   
 Overall a two-fold risk of foetal loss   
 First trimester   
 - probable increased frequency of spontaneous 
abortions  
Active disease? APLS?  
 Second and third trimesters   
 - increased frequency of foetal loss  Antiphospholipid syndrome 
(particularly in LA)  
  Low renal function  
  Low serum C3  
 Pre-term birth and intrauterine growth retardation   
 - 24-59% pre-term deliveries  Active disease in general  
  Renal disease and hypertension  
  Prednisone  
  Poor obstetric history 
(anticoagulant therapy because of 
antiphospholipid syndrome)  
Neonatal outcome   
 Neonatal lupus syndrome   
 Transient   
 - skin rashes  Anti-SSA/Ro and Anti-SSB/La  
 - cytopaenias   
 - hepatosplenomegaly   
 - myocarditis/pericarditis   
 Permanent   
 - neurocognitive abnormalities  
 - complete heart block  Anti-SSA/Ro and Anti-SSB/La  
 Neonatal antiphospholipid syndrome (extremely rare) Primary APLS/ secondary APLS in 
SLE 
Obstetric complications  
Obstetric morbidity is a serious problem in SLE. Obstetric morbidity is higher in 
lupus patients than in controls. In particular, hypertension, pre-eclampsia, 
diabetes mellitus, hyperglycaemia, and bladder infections are common with a 
four- to six-fold increased risk compared to controls (25, 35). Corticosteroid 
therapy strongly contributes to this comorbidity, particularly in patients taking 
more than 10 mg/day. Lupus patients are more likely to have premature rupture 
of membranes and they require also more frequently caesarean sections. The 
rare, but more serious obstetric complications are uterine rupture, bilateral 
retinal detachment during labour, severe retinopathy, deep venous thrombosis, 
and recurrent liver necrosis (43) and stroke (both associated with secondary 
antiphospholipid syndrome, APLS) and the HELLP syndrome (haemolysis, 
elevated liver enzymes, and low platelets). The APLS-associated complications 
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can occur in patients who are already receiving antithrombotic treatment. 
Women with APLS and a previous arterial thromboembolism should be 
discouraged to become pregnant because of the high risk of recurrent 
thromboembolism, even with anticoagulant treatment (35, 44, 45). A substantial 
proportion of all thrombotic events in women with APLS occurs during 
pregnancy or in the postpartum period. 
Fertility 
SLE does not apparently affect fertility (46), unless patients have been treated 
previously with cyclophosphamide. Despite the fact that women who have, or 
later develop, SLE are at greater risk of pregnancy loss, their ultimate family 
size is comparable to that of healthy controls (47). However, infertility may be a 
factor in a small group of women with high levels of APL antibodies seeking 
help for inability to conceive (48). Some clinicians recommend that infertile 
women with APLS should be treated with heparin/aspirin when they are 
undergoing in vitro fertilization. In particular, women with APL antibodies against 
phosphatidylethanolamine (PE) or phosphatidylserine (PS) appear to have low 
success rates with in vitro fertilization. In these women, treatment with 
intravenous immunoglobulin might help if heparin/aspirin fails. 
The foetal perspective 
Foetal loss 
There is an increased foetal loss in SLE pregnancies, in particular in the second 
trimester. Most studies report foetal loss in 20-30 percent of the SLE 
pregnancies, which is more than a twofold risk of foetal loss compared to 
controls (35, 36, 39, 44, 47). Secondary APLS is strongly associated with foetal 
loss in the second trimester, but not with foetal loss in the first trimester. The 
risk of foetal loss in APLS is strong for the presence of lupus anticoagulant (LA) 
(odds ratio 27.7), but less strong for anticardiolipin (odds ratio 1.7). Other risk 
factors for foetal loss are impaired renal function and active disease, for 
example, measured by low serum C3, and placental compromise (35, 36, 49). 
Pre-term birth  
The rate of pre-term delivery in SLE patients ranges from 24 to 59 percent. 
Disease activity, measured with whatever marker for SLE activity, is probably 
the most important risk factor for pre-term birth (35). Renal disease with 
proteinuria in the nephrotic range and hypertension are particularly important in 
causing prematurity. High prednisone doses either as a marker of active (renal) 
disease, or by a direct effect contributes to the prematurity risk. In addition, poor 
obstetric history also predicts pre-term birth. Prematurity in SLE is often 
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multifactorial and preventive measures should include optimal antihypertensive 
treatment, treatment of SLE activity and treatment of secondary APLS. 
 
Women with SLE are also at risk for foetal growth impairment and foetal 
distress caused by placental insufficiency. Placental pathology in SLE patients 
is characterized by decidual vasculopathy and infarction. The latter feature in 
particular can be extensive in APLS patients (48). 
Neonatal outcome  
Women with circulating anti-52 kDa SSA/Ro or SSB/La antibodies are at risk of 
having a child with neonatal lupus syndrome. Transient symptoms of neonatal 
lupus are rash, cytopaenias, hepatosplenomegaly, and myocarditis/pericarditis. 
A permanent, and potentially lethal, manifestation of neonatal lupus is complete 
congenital heart block. Mortality in congenital heart block may accumulate to 20 
percent in utero. Of the new-born babies with a congenital heart block 64 
percent need a pacemaker (50). The risk of having a subsequent child with 
congenital heart block appears to be between 12 and 16 percent (48). Series of 
foetal echocardiograms are indicated between weeks 16 and 24 of gestation to 
follow the foetal cardiac function in women with anti-SSA/Ro, anti-SSB/La 
antibodies or with a previous child with congenital heart block. Oral 
dexamethasone and/or plasmapheresis have been used to attenuate or to 
reverse the serious complication of congenital heart block in utero with varying 
degree of success (50, 51). Another extremely rare complication of women with 
SLE and secondary APLS can be a neonatal antiphospholipid syndrome. Its 
occurrence may depend on the passage of antibodies through the placenta or, 
by the production of de novo antibodies by the fetus (52). In later life, offspring 
of patients with SLE showed neuropsychological abnormalities in learning and 
memory and behaviour domains. These abnormalities were not associated with 
neither the development of SLE in the offspring nor disease activity during the 
pregnancy in the mother (53). 
Patient management with SLE pregnancy  
Successful pregnancies are now possible in 85 percent of the women with SLE. 
This is only made possible through partnership between expert rheumatologists, 
obstetricians, and neonatologists. SLE still carries a high risk for adverse 
pregnancy outcome. Counselling and obstetric care ideally begins before 
conception (25, 39, 54). Risk factors can be assessed and treatment can be 
optimized aiming at a quiescent disease at least 6 months before conception. A 
series of laboratory assessments will provide the baseline measures for further 
follow up during pregnancy and the potential risk factors for adverse outcome 
(Table 1.1.4). In normal pregnancy the C3 and C4 should rise. Monthly 
monitoring - if necessary more often - by rheumatologist, obstetrician, and 
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possibly other specialists may pick up important change that have to be acted 
upon. Particular attention has to be given to disease flare, renal deterioration, 
hypertension, and adverse foetal development. The medication has to be 
adapted to the patient's needs depending on disease activity, prior obstetric 
history, presence of APLS, presence of anti-SSA/Ro or anti-SSB/La antibodies, 
and the course of the present pregnancy. Management of lupus flares can be 
problematic because of the limitations on medications that can be used safely 
during pregnancy. Mild flares can be treated with prednisone, although high 
doses of prednisone are not favoured because of the increased risk of obstetric 
problems and pre-term birth. For moderate to major flares intravenous 
methylprednisolone pulse therapy, 1000 mg/day, for 3 days may be an option 
combined with azathioprine, which has been used without much problem in 
lupus flares during pregnancy. Hydroxychloroquine has been shown to control 
disease activity during pregnancy and can be continued during pregnancy in 
SLE without harm to the foetus (35, 39). Treatment with NSAIDs after the 
second trimester is not advised because of the potential adverse effect on the 
foetal renal and cardiac system. The preferred treatment for APLS nowadays is 
a combination of low-dose aspirin and low-molecular-weight heparin that can be 
given for the duration of pregnancy (35, 44). The use of prednisone to prevent 
APLS complications is not advocated anymore because of the lack of effect and 
the risk of prednisone associated obstetric complications such as diabetes 
mellitus, hypertension, pre-eclampsia, and pre-term delivery (Table 1.1.3). 
Antihypertensive treatment is often necessary in lupus pregnancy but should 
not be too aggressive because of the differential effect on maternal 
hypertension and placental blood flow. Antihypertensives that are most 
commonly used in SLE pregnancies include methyldopa, hydralazine, and—in 
more severe hypertension - labetolol. Patients who are chronically on thiazide 
diuretics or nifedipine because of renal disease could potentially remain on 
these drugs if closely monitored. ACE inhibitors should be stopped because of 
effects on foetal kidney development (39). 
 
Prednisone and hydrocortisone are inactivated in the placenta and therefore 
have little effect on the foetus. Dexamethasone and betamethasone do cross 
the placenta in an unmetabolized form and are therefore used if the foetus has 
to be treated, for example, in case of anti-SSA/Ro or anti-SSB/La foetal 
myocardiopathy. 
 
Approaching delivery, the team has to include a neonatologist. Obstetric 
management during labour is not dissimilar from normal pregnancy care. Stress 
dose steroids should be administered to patients who are on prolonged courses 
of steroids. Any antithrombotic therapy should be stopped if labour is imminent. 
Because of the high-risk nature of SLE pregnancies, the rate of caesarean 
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sections will be higher than usual. The usual precautions for anaesthesia and 
surgery should be taken in case of prednisone and/or anticoagulant use. After 
delivery the newly born baby has to be observed for signs and symptoms of 
neonatal lupus. There are no objections against breastfeeding, unless certain 
medications prevent it because of risk for the baby. 
Table 1.1.4: Baseline laboratory assessments in SLE-pregnancy 
Investigations  Parameter  
Immunological  ANA titre  
 Anti-dsDNA and titre  
 Anti-SSA/Ro  
 Anti-SSB/La  
 Anticardiolipin IgM and IgG  
 Lupus anticoagulant (LA)  
 Complement levels: C3, C4, and CH50  
Haematological and chemical  Haemoglobin  
 Haematocrit  
 Leucocytes  
 Platelets  
 Full serum electrolyte panel  
 Serum creatinine  
 Liver enzymes  
 Glucose  
Urinalysis  24 h creatinine clearance  
 24 h total protein  
 Sediment  
SCLERODERMA 
Effect of pregnancy on maternal disease 
Pregnancy in general does not change the disease status of scleroderma. The 
few studies that systematically evaluated the disease status during pregnancy 
reported no change in 72-88 percent, improvement in 5-14 percent, and 
worsening in 7-14 percent of scleroderma patients (55, 56). Scleroderma 
symptoms such as oedema, arthralgias, gastrointestinal reflux, and mild 
shortness of breath are also common in normal pregnancy. Raynaud's 
phenomenon usually improves, but will come back after delivery. Hypertension, 
a frequent symptom during pregnancy, should be aggressively treated, since 
renal crisis is the most serious complication of scleroderma and cause of death 
in scleroderma pregnancies. The presence of hypertension and proteinuria 
related to pre-eclampsia could be confused with a renal crisis and it may be 
difficult to distinguish between the presence of pre-eclampsia or scleroderma 
renal crisis per se or a renal crisis in scleroderma induced by pregnancy. 
Recent studies showed far fewer episodes of renal crises than earlier anecdotal 
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case reports (55, 56). Women with symptoms of scleroderma of less than 4 
years, those with diffuse cutaneous scleroderma and those who have 
antitopoisomerase antibodies (anti-Scl70) have a greater risk of aggressive 
disease than those with longstanding disease with anticentromere antibodies 
(55). Women with early progressive disease are therefore more at risk of renal 
crisis during pregnancy than women with limited scleroderma or longstanding 
stable disease. Prednisone therapy is another precipitating factor for renal crisis 
in scleroderma and should therefore be avoided, particularly during pregnancy. 
The overall outcome of scleroderma is not influenced by pregnancy; the 10-year 
cumulative survival for women with and without a pregnancy was similar (Table 
1.1.5). 
Table 1.1.5: Clinical observations in relation to scleroderma and pregnancy  
Issues  Clinical observation  
During pregnancy   
 Disease activity  No change in 72–88%, 5–14% improvement, 7–14% 
worsening  
   Only Raynaud's phenomenon usually improves  
 Onset scleroderma  No relation between the timing of onset and pregnancy  
   Parous women have threefold decreased risk of developing 
scleroderma  
 Obstetric problems  Hypertension: treat aggressively  
  
  
  
Renal crises: most serious complication that can cause death 
in scleroderma patients. Must be treated with ACE-
inhibitor  
- Risk factors of renal crisis: early progressive disease (<4 
year), diffuse cutaneous scleroderma, presence of anti-
topoisomerase antibodies (anti-Scl70) and prednisone 
therapy  
- Low risk of renal crisis: longstanding disease with anti-
centromere antibodies  
  
Measures 
- Need frequent 
evaluations of blood 
pressure, urinalysis 
and foetal growth by 
ultrasound 
- Prednisone is 
contraindicated 
Pre-eclampsia: difficult to distinguish from renal crisis in 
scleroderma induced by pregnancy  
 Foetal outcome  Slightly increased risk of prematurity and miscarriages in 
diffuse scleroderma  
Delivery  Caution with the use of beta-adrenergic agonists to prevent 
pre-term labour, because of its potential side-effects of 
myocardial ischaemia and pulmonary oedema  
   In case of general anaesthesia difficult intubation because of 
restricted opening of scleroderma mouth  
   Special care needed for surgical repair of caesarean wound 
and episiotomy  
Postpartum   
 Disease activity  Raynaud's comes back  
Long-term (>10 years)  Overall outcome and 10-year cumulative survival is not 
influenced by pregnancy  
Fertility  No evidence of decreased fertility in scleroderma patients  
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Pregnancy in relation to onset of scleroderma  
There is no relation between the onset of scleroderma and pregnancy. The 
disease can develop during as well as outside pregnancy with similar risks. 
Parity has been implicated in the causation of scleroderma through persistent, 
HLA similar (but not entirely identical), foetal microchimerism disrupting the 
maternal immunoregulatory mechanisms (57, 58). Parous women and women 
who had abortive pregnancy, however, were found to have three-fold decreased 
risk of scleroderma compared to nulliparous women, which excludes the 
possibility of pregnancy itself being a risk factor for the development of 
scleroderma (59). 
Fertility  
The most recent studies show no evidence of decreased fertility in scleroderma 
(60), though older studies suggested that fertility was decreased (55). Patients 
with systemic sclerosis are more often nulliparous than controls. When 
nulliparity was adjusted for number of women who never married, women who 
were sexually active, and women who chose not to have children, the 
differences from the controls disappeared. Only 2-5 percent of both the 
scleroderma and control women who attempted to become pregnant was 
unsuccessful. All other determinants of fertility were also similar in both groups 
(60). 
Foetal outcome  
Pregnancy outcome in scleroderma is variable but the overall adverse 
pregnancy outcome rate is increased in most case-control studies (55). 
Scleroderma patients are more likely to have adverse pregnancy outcome after 
disease onset than before, in particular, prematurity. An increased rate of 
miscarriages and prematurity is reported especially in patients with longstanding 
diffuse scleroderma but not in limited scleroderma. Recent studies show, 
however, more favourable pregnancy outcomes in scleroderma than the older 
case series (60). The current consensus is that the overall success of 
pregnancy in scleroderma is good, and only in the diffuse disease is there a 
slight increased risk of adverse pregnancy outcome, in particular, prematurity.  
Patient management of scleroderma pregnancy  
The overall outcome of pregnancy in scleroderma is favourable though, in the 
individual patient, the risk of maternal harm and foetal prematurity may be 
substantial (61). Careful management of the pregnant scleroderma patient is 
therefore indicated. Patients with early diffuse scleroderma should wait to 
become pregnant until their disease stabilizes and the risk of renal crisis has 
decreased. Patients with longstanding diffuse systemic sclerosis and extensive 
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organ involvement have to be assessed regarding the risk of serious health 
problems during the physical demands of pregnancy. When cardiac, renal, or 
lung function are greatly impaired the patient should be strongly advised against 
pregnancy. This decision is based on the abnormalities found and is 
independent of the fact that scleroderma is the cause of these abnormalities.  
 
Management of the pregnant scleroderma patient includes frequent evaluation 
of blood pressure, urinalysis, and foetal growth by ultrasound. Prednisone 
therapy is contraindicated because of the risk of a renal crisis. Patients with 
diffuse scleroderma are advised to monitor their blood pressure very frequently, 
if possible several times a week, by home monitoring. Even a slight elevation in 
blood pressure compared to previous levels should be considered potentially 
serious and be treated promptly. In case of (suspicion of) a renal crisis the first 
choice of treatment is an ACE inhibitor; this could make the difference in the life 
or death of the mother and the foetus. ACE inhibitors have been reported to 
cause foetal abnormalities, but successful use in pregnancies has been 
documented. The risk of renal failure and foetal loss may outweigh the risk of 
the birth defects associated with the use of ACE inhibitors and justify the use of 
these drugs in pregnancy of a scleroderma patient. 
 
Antacids and anti-reflux measures can manage common problems such as 
oesophageal dysmotility. The use of histamine blockers and proton pump 
blockers has not been reported to cause significant problems in pregnancy.  
The risk of pre-term labour, in particular in diffuse scleroderma, is increased. 
The use of beta-adrenergic agonists to prevent pre-term labour particularly in 
this patient group should be used with great caution, because of the potential 
side effects of myocardial ischaemia and pulmonary oedema. Before delivery 
venous access should be secured because of the potential difficulties finding 
access in the taut skin. General anaesthesia should be avoided because of the 
difficulties in intubating a scleroderma patient with a minimal mouth opening and 
the risk of aspiration. An epidural block can normally be used without problem. If 
a caesarean section is indicated, the wound normally heals without difficulty if 
care is taken in the surgical repair. The same applies for an episiotomy incision.  
 
If the baby is born full term, no special care has to be taken.  
DERMATOMYOSITIS/POLYMYOSITIS  
Pregnancy in dermatomyositis (DM) or polymyositis (PM) is infrequent because 
of the rarity of the disease and the late age at onset. In over 85 percent of the 
patients, the disease starts after childbearing age. The knowledge about 
pregnancy in DM/PM, is based on some case series and several case reports 
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(62-65) and can best be divided into: (i) influence of pregnancy on childhood 
DM/PM; (ii) influence of pregnancy on adult DM/PM; and (iii) onset of DM/PM 
related to pregnancy (Table 1.1.6). 
Table 1.1.6: Clinical observations in relation to dermatomyositis/polymyositis and pregnancy 
Issues  Clinical observation  
Child DM/PM    
 Risk of flare during pregnancy  Low  
 Foetal outcome  Favourable  
Adult DM/PM    
 Risk of flare during pregnancy  Low  
 Foetal outcome  Moderate-poor (± 50% at term)  
   Risk factor for adverse outcome: active disease 
at start of pregnancy  
Onset of DM/PM during pregnancy    
 Risk of uncontrollable disease  High  
 Foetal outcome  Moderate-poor (± 50% adverse outcome)  
   Remarkable postpartum remission reported  
Maternal disease and pregnancy outcome  
All reported cases of childhood DM/PM started their pregnancy in an inactive 
phase of their disease. Two patients had an abortion (one spontaneously, one 
induced) and a flare post-abortion. Of the remaining eight patients, only two (25 
percent) flared during pregnancy. Seven out of 10 patients (70 percent) had full 
term new-borns. One baby was born prematurely. In adult DM/PM, 88 percent 
of the patients remained stable during pregnancy and the corticosteroid 
dosages were not changed. The pregnancy outcome was worse than in 
childhood DM/PM with only 50 percent full-term new-borns. Of eight 
pregnancies two ended with an abortion, one in pre-term birth and one in 
neonatal death of a pair of twins.  
Risk for adverse outcome of pregnancy  
It appears that the outcome is best in mothers with inactive disease (n = 12), 
with 72 percent full term birth, 11 percent spontaneous abortions and no pre-
term birth (when excluding the induced abortion). In active disease (n = 14) the 
outcome is worse with only 47 percent full-term birth, 33 percent foetal loss, and 
13 percent premature birth. The babies did not show any sign of an 
autoimmune disease. Recently three cases of a pregnant patients with active 
DM were described who were successfully treated with IVIG. This might 
suggest that IVIG therapy is a possible therapeutic option in active DM during 
pregnancy, given its corticosteroid-sparing effect and the reduced risk of 
steroid-related side effects (66-68).  
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Onset of DM/PM during pregnancy  
There are several case reports of DM/PM starting during pregnancy, mostly in 
the first, sometimes in the second and rarely in the third trimester (62, 63). The 
group of patients with onset of DM/PM during pregnancy has the poorest 
outcome of pregnancy with over 50 percent foetal death. Conversely, 
pregnancy appeared to have a negative influence on the disease in the mother, 
with very active therapy-resistant disease during pregnancy. In some of these 
cases, patients showed remarkable postpartum remissions.  
PRIMARY SJÖGREN'S SYNDROME  
There are few studies on pregnancy in primary Sjögren's syndrome. Fertility, 
parity, and sexual activity of patients with primary Sjögren's syndrome do not 
appear to differ from that of the healthy population. There are, however, some 
contradictory results on the risk of foetal loss (69-72). In some studies the risk of 
foetal loss is approximately two-fold increased and comparable to that of SLE, 
while in other studies no such risk is observed. Foetal growth retardation and 
pre-term birth are not problems in primary Sjögren's syndrome. APLS 
antibodies or antibodies to SSA/Ro or SSB/La appeared to play no major role in 
the increased risk of foetal loss in Sjögren's patients. There may be the risk of 
congenital heart block, but only few prospective data are available. 
RARE DISEASES  
Adult onset Still's disease  
Reviewing the scarce case reports, pregnancy seems to have no effect on adult 
onset Still's disease, and conversely, adult onset Still's disease has no obvious 
influence on pregnancy, foetal growth, or infant maturity and health (73, 74).  
Vasculitis syndromes  
Polyarteritis nodosa  
Polyarteritis nodosa (PAN) developing during pregnancy has an extremely bad 
prognosis. All seven women diagnosed during gestation or in the immediate 
postpartum period died within 6 weeks postpartum (75-77). This grave 
prognosis may be explained to a certain extent by difficulties in diagnosing PAN 
in the setting of pregnancy and by the very active disease during pregnancy. 
Pregnant women with a known, quiescent PAN have a much better prognosis, 
with only one in four women experiencing an exacerbation. Perinatal outcome 
was surprisingly good, with approximately 70 percent survival of the child.  
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Wegener's granulomatosis  
About 30 pregnancies have now been reported in Wegener's granulomatosis 
(WG) of which half occurred during or immediately after pregnancy (76-79). If 
the disease is inactive prior to pregnancy the chance of disease activation 
during pregnancy is not particularly high and the foetal outcome is generally 
favourable. In contrast, obstetric problems, such as pre-eclampsia, prematurity, 
and foetal deaths occurred when maternal disease was not controlled. 
Takayasu arteritis  
Pregnancy does not seem to worsen Takayasu arteritis, although symptoms 
common to both the disease and pregnancy—such as hypertension and 
abdominal discomfort—have to be correctly interpreted (77, 80, 81). There is an 
increased risk of foetal loss, intrauterine growth retardation, and pre-term birth. 
All patients with poor perinatal outcome had abdominal aortic involvement and a 
significant delay in seeking medical attention. 
Behçet's disease  
In women with Behçet's disease, convincing reports of both pregnancy-related 
flares and remissions, mainly of mucocutaneous involvement, are found in the 
literature. Gestational exacerbations of the more serious manifestations of 
Behçet's including major eye problems, vasculitis, and CNS disease are 
uncommon. Also, foetal development and survival is generally good in Behçet's 
syndrome (75, 77, 82, 83). 
 
The general advice for management of pregnancy in a vasculitis syndrome is 
that pregnancy should be planned during a remission of the disease. If 
vasculitis activity reappears, rigorous treatment of the vasculitis is required in 
order to protect mother and child against serious morbidity and mortality. If 
necessary, cyclophosphamide pulse therapy in the second and third trimesters 
should be considered as a therapeutic option, since maximal suppression of the 
vasculitis activity is the goal.  
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INTRODUCTION 
The inflammatory rheumatic diseases predominantly affect women, often in the 
childbearing years. Antirheumatic drugs are necessary to control the disease 
and many times the medication cannot be stopped in pregnancy because of risk 
of a disease flare potentially threatening the health of mother and child. Some 
drugs appear to be safe during pregnancy, though an association between 
drugs and malformations is hard to exclude totally. It therefore seems prudent to 
stop all medications during pregnancy if possible. In general, the outcome for 
mother and child is best if pregnancy occurs in a period of disease remission 
(1). Often, pregnancy will or cannot be planned in a period of remission or, 
conversely, the disease will flare during pregnancy and the doctor will face the 
question which antirheumatic drugs to use during pregnancy. The most critical 
phase for the foetal outcome in relation to use of medication is in the first weeks 
of pregnancy during conception, embryogenesis, and organogenesis. It is 
therefore important that a pregnancy is carefully planned and the antirheumatic 
medication is adapted as soon as the patient seriously wishes to conceive. 
 
There are virtually no controlled data on the safety of drug use during 
pregnancy, since pregnant women are always excluded from randomized 
controlled trials. Placental transfer has been described for the majority of 
antirheumatic drugs. The foetal concentrations of drugs can vary considerably 
compared to the maternal concentrations depending on the type and dosage of 
the drug, duration of treatment, and timing. Both protein binding and hepatic 
metabolism in the foetus differ from those in the mother and depend on the 
stage of development of the foetus. The first trimester and the few weeks before 
delivery are the most vulnerable periods for the foetus: the former because of 
the early foetal development and the potential risk of malformations during 
foetal organogenesis (teratogenesis), the latter because of the risk of functional 
abnormalities and post-natal problems in the neonate due to exposure to a 
specific drug. 
 
Knowledge about safety for mother and child during pregnancy comes from 
observations during long-term clinical experience, case series, and case 
reports. The last of these tends to overestimate adverse effects of drugs on the 
foetus due to publication bias. Animal studies may provide some guidance in 
the usage of drugs during pregnancy though they cannot be easily extrapolated 
to the human situation. Physicians should be aware of the potential adverse 
effects of antirheumatic drugs during conception, pregnancy, and lactation, and 
should carefully weigh the risks and the benefits of these medications for 
mother and child. Comprehensive management of the patient starting before 
conception is prerequisite for an optimal outcome. Recently the prescribing 
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patterns of rheumatologists regarding DMARDs in rheumatic diseases were 
described (2). This chapter describes what is known about the effects of 
antirheumatic drugs on fertility, conception, pregnancy, and lactation for both 
mother and child. This information is summarized in Tables 1.2.1 - 1.2.6 . This 
chapter is based on some excellent reviews (3-12) and the information from the 
Micromedex and a Dutch pharmacologic registry containing information on 
antirheumatic drugs during pregnancy and lactation (13, 14). 
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Table 1.2.1 Use of NSAIDs and corticosteroids in pregnancy 
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Table 1.2.2 Use of conventional DMARDs in pregnancy 
 Hydroxy- 
chloroquine  
Sulfasalazine  Gold  D -Penicillamine 
Fertility  No effect  Women: no effect 
Men: reversible 
infertility  
No effect  Unknown  
Teratogenicity  Probably not in 
average dose 
(< 6.5 mg/kg 
body weight) 
No  Probably not 
(little data) 
Definite: 
physical defects, 
tissue 
abnormalities  
Late pregnancy  No problems  No problems  Little data  Connective 
tissue 
abnormalities 
(cutis laxa)  
Risk/benefit ratio a  Positive in SLE  Positive  Neutral  Negative  
FDA category b  C (in high 
doses)  
B  C  D  
Breastfeeding c  Use with 
caution  
Use with caution  Use with 
caution 
No reports of 
use  
a Positive, disease is worse than the drug; neutral, always better to stop the drug if possible; 
negative, drug is always worse than the disease. 
b FDA category: A, no foetal risk in controlled studies; B, no risk in animals, no controlled 
human studies; or abnormalities in animal studies but not in controlled human studies; C, 
studies show teratogenic or embryocidal effects in animals, but no controlled human studies; 
or no studies are available in either human or animals; D, positive evidence for foetal 
abnormalities but potential benefits may outweigh potential risks; X, contra-indicated. 
c According to the Micromedex and ‘Farmacotherpeutisch Kompas’ advice (13, 14). 
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 Table 1.2.3 Use of cytotoxic medications in pregnancy 
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Table 1.2.4 Use of new antirheumatic drugs in pregnancy 
 Cyclosporine A Leflunomide  TNF-alfa blockade  
Fertility  Women/Men: 
No effect  
Not known Not known: may even 
facilitate ovulation 
induction 
Teratogenicity  Probably not  Definite in animals; 
human not known 
Possibly not,  
no teratogenicity found in 
animal studies 
Late pregnancy  Growth retardation  
Prematurity  
Not known Not known 
Risk/benefit ratio a  Negative–Neutral 
depending on 
disease  
Negative Possibly Neutral–Positive 
FDA category b  C  X B (etanercept) c 
B (infliximab) 
B (adalimumab) 
Breastfeeding d  Contra-indicated  Contra-indicated  No data  
a Positive, disease is worse than the drug; neutral, always better to stop the drug if possible; 
negative; drug is always worse than the disease. 
b FDA category: A, no foetal risk in controlled studies; B, no risk in animals, no controlled 
human studies; or abnormalities in animal studies but not in controlled human studies; C, 
studies show teratogenic or embryocidal effects in animals, but no controlled human studies; 
or no studies are available in either human or animals; D, positive evidence for foetal 
abnormalities but potential benefits may outweigh potential risks; X, contra-indicated. 
c High doses of these drugs have been tested in animals, without leading to teratogenicity, 
controlled human studies have not been done. 
d According to the Micromedex and ‘Farmacotherpeutisch Kompas’ advice (13, 14). 
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Table 1.2.5 Use of miscellaneous antirheumatic drugs in pregnancy 
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 Table 1.2.6 Summary of recommendations 
 1. Aspirin Low dose,  80 mg/day of aspirin can be used safely throughout pregnancy 
without evident risk of foetal malformations, clotting problems in either mother or child, or 
abnormality in foetal renal function or premature closure of the ductus arteriosus. Cautious 
use of low dose of aspirin during breastfeeding will not adversely affect the child. High, anti-
inflammatory doses of aspirin should be avoided during all stages of pregnancy, in particular 
in the last trimester. 
 2. NSAIDs can be safely used in the first and second trimester of pregnancy, if necessary to 
control maternal disease. Recently, a higher risk on miscarriages was found in women using 
NSAIDs in a population based study, however the study’s retrospective design may limit the 
reliability of the results (15, 16). There is no consistent reported risk of foetal malformation. 
Indomethacin may induce oligohydramnios as they can inhibit fetal renal urinary output. 
NSAIDs should be stopped in the last 6–8 weeks of pregnancy because of the prostaglandin 
inhibiting effects on mother and child potentially leading to a delayed labour, renal, and 
vascular effects on the child and perinatal bleeding in mother and child. NSAIDs with a short 
half-life and inactive metabolites, such as ibuprofen, flurbiprofen, and diclofenac may be 
used more safely, in particular during breastfeeding (17). Since only trace amounts of 
NSAIDs will appear in breast milk, breastfeeding is recommended to be compatible with 
NSAID use. There is a lack of data on the new COX-2 selective inhibitors in pregnancy and 
their use in pregnant or lactating women should be avoided. 
 3. Corticosteroids Low dose of prednisone is considered safe in pregnancy for both mother 
and child. High doses (1–2 mg/kg/day) should be avoided during the first trimester because 
of the possible risk of oral cleft in the child. Prednisone and hydrocortisone are inactivated to 
cortisone in the placenta. The fluorinated corticosteroids, dexamethasone, and 
betamethasone, will pass the placenta and are only used to treat the foetus, if necessary. 
The lowest possible dose of prednisone needed to control the maternal disease should be 
used to minimize the risk for gestational diabetes and hypertension. Calcium and vitamin D 
supplementation for prevention of osteopaenia is advisable. Emergency surgery, caesarean 
section and prolonged labour are indications for 'stress doses' of corticosteroids. 
Breastfeeding is compatible with prednisone doses up to 20 mg/day, 3–4 h before actual 
breastfeeding. 
 4. Antimalarials The favourable effects of hydroxychloroquine in preventing flares in SLE 
outweigh the potential risk for the unborn child. No adverse effects on the child have been 
found in the doses of hydroxychloroquine of 200–400 mg/day commonly used to treat the 
rheumatic diseases. Breastfeeding should be undertaken cautiously because of the long 
elimination half-life and the risk of accumulation. 
 5. Sulfasalazine can be safely used prior to and during all stages of pregnancy. Men with a 
wish to produce offspring should stop the drug because of its adverse effect on 
spermatozoa. This effect is reversible after discontinuation of the drug. Breastfeeding is 
compatible with sulfasalazine treatment though should be advised with caution because of 
the rare event that the mother is a slow acetylator. 
 6. Gold Common practice is to continue gold treatment until pregnancy is recognized and 
then stop the treatment. There seems no risk of foetal malformation, although this is based 
on very limited information (18). Gold therapy is compatible with breastfeeding, but it seems 
most prudent to avoid nursing because of the possible toxic effect on the infant 
 7. Penicillamine should be stopped in women who wish to become pregnant because of 
the serious risk of congenital malformations and the far better alternatives available for the 
treatment of the rheumatic diseases during pregnancy  
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Table 1.2.6 (continued) Summary of recommendations 
 8. Methotrexate is contra-indicated in the treatment of the rheumatic diseases during 
pregnancy. The rate of abortion and congenital abnormalities is significantly increased 
particularly with exposure during the first trimester. Strict contraception is needed when a 
patient is on methotrexate. Fertility appears not to be adversely effected by prior 
methotrexate use. Women and men who wish to conceive have to stop methotrexate 
treatment 4–6 months prior to conception. Continuation of folate supplementation is advised 
to prevent adverse outcome due to folic deficiency. Breastfeeding is contra-indicated 
because of excretion of methotrexate in breast milk. 
 9. Azathioprine Women with severe rheumatic diseases that are otherwise hard to control 
may use azathioprine during pregnancy. No apparent congenital malformations are known 
with doses of azathioprine up to approximately 2 mg/kg/day. Exposure to azathioprine 
throughout pregnancy may lead to immunosuppression and low blood cell counts in the 
neonate. Strict adjustment of the azathioprine dosage to maintain normal maternal blood 
cell counts may prevent neonatal abnormalities. Breastfeeding is not recommended. 
 10. Cyclophosphamide treatment leads to infertility in particular after cumulative doses and 
in patients aged over 30 years. Cryopreservation of semen and oocytes can help to 
preserve the changes of future offspring. Oral contraception is advised to possibly protect 
ovarian function during cyclophosphamide treatment. Adequate contraception is anyhow 
necessary because of the teratogenicity of the drug. Exposure to cyclophosphamide during 
the first trimester of pregnancy leads to congenital malformation and should be avoided. 
Treatment with cyclophosphamide during the second half of pregnancy may be considered 
in case of severe, life threatening disease of the mother. Breastfeeding is contra-indicated  
 11. Cyclosporine A is apparently not associated with congenital malformation, but can 
cause prematurity and intra-uterine growth retardation. Long-term effect of intrauterine 
exposure is not known. It is generally advised not to use cyclosporine during pregnancy 
unless the severity of the maternal disease urges to do so. Breastfeeding should be 
discouraged in women using cyclosporine. 
 12. Leflunomide is contra-indicated during pregnancy and safe contraception during its use 
is warranted. Due to the long half-life and slow elimination time, leflunomide should be 
washed out in both male and female patients who wish to conceive. The wash-out 
procedure consists of 8 g of cholestyramine three times daily for 11 days, followed by two 
separate tests to verify whether the drug has been eliminated. If blood levels remain high 
the procedure has to be repeated. Without a wash-out the levels of leflunomide may stay 
too high for pregnancy for up to 2 years. Breastfeeding is considered unsafe  
 13. Biologicals Little information on use of any of the biologicals (etanercept, infliximab, 
adalimumab, anakinra) during human pregnancy has been published until now. Based on 
the minimal or lack of data on human pregnancy the teratogenic risk is undetermined. Until 
now, use is not recommended during pregnancy and lactation. At least 5 months before 
conception and/or before breastfeeding will be given, the use of infliximab and adalimumab 
should be stopped 
 14. Colchicine is considered safe during pregnancy as well as during breastfeeding. 
Fertility is probably not decreased with the possible exception of men taking colchicine 
because of Behçet's disease. 
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GENERAL CONSIDERATIONS OF ANTIRHEUMATIC TREATMENT DURING 
PREGNANCY 
Treatment of (rheumatoid) arthritis 
The majority of the patients with rheumatoid arthritis (RA) improve during 
pregnancy and in most cases the antirheumatic treatment can be stopped as 
soon as the woman becomes pregnant. The same applies for arthritis 
symptoms in other rheumatic diseases, such as juvenile idiopathic arthritis and 
peripheral arthritis in spondyloarthropathies (19). Cytotoxic drugs have to be 
stopped before conception, because of the teratogenic effect on the foetus. This 
holds for both male and female patients. In case of an arthritis flare during 
pregnancy, the symptoms can often be safely controlled with intra-articular 
steroids, non-steroidal anti-inflammatory drugs (NSAIDs) or, if necessary, low 
dose oral prednisone. 
Treatment of systemic lupus erythematosus (SLE) and other systemic 
diseases during pregnancy 
SLE and other systemic rheumatic diseases should be planned when the 
disease is quiescent. Similar to RA treatment with cytotoxic drugs should be 
stopped several months before conception because of the teratogenic effect on 
the foetus. In SLE, there is a possible risk of a flare during pregnancy and 
treatment may be necessary. Both the disease and the treatment may harm 
mother and child. It can be difficult to interpret whether an adverse outcome of 
mother or child is due to the disease manifestations or to the drug treatment 
(see also previous chapter). A rheumatologist and an obstetrician with expertise 
in treating these kinds of patient should frequently see every mother with SLE 
throughout pregnancy (20). 
Aspirin 
Aspirin is the oldest and most commonly used NSAID and is the most often 
researched NSAID during pregnancy. In high doses it has adverse effects on 
both mother and child, whereas in low doses it is safe. 
Effects on the mother 
High doses of aspirin in the third trimester inhibit uterine contractility and 
prolong labour and gestation. Labour may be complicated by pre- and post-
partum haemorrhage. Low-dose aspirin appears to be safe and is even of 
benefit in patients at risk for pregnancy-induced hypertension and 
preeclampsia. Low-dose aspirin is prescribed in patients with SLE and 
antiphospholipid syndrome at risk for recurrent foetal loss. 
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Effects on the child 
There are several conflicting reports on teratogenicity of high doses of aspirin in 
the first trimester of pregnancy in animals as well in humans (4, 5, 7, 13, 21, 
22). There is no evident teratogenic effect of low dose aspirin. High doses of 
aspirin in the perinatal period lead to clotting defects in mother and child 
through irreversible binding to platelet cyclooxygenase enzymes. The mother 
can experience increased blood loss during delivery. An increased incidence of 
intra-cerebral haemorrhage in the newborns exposed to aspirin in the last 
weeks before delivery has been reported (4, 5, 21). This problem has been 
found in newborns exposed to a total of 325-650 mg/day within 1 week prior to 
delivery. Nowadays, more than 10 000 pregnancies have been exposed to 60–
80 mg/day of aspirin that has been shown to have a positive effect on 
interleukin-3, a cytokine that affects pregnancy and foetal development. No 
adverse effect of low-dose aspirin of 80 mg/day or lesser on clotting ability, 
renal function, or ductus arteriosus in the newborn has been demonstrated. 
Doses up to 80 mg/day of aspirin can be used safely throughout pregnancy. 
Breastfeeding 
Aspirin is found in breast milk up to approximately 20 percent of the amount 
ingested by the mother. Peak salicylate concentrations in milk occur about 2 h 
after peak serum levels in the mother. In case of high anti-inflammatory doses 
of aspirin ingested by the mother the child is potentially at risk of developing 
salicylate intoxication and bleeding problems during lactation. It is therefore 
recommended that aspirin can be used during breastfeeding, but with caution 
and in low doses. 
NSAIDs 
The most commonly used antirheumatic drugs during pregnancy are NSAIDs. 
They readily cross the placenta and block prostaglandin synthesis in a variety of 
foetal tissues. Because of the prostaglandin blocking effect NSAIDs have been 
used for pregnancy related indications such as premature labour, 
polyhydramnion, and pregnancy-induced hypertension. 
 
Far less information is available on the relatively new NSAIDs and pregnancy 
than on aspirin and pregnancy. The risk of NSAIDs during pregnancy is best 
researched for indomethacin, sulindac, naproxen, ibuprofen, ketoprofen, and 
diclofenac (8, 21), mostly because of their ability to suppress premature labour. 
The potential adverse effects of NSAIDs in pregnancy have been described 
most extensively for indomethacin (23), though these adverse effects have also 
been reported to a certain extent for the other NSAIDs. The potential side 
effects of NSAIDs in pregnancy are linked to their ability to inhibit prostaglandin 
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synthesis. Dose, duration, and period of gestation are important determinants of 
the extent of these effects. 
Effects on the mother 
There is some evidence that women who have problems in conceiving should 
stop NSAIDs when attempting to become pregnant because of the findings in a 
variety of animal models indicating that prostaglandin inhibitors block blastocyst 
implantation (7, 24). Ingestion of NSAIDs near term will significantly delay and 
prolong labour. There is a serious risk of increased maternal blood loss at 
delivery. If NSAIDs are stopped at least 1 month before the expected delivery 
these problems can be avoided. 
Effects on the child 
NSAIDs can cross the placenta and have been detected in foetal tissues (25). A 
recent study reported a higher risk on miscarriages in healthy women using 
NSAIDs compared to non using women, however the cohort’s retrospective 
design limits the reliability of its results (15). A recent study reported no 
increased risk for any congenital malformation with NSAID use in early 
pregnancy. But when controlled for maternal age, parity, and smoking habits, in 
a small number of women there was an increased risk for cardiac defects and of 
oral facial clefts (26). The general advice from the European Medicines Agency 
(27) regarding NSAID use during pregnancy is not to give NSAIDs in the first 
and second trimester of pregnancy, and should not be given unless clearly 
necessary. If NSAIDs are used by a woman attempting to conceive, or during 
the first and second trimester of pregnancy, the dose should be kept as low and 
durations of treatment as short as possible to control maternal disease (4,7,13, 
21,28,29). 
 
NSAIDs administered in the last trimester of pregnancy can cause premature 
constriction of the ductus arteriosus, pulmonary hypertension, impaired renal 
function, a reduction in foetal urine output, and oligohydramnion. These effects 
are reversible if the NSAID is stopped (30). Due to the effect on platelets, 
NSAIDs administered in the perinatal period can cause intracerebral 
haemorrhage in the child. Discontinuation of NSAIDs 6–8 weeks before delivery 
is considered safe. Theoretically the effects of the new COX-2 selective 
inhibitors on the duration of labour and clotting function should be less 
compared to that of the non-selective COX inhibitors. The effects on the foetal 
vasculature and renal function are, however, the same as for the non-selective 
COX inhibitors and for the benefit of the child discontinuation of any NSAID 6–8 
weeks prior to the expected delivery is warranted. Because of the lack of data 
on these new drugs, the COX-2 selective inhibitors are better avoided in 
pregnant women altogether. 
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Breastfeeding 
Because breast milk has a pH of 6.9-7.6, weak acids are ionized so drugs such 
as NSAIDs are not readily distributed into the breast milk. Trace amounts of 
naproxen, piroxicam, ibuprofen, and diclofenac have been reported in breast 
milk (7, 13). NSAID use is considered compatible with breastfeeding, though 
some NSAIDs (indomethacin, sulindac) circulate enterohepatically and should 
therefore be avoided. NSAIDs are contraindicated in the jaundiced neonate 
because of their property to displace bilirubin and by that increasing the risk of 
kernicterus. 
Paracetamol (acetaminophen) 
Paracetamol is the most widely used analgesic during pregnancy. Therapeutic 
doses are safely used during pregnancy without apparent adverse affects on 
mother or child. The drug is distributed in breast milk in amount ranging from 
approximately 1-2 percent of the maternal dose (13). The usage of paracetamol 
during pregnancy and breastfeeding is considered safe (17). 
 
Since paracetamol is only a moderate painkiller without anti-inflammatory 
properties the drug is for most pregnant women with an active rheumatic 
disease often not sufficient to treat the maternal disease. 
Glucocorticoids 
Glucocorticoid therapy is the mainstay treatment for SLE during pregnancy and 
is also a popular choice in joint diseases when NSAIDs are insufficient to 
control the arthritis. Many potentially serious adverse effects of high dose 
corticosteroids in pregnancy have been reported for both mother and child, 
although one should realize that active SLE per se, for which the corticosteroids 
are prescribed, may equally well be the culprit of the observed adverse effects 
(see previous chapter). The non-fluorinated steroid preparations such as 
prednisone, prednisolone, and methylprednisolone are the drugs of choice to 
treat active maternal disease. They are metabolized by placental 11-
hydroxygenase, and the foetus is exposed to only 10 percent of the maternal 
dose. If the foetus has to be treated, for example, in case of immature lungs or 
foetal carditis due to anti-SSA/SSB antibodies, fluorinated corticosteroids such 
as dexamethasone and betamethasone are preferred because they are less 
well metabolized in the placenta and higher doses are available to the foetus. 
Effects on the mother 
All the well-known side effects of corticosteroids may be more marked when 
used during pregnancy. Pregnancy is associated with hypertension, 
hyperglycaemia, striae, osteopaenia, and immunosuppression, the risk of these 
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conditions will be enhanced by corticosteroid use. Premature rupture of the 
membranes has been observed during steroid use, although the causative role 
of corticosteroids cannot be separated from the possible role of a flare of the 
underlying rheumatic disease. 
Effects on the child 
Exposure to corticosteroids during pregnancy has been studied in various 
animal species resulting in reports on deleterious effects on the offspring, 
including cleft palate. In the human series, no evidence was found for 
congenital abnormalities due to corticosteroid use in pregnancy (3-5,7,8,21). 
However, in a meta-analysis of epidemiological studies an increased risk for 
oral clefts after exposure to corticosteroids during the first trimester was found 
(31). There are some case reports on masculinization of female infants, growth 
restriction, neonatal cataract, and adrenal suppression in children exposed to 
high doses of corticosteroid before birth (8). 
Breastfeeding 
The dose of corticosteroids found in breast milk is negligible when the mother 
receives prednisone 20 mg or less. Abstaining from breastfeeding in the 3–4 h 
after the mother has taken her medication can minimize the dose received by 
the infant (13). 
Chloroquine and hydroxychloroquine 
Most observations of the effects of antimalarials during pregnancy have been 
made in women taking malaria prophylaxis with chloroquine. 
Hydroxychloroquine is widely used in the treatment of rheumatic diseases. The 
use of antimalarials in RA is relatively easy to avoid but it is a mainstay of 
treatment in many patients with SLE and can help to prevent flares during 
pregnancy. 
Effects on the mother 
Knowledge is now accumulating about hydroxychloroquine exposure in 
pregnant SLE patients (3, 7, 8, 32, 33). A double blind, placebo-controlled trial 
of hydroxychloroquine in lupus pregnancy was published recently (34). 
Discontinuation of hydroxychloroquine may precipitate a flare of the SLE with 
harmful consequences for mother and child. For both it appears to be better to 
continue the hydroxychloroquine therapy during pregnancy since women on 
hydroxychloroquine experienced less disease activity and better neonatal 
outcome than women who stopped hydroxychloroquine (34). 
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Effects on the child 
Chloroquine crosses the placenta and accumulates preferentially in melanin-
containing structures in the foetal uveal tract and inner ear. In animal models, 
abnormalities of the foetal eye have been reported as well as in some infants 
who had been exposed to higher than the daily recommended dose of 
chloroquine throughout pregnancy (3, 4, 8). No increase in the rate of 
congenital abnormalities, prematurity, or foetal growth restriction was found in a 
cohort study of 169 pregnancies of women exposed to chloroquine 300 
mg/week for malaria prophylaxis as compared to a four times larger control 
group. 
 
In the last few years, it has become apparent that hydroxychloroquine used in 
doses of 200-400 mg/day to prevent SLE flare carries no risk of congenital 
malformation or adverse neonatal outcome (32-36). Discontinuation of 
hydroxychloroquine in controlled SLE runs the risk of flares and consequently 
harms the child. It is therefore advised not to stop hydroxychloroquine during 
gestation. Moreover, due to the very long elimination time of 
hydroxychloroquine, the foetus will still be exposed to the drug long after the 
mother has stopped taking the drug. 
Breastfeeding 
Low concentrations of hydroxychloroquine are found in breast milk. Although 
hydroxychloroquine is considered compatible with breastfeeding, the slow 
elimination rate and the potential accumulation of a toxic amount of 
hydroxychloroquine in the infant, breastfeeding should be undertaken with 
caution (13, 14). 
Sulfasalazine 
Sulfasalazine is an effective treatment for RA in a daily dose up to 3 g/day. 
About 30 percent of the drug is absorbed in the small intestine; the other 70 
percent passes into the colon where it is cleaved into 5-aminosalicylic acid and 
sulfapyridine. Sulfasalazine and sulfapyridine cross the placenta and foetal 
blood concentrations will come close to maternal concentrations. The 5-amino 
salicylic acid has very limited placental transfer. There are data available for the 
safe use of sulfasalazine in over 2000 pregnancies of women with inflammatory 
bowel disease (37). There is no reason to assume that the safety of 
sulfasalazine in pregnant women with arthritis would prove to be different from 
its safety in pregnant women with inflammatory bowel disease. 
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Effects on the mother 
Sulfasalazine does not adversely affect fertility in women and can therefore 
safely be prescribed in women who wish to become pregnant. If the arthritis is 
not adequately controlled after conception the drug can be continued during 
gestation without problems. In contrast to the situation in women, men have 
decreased fertility with sulfasalazine due to oligospermia, impaired sperm 
motility, and an increase in abnormal spermatozoa (3, 7, 37). The decreased 
fertility has been shown reversible when treatment with the drug is discontinued. 
Effects on the child 
The wealth of data regarding pregnancy and sulfasalazine use in inflammatory 
bowel disease shows no increased rate of congenital malformation, prematurity 
or low gestational weight (4, 7, 37). Theoretically, sulfasalazine may increase 
the risk of kernicterus when used near term because of its bilirubin-displacing 
ability. Severe neonatal jaundice, however, has never been reported in 
connection with maternal sulfasalazine use. 
 
Sulfasalazine is thought to have an effect on folate metabolism and may cause 
folate deficiency. Folate supplementation would seem prudent both prior to and 
during pregnancy in women taking sulfasalazine (7, 37). Nowadays, folate 
supplementation is recommended for all women considering pregnancy. 
Breastfeeding 
Sulfasalazine concentrations in breast milk may reach 40-50 percent of the 
concentration found in the mother. Sulfasalazine use is considered compatible 
with breastfeeding. Substantial adverse effects have been published in some 
infants, probably because of high drug concentrations in the mother due to slow 
acetylation. It has been advised to use sulfasalazine with caution during 
breastfeeding (13). 
Gold 
Intramuscular gold has been used extensively to treat RA in the past, although 
the data on its use during pregnancy are very limited (3-5, 7, 8). Gold is not one 
of the first choice drugs for RA anymore, but it may still be an alternative drug in 
the treatment of arthritis of women or men who choose to have offspring (18). 
Effects on the mother 
Rheumatologists often advise their patients to continue gold therapy until 
pregnancy is recognized and then stop the injections. One approach in long-
term gold treatment is to give monthly injections on the first day of menses. 
Gold does not seem to impair fertility in either women or men. Data on gold 
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therapy during pregnancy, albeit scarce, does not reveal adverse effects on the 
mother. Generally, the drug can be stopped during gestation because of the 
favourable effect of pregnancy itself on the arthritis. 
Effects on the child 
The limited data on possible adverse effects of gold treatment on the foetus are 
conflicting and uncontrolled. Gold compounds cross the placenta and are found 
in foetal tissues. In over 100 reports on gold therapy during pregnancy, no 
congenital malformations have been observed (8, 18). One case of multiple 
foetal malformations in a mother who received aurothiomalate has been 
reported, though a causal relationship between the malformations and the drug 
was disputed. To date, little is known about the effect of oral gold (auranofin) on 
the human foetus, but no abnormalities occurred in the few pregnancy reported 
during oral gold treatment. 
Breastfeeding 
Gold is excreted in human breast milk in significant amounts. There have been 
reports of skin rash, nephritis, hepatitis, and blood dyscrasias in children of 
mothers treated with gold injections while nursing their infants (7, 13). Although 
gold is usually considered compatible with breastfeeding, caution is 
recommended because of the long retention of gold in the body and the 
potential toxic effects in the infant. 
Penicillamine 
Penicillamine is used in the treatment of RA and scleroderma. Its popularity is, 
however, waning because of a wider choice of more effective treatments, in 
particular for RA. The possible risks of this drug during pregnancy definitely 
outweigh the benefits (4, 7, 8). In contrast, the use of penicillamine in Wilson's 
disease is crucial for a successful outcome of pregnancy in this disease. 
Therefore, knowledge about the teratogenicity of penicillamine mainly comes 
from the experience in the treatment of pregnant women with Wilson's disease. 
Effects on the child 
In animals as well as in humans a variety of connective tissue abnormalities 
have been found in the neonates, including cutis laxa, physical defects such as 
wide nasal bridge, low set ears, flattened face, club feet, inguinal hernia, 
congenital hip dislocation, and ventricular septal defects have been reported 
(13). There are also reports on favourable outcomes of pregnancy after prenatal 
exposure to penicillamine, which make its use acceptable for women with 
Wilson's disease. The risks of penicillamine during pregnancy are not 
acceptable for women with a rheumatic disease, for them the risk/benefit ratio is 
much too high. 
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Breastfeeding 
There are no reports on breastfeeding and mothers on penicillamine should not 
nurse their infants (13). 
Methotrexate  
Methotrexate (MTX) is the mainstay drug in the treatment of RA and is also 
frequently used in many other rheumatic diseases. It is the drug of choice in 
early RA and patients of child-bearing age will often be on MTX treatment (38). 
 
The experience with MTX during pregnancy mainly comes from women treated 
with high dose MTX often in combination with other cytotoxic drugs, and from 
women who have taken the drug to terminate pregnancy, for example, because 
of an ectopic pregnancy. Also, some very small series of pregnancies exposed 
to low-dose MTX have been published (3-5, 7, 8). An extensive review on the 
effects of MTX on pregnancy, fertility, and lactation was published in 1999 (39). 
Effects on the mother 
MTX does not impair fertility, even in high doses. Oligospermia has been 
reported, though further studies showed no long-term effects on ovarian or 
testicular function (39). The presence of MTX in liver tissue has been reported 
up to 116 days after MTX exposure. The duration of spermatogenesis is 
approximately 74 days. Consequently, a period of 6 months off MTX therapy 
seems safe for men before attempting conception. 
 
MTX is a strong abortifacient and has been used for that purpose. It can be 
expected that exposure to low dose MTX in early pregnancy will lead to an 
increased abortion rate. In small series of patients exposed to low dose MTX in 
the first trimester there was indeed an increase in the abortion rate (3-5, 7, 8, 
39). Because of the embryo toxicity, women of child bearing age on MTX must 
use adequate contraception. Women who wish to conceive must stop MTX at 
least 3-6 months prior to conception and folate supplementation is best 
continued to avoid folic depletion. 
Effects on the child 
MTX treatment is associated with increased risk of congenital malformation. 
Women who wish to continue pregnancy when exposed to MTX in the first 
trimester have a 20-30 percent chance of an abnormal child (39). The MTX-
induced congenital defects are similar to those produced by aminopterin, 
another folic antagonist. The defects to be expected with severe folate 
deficiency include neural tube defects resulting in anencephaly, hydrocephaly, 
meningomyelocele, and ossification defects resulting in craniofacial and limb 
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defects. Also an increase nuchal translucency was reported after use of low 
dose MTX, therefore after exposure of the mother to low dose MTX during first 
trimester, a structural ultrasound at 20 weeks of gestation is strongly advised 
(40). 
 
Developmental delay has also been reported (41). The most vulnerable period 
for the development of foetal malformations is 6-8 weeks of gestation (39). 
Women who wish to continue pregnancy having had exposure during the first 
trimester of pregnancy should be offered treatment with folinic acid in order to 
minimize MTX effects on the foetus. MTX exposure in the second and third 
trimesters of pregnancy is associated with growth retardation and 
myelosuppression (3, 7, 39, 41). 
Breastfeeding 
MTX is excreted in breast milk in low concentrations and may accumulate in 
neonatal tissues. Breastfeeding is contra-indicated because of potentially 
severe problems in the neonatal infant (7, 13). 
Azathioprine  
Experience of azathioprine exposure during pregnancy is derived mainly from 
the treatment of transplantation patients complemented by some reports of 
treatment in SLE and inflammatory bowel disease (3,4,6-8,13). Azathioprine 
crosses the placenta, but the foetal liver lacks the enzyme inosate 
pyrophophorylase and is therefore unable to convert azathioprine to its active 
and more toxic metabolite, 6-mercaptopurine. This foetal enzyme deficiency 
theoretically protects the foetus from any teratogenic effect of azathioprine in 
early pregnancy. 
Effects on the mother 
There seems to be no adverse effect on fertility and no increase in the abortion 
rate in women exposed to azathioprine. This drug is used to preserve allografts 
or to control systemic autoimmune disease. The choice to continue treatment 
during pregnancy is dependent on the need to treat maternal disease. 
Effects on the child 
No predominant or specific pattern of malformation has been identified during 
40 years of experience. There are some reports of congenital malformations, 
but a causal relationship with azathioprine is hard to prove. Women with 
abnormal babies took significantly higher doses of azathioprine than women 
with normal babies, suggesting some risk for congenital deformities with 
increasing doses of azathioprine (3,7,8,13). Exposure throughout pregnancy 
has been associated with a variety of adverse effects including thymic atrophy, 
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intra-uterine growth retardation, foetal immunosuppression, foetal 
pancytopaenia, and chromosomal aberrations. Often, the mother received 
several drugs and it was not possible to blame either one of the drugs or the 
underlying disease for the adverse effects on the child. It has been suggested 
that adjustment of the azathioprine dosage to maintain normal maternal blood 
cell counts might prevent neonatal cytopaenias. 
Breastfeeding 
Low concentrations of azathioprine have been found in breast milk. 
Breastfeeding is not recommended because of the potential adverse effects for 
the child. 
Cyclophosphamide 
Cyclophosphamide is an alkylating agent only used in rheumatology to treat 
severe, potentially life threatening disease. The observations of 
cyclophosphamide exposure during pregnancy are predominantly in women 
with malignancies (3-8, 13). 
Effects on the mother 
The adverse effect of cyclophosphamide on fertility in both men and women is 
well recognized. The key risk factors for ovarian failure after cyclophosphamide 
exposure are age 31 years or more, total doses of more than 10 g and 
treatment greater than 15 pulse cycles (5, 7). Men who start cyclophosphamide 
treatment have the option of cryopreservation of their semen. Cryopreservation 
of oocytes is much more complicated and often not possible due to the 
underlying disease. Inhibition of ovulation, for example, by oral contraceptives is 
believed to protect ovarian follicle viability. Adequate contraception during 
cyclophosphamide therapy is necessary because of the teratogenic effects of 
the drug. 
Effects on the child 
Both in animals and in humans congenital malformations and changes in the 
foetal genome have been found when exposed to cyclophosphamide in the first 
trimester of pregnancy, although normal newborns have also been reported. 
Abnormalities include facial clefts, limb reduction defects, and craniofacial 
dysmorphisms. Exposure of the foetus to cyclophosphamide in second half of 
pregnancy may lead to myelotoxicity of the foetus and growth retardation. It is 
not established whether the latter adverse effect is due to the underlying 
disease or to the drug. The risk/benefit ratio may permit cyclophosphamide 
treatment in the second half of pregnancy in case of severe systemic disease of 
the mother. 
58
1 Introduction 
52 
Breastfeeding 
Cyclophosphamide has been found in substantial amounts in human breast 
milk. Breastfeeding is therefore unsafe for the newborn child. 
Cyclosporine A 
More than 600 pregnancies exposed to cyclosporine have been reported, 
mainly in transplant recipients (3,4,7,8,13,42,43). 
Effects on the mother 
There is no indication that cyclosporine impairs human fertility. In case of 
rheumatoid arthritis the drug can be stopped before pregnancy and, if 
necessary, replaced by an alternative drug more compatible with pregnancy. 
When the woman is treated because of systemic disease the possible benefits 
of the treatment have to be weighted against the possible harm the drug can 
caused during pregnancy. Renal impairment and hypertension are of particular 
concern during pregnancy. 
Effects on the child 
Cyclosporine crosses the placenta and foetal levels may reach between 37 and 
64 percent of the maternal plasma levels. It has been shown to have 
embryotoxic and fetotoxic effects in animals, but only at supra-therapeutic dose 
levels. In women receiving an average dose of cyclosporine of 5 mg/kg/day 
during pregnancy no increased rate of congenital malformations was seen. The 
major problems were prematurity and low birth weight in approximately 50 
percent of the pregnancies. It is difficult to estimate what the independent 
contribution of cyclosporine treatment to these pregnancy complications is, 
since concomitant medication or the underlying disease may cause these 
problems as well. The effects of foetal exposure to cyclosporine in the long term 
are not known. 
Breastfeeding 
Cyclosporine is excreted in human breast milk, therefore breastfeeding should 
be avoided. 
Leflunomide 
Leflunomide is a new drug amongst the medications to treat arthritis. There are 
no data published on leflunomide exposure during human pregnancy (3,7,8,12, 
44,45). Animal data indicate that exposure to leflunonide during pregnancy has 
teratogenic and foetotoxic effects at normal therapeutic levels. The 
malformations observed include anophthalmia, micro-ophthalmia, and 
hydrocephalus. In addition, embryolethality and reduced foetal weight were 
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noted in animals. Due to the long half-life and slow elimination time, leflunomide 
should be washed out in both male and female patients who wish to conceive 
(Table 1.2.6). Distribution of leflunomide into breast milk is unknown. 
Biologicals 
TNF-Į inhibition is becoming increasingly popular in the treatment of various 
rheumatic diseases, in particular, rheumatoid arthritis. There are some reports 
on human pregnancies exposed to TNF-Į inhibitors until now (3,7,8,11,13), 
however, reports on other biologicals inhibiting IL-1, or B-cel depleting therapies 
are scarce (3). 
Etanercept 
Soluble TNF-Į receptor fusion protein that crosses the placenta in mice, but 
does not impair foetal development (11). Studies in rats and rabbits did not find 
teratogenicity or fetotoxicity with doses by far exceeding the therapeutic human 
doses. Because of insufficient data in humans it is advised to abstain from 
pregnancy while on etanercept treatment. In previous reports few fetal and neo-
natal complications were reported after anti-TNF-Į use. The association with 
VATER in a child born to a woman with psoriatic arthritis and treated with 
etanercept throughout her pregnancy is alarming and may be attributable to 
TNF-Į inhibition (46). Etanercept levels were measured in a RA patient and 
showed that it was secreated in human breast milk. Because of the potential for 
serious adverse effects in nursing infants breastfeeding should be discouraged 
during etanercept treatment (3). 
Infliximab 
In mice, no embryo- or foetotoxicity was noted. Only one case of exposure to 
infliximab in early pregnancy in a woman with inflammatory bowel disease and 
an adverse outcome (prematurity and death) was reported (47). The patient had 
active disease at time of conception that also may explain the adverse outcome 
of the pregnancy. Initial observations in a series of human pregnancies exposed 
to infliximab in the first trimester did not show an increase in birth defects or 
adverse pregnancy outcomes (3, 8, 11). Since the safety of infliximab during 
pregnancy has not been sufficiently documented, safe contraception is 
recommended during its use. Either no infliximab was secreted in breast milk or 
the infliximab concentration was undetectable by standard assays. Since TNF-Į 
antagonists and lactation have not been well studied, breastfeeding should 
probably be avoided while on TNF- Į therapy (3). 
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Adalimumab 
Adalimumab is a recombinant human IgG1 monoclonal antibody that binds to 
human TNF-Į with high affinity. Until now only of 2 RA patients information has 
been reported about adalimumab and pregnancy outcome (11). No 
breastfeeding will be advised because of the lack of data. 
Anakinra 
Anakinra is a recombinant, nonglycosylated form of the human interleukin-1 
receptor antagonist, which has been used in the treatment of moderate-to-
severe RA. There have not been any adequate or well-controlled studies in 
pregnant women, but reproductive studies on rats and rabbits at doses up to 
100 times the human dose have not revealed evidence of impaired fertility or 
harm to the fetus. Because of the lack of data regarding use in humans, it 
should be used in pregnancy only if clearly needed. Since it is not known 
whether anakinra is secreted in human breast milk, it should be avoided during 
lactation (3). 
Rituximab 
Rituximab is a chimeric monoclonal antibody directed against the CD20 antigen 
on B-lymphocytes, which has been studied and used in the treatment of SLE 
and RA. There are only two case-reports of women treated with (high dose) 
rituximab for Non-Hodgkin’s Lymphoma becoming pregnant during therapy (3). 
Their pregnancies were successful without maternal complications, but one 
child had transient granulocytopaenia and lymphopaenia at birth, while the other 
child was born premature at 35 weeks of gestational age. At this time it is 
advised to avoid rituximab therapy in pregnancy. Whether rituximab is excreted 
in breast milk is unknown, therefore it should be avoided during lactation. 
Intravenous immunoglobulins 
Intravenous immunoglobulins are sometimes used in specific autoimmune 
conditions such as antiphospholipid syndrome, myositis, and autoimmune 
thrombocytopaenia. Information regarding teratogenicity in animals is limited. In 
humans, immunoglobulins will cross the placenta after 32 weeks of pregnancy. 
No harmful effects to the foetus have been reported (10). Care has to be taken 
to prevent hepatitis virus transfer through the infusion. If necessary for the 
treatment of the mother, intravenous immunoglobulins may be administered 
during pregnancy without apparent adverse effect to the foetus. There seems to 
be no harm in breastfeeding during intravenous immunoglobulins therapy, 
because of transfer of protective immunoglobulins to the child. 
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Colchicine 
Colchicine is mainly used for gout, which is very uncommon in women of child-
bearing age. It is also used in conditions such as Behçet's disease. 
Effects on the mother 
In high doses, colchicine arrests mitosis through an inhibitory effect on 
microtubuli. Theoretically colchicine may induce infertility. In men an increased 
frequency of oligospermia and azoospermia has been found in patients with 
Behcet's disease but not in patients with Familial Mediterranean Fever (FMF) 
during treatment with colchicines (48). In women the fertility rate appears to 
remain normal when on colchicine. With colchicine treatment FMF patients 
seem to have even higher fertility and better pregnancy outcome than without 
treatment due to a better control of the disease. 
Effects on the child 
Colchicine has been found to be teratogenic in mice and transplacental 
passage has been described in humans (4, 13, 48). In humans treated with 
colchicine during pregnancy - mainly because of FMF - no increase in the rate 
of congenital malformations, miscarriages or stillbirths was seen. A slight 
increase in trisomy 21 was noted in the FMF patients using colchicine during 
pregnancy, though this was ascribed to a probably slight increased risk for this 
abnormality in FMF itself (48). 
Breastfeeding 
Colchicine is excreted in human milk reaching similar levels to that in the serum 
of the mother (13, 48). However, the estimated daily amount of colchicine 
ingested by the nursing infant was at least 10 times less than the therapeutic 
dose (per kilogram) given to the mother. Breastfeeding is considered safe for 
the child. 
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PARA-study 
Pregnancy-induced Amelioration of Rheumatoid Arthritis 
 
 
 
 
 
HEALTHY POPULATION 
Thirty-two healthy pregnant women were recruited from a midwifery practice, 
Verloskunde Praktijk Voorburg (VPV), Voorburg, The Netherlands, between 
July 2002 and January 2004. At first visit women were < 13 weeks pregnant. 
These healthy women were visited at the same time points during pregnancy as 
women with rheumatoid arthritis (RA), postpartum, however, they were only 
visited at 6 and 12 weeks. Same assessments, except joint examination, and 
same laboratory tests were performed in healthy women and RA women. 
PATIENT POPULATION 
All rheumatologists working in the Netherlands were contacted by mail twice a 
year from the start in May, 2002, till May, 2008. They were asked to recruit 
patients with RA who had a wish to conceive or who were already pregnant 
(preferably in their first trimester). Patients were eligible for the study if they 
fulfilled the 1987 revised criteria of the American College of Rheumatology 
(ACR) for RA and had a good understanding of the Dutch language. During the 
study the patient’s own rheumatologists provided patient care. 
DATA COLLECTION 
Patients were visited six or seven times at their home address. They were 
visited before conception (if possible), at each trimester (8-12 weeks of 
gestation, 18-22 weeks, and 28-32 weeks) and three times postpartum (4-6 
weeks, 12 weeks and 26 weeks) (see Figure 2.1.1). The visit before conception 
took place if the woman had a wish to conceive, i.e. she and her partner did not 
use any contraceptives. If a woman did not conceive within a year after the first 
visit, another visit took place. Data collected before conception was classed as 
‘before pregnancy’. Medical and obstetrical history were taken at the first visit by 
interview. Erosions were ascertained from the patient’s medical records. 
Pregnancy outcome was ascertained, only if complicated, from patient’s 
medical records. 
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Figure 2.1.1: Study design PARA-study 
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Objective. Pregnancy has a favourable effect on the course of rheumatoid 
arthritis (RA), although the magnitude of this effect is equivocal because RA 
assessment tools have never been validated in pregnancy. The goal of this 
study was to assess how pregnancy influences the scoring of the Disease 
Activity Score in 28 joints (DAS28) and the Health Assessment Questionnaire 
(HAQ), and how both scores perform in pregnant patients with RA. 
Methods. Thirty-two healthy women and 30 pregnant patients with RA were  
prospectively studied during pregnancy and at postpartum. At each trimester 
and postpartum the components of the DAS28 (global health (GH), erythrocyte 
sedimentation rate (ESR), and C-reactive protein level (CRP)) and HAQ scores 
were determined. Maximal influences of healthy pregnancy on each component 
of the DAS28 were calculated. The performances of different DAS28 scores 
and the HAQ were also determined in RA patients. Furthermore, variants of the 
HAQ were developed within the HAQ scoring rules. 
Results. The components of the DAS28 were influenced by healthy pregnancy, 
with average increases in DAS28 score of 0.22 (GH), 1.1 (ESR), and 0.25 
(CRP). The DAS28 calculated with CRP (DAS28-CRP) and without GH 
performed the best in pregnant RA patients. In healthy pregnancy, the median 
HAQ increased to 0.50 in the third trimester and was reduced by the HAQ 
variants to 0.25. 
Conclusion. Pregnancy considerably influences the scoring of the DAS28 and 
HAQ. RA disease activity in pregnant patients should preferably be calculated 
with DAS28-CRP without GH. Even with HAQ variants, influences of pregnancy 
on the assessment of functionality cannot be precluded. 
INTRODUCTION 
Pregnancy has an important impact on rheumatoid arthritis (RA). It is the only 
natural situation in which affected women can experience complete remission of 
RA. During pregnancy, patients may experience signs and symptoms of 
amelioration of RA, followed by deterioration postpartum (1-3). The 
immunologic phenomena contributing to this favourable effect of pregnancy are 
of great interest in understanding the pathogenesis of RA. 
 
Because remission has always been defined differently, the retrospective and 
prospective studies to date have shown substantial variations in disease activity 
during pregnancy (4-9). Criteria for remission were based variously on changes 
in clinical assessments, medication, and Health Assessment Questionnaire 
(HAQ) scores. These studies also used methods that were never validated 
during pregnancy. 
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To properly study the course of RA, disease activity and functioning of pregnant 
patients with RA should be studied prospectively throughout pregnancy using 
currently accepted scores for the assessment of RA, such as the modified 
Disease Activity Score including 28-joint counts (DAS28) (10,11) and the HAQ 
(12,13). However, these widely used RA assessment tools may not be valid for 
assessing RA during pregnancy. This is because pregnancy itself may influence 
not only the parameters of the DAS28, i.e., the visual analogue scale (VAS) of 
global health (GH), erythrocyte sedimentation rate (ESR) (14), or C-reactive 
protein (CRP) level (15), but also the rating of some categories of the HAQ. For 
example, a 30-week pregnancy will most certainly cause some difficulties in 
functioning (16). Some adaptation or correction for the influence of pregnancy 
on currently accepted scores might therefore be warranted. The goal of our 
study was to investigate 1) how pregnancy itself influences the scoring of the 
DAS28 and HAQ and reliability of the DAS28 and HAQ as RA assessment tools 
in pregnancy, 2) how the HAQ can be adapted for use in pregnant patients with 
RA, and 3) how different DAS28 formulas and adaptations of HAQ perform 
during pregnancy in women with RA. 
PATIENTS AND METHODS 
The Pregnancy-induced Amelioration of Rheumatoid Arthritis (PARA) study is a 
prospective, nationwide cohort study designed to investigate the amelioration of 
RA during pregnancy and the postpartum flare. The PARA-study was started in 
2002. In this study, healthy women serve as a reference group to determine the 
pregnancy-induced deviations of current scoring methods and laboratory tests. 
All participants gave their informed consent.  
Patient population 
At the time of this study, the data collected on 30 consecutive full pregnancies 
of 30 patients with RA were available. All patients fulfilled the American College 
of Rheumatology (formerly the American Rheumatism Association) 1987 
classification criteria for RA (17). Patients were visited at each trimester (9-12 
weeks of gestation, 20 weeks, and 30 weeks) and twice postpartum (6 weeks 
and 12 weeks). At each visit patients filled out the HAQ and a VAS GH, and a 
standardized 28-joint count was performed. At the same time, ESR and CRP 
level were measured in blood samples. 
Healthy women 
Thirty-two healthy pregnant women were recruited from a midwifery practice 
between July 2002 and January 2004. Each woman was < 13 weeks pregnant. 
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The healthy women were visited at the same time points as the patients. The 
same assessments and laboratory tests were performed, except for the joint 
count. 
Assessments 
Disease activity 
The disease activity of patients can be defined by several DAS formulas. In 
general, a DAS is a statistically derived index combining tender joints, swollen 
joints, a laboratory parameter for inflammation (ESR or CRP), and global 
disease activity. In this study, the DAS28 was chosen as an assessment tool for 
disease activity. 
 
Currently, 4 formulas are available to calculate the DAS28 (see Appendix 2.2). 
In general, these 4 variants are composed of a 28-joint count for swelling and 
for pain, combined with either an ESR or CRP level and with or without a VAS 
GH (10). Joint examinations were performed for pain and swelling as 
recommended by the European League Against Rheumatism (EULAR) 
Standing Committee for International Clinical Studies Including Therapeutic 
Trials (ESCISIT) (18). GH was scored on a VAS from 0 (very well) to 100 (very 
poor). ESR was measured in mm/hour by the Westergren technique using a 
StaRRsed analyzer (Mechatronics LLC, Etten-Leur, The Netherlands). CRP 
level was measured in mg/dL by Tinaquant CRP (Roche Diagnostics, 
Mannheim, Germany). 
 
A sensitivity analysis of the performance of the 4 DAS28 formulas in pregnant 
women was performed. For this purpose, we first determined the pregnancy-
induced deviations of each component of the DAS28 observed in the healthy 
women. For each healthy woman, the third trimester and 12 weeks postpartum 
values of each component of the DAS28 were entered into the DAS28 formulas. 
Then the pregnancy-induced deviation in DAS28 for each component was 
calculated by subtracting the results of each woman separately at these 
different time points. Subsequently, the mean pregnancy-induced deviations in 
DAS28 were calculated for each component using the results of all healthy 
women. Finally, the mean pregnancy-induced deviations were entered into the 
4 different DAS28 formulas to perform the sensitivity analysis. 
 
Patients with RA were categorized according to their disease activity as 
determined by the 4 different DAS28 formulas in the third trimester of their 
pregnancy. This was rated according to the 4 criteria for categorizing disease 
activity as defined by ESCISIT (18). The categories are defined as high disease 
activity (DAS28 score > 5.1), intermediate disease activity (3.2 < DAS28 score 
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 5.1), low disease activity (2.6 < DAS28  3.2), and clinical remission (DAS28 
score  2.6) (10). 
Functionality 
The conventional HAQ score was determined using the validated Dutch 
translation of the Stanford HAQ, which considers the use of devices and aids 
(12,13,19). In a consensus meeting with researchers of our department, we 
defined the items and categories that might be most influenced by pregnancy. 
To determine whether the assumptions of the consensus meeting were valid, 
we calculated the percentages of our healthy women scoring on the individual 
HAQ items. Based on the consensus and the rating of the individual HAQ items, 
modification of the conventional HAQ into 2 HAQ variants was recommended, 
both within the HAQ scoring rules (12). The first HAQ variant (HAQv1) was 
calculated on the basis of 6 rather than 8 categories, omitting arising and doing 
activities. The second HAQ variant (HAQv2) was calculated without selected 
items per category, i.e., dressing, getting in and out of bed, climbing 5 steps, 
getting in and out of a bath, bending down to get clothes from the floor, and 
getting in and out of a car. The 2 HAQ variants were calculated for patients with 
RA as well as for the healthy women. Finally, the performances of the 
conventional HAQ scores and the 2 HAQ variants were compared for all time 
points. The pregnancy-induced deviations of the conventional HAQ and of the 2 
HAQ variants were calculated by the subtraction of the third trimester HAQ 
scores from that of 6 weeks postpartum. 
Statistical analysis 
Disease activity. Continuous variables were presented as the mean ±SD, i.e., 
VAS GH, ESR, and CRP level. Student’s t-test was used to compare different 
time points of the continuous variables. Patients with RA were categorized in 
the 4 disease activity groups according the 4 different DAS28 formulas in the 
third trimester. 
 
Functionality. HAQ scores were presented as medians and interquartile ranges. 
The differences in HAQ scores between the first and third trimester and 
between conventional HAQ and HAQ variants were tested by Wilcoxon’s 
nonparametric test. A difference in HAQ score of > 0.25 between 2 time points 
was considered to be clinically relevant (12). A 2-sided p value < 0.05 was 
considered statistically significant. SPSS for Windows, version 12.0 (SPSS, 
Chicago, IL) was used. 
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Ethics 
This study was in compliance with the Helsinki declaration, and the ethical 
committee at the Erasmus University Medical Center Rotterdam approved this 
study. 
RESULTS 
Demographics 
All 30 patients and 32 participating healthy women had successful pregnancies. 
As shown in Table 2.2.1, mean age, percentage of nulliparity, and parity were 
comparable between the healthy women and the patients with RA. 
Table 2.2.1: Demographics of subjects 
* RA = rheumatoid factor; RF = rheumatoid factor; NS = not significant.  
Pregnancy-induced deviations of components of the DAS28 
Healthy women. In the healthy women, the influence of pregnancy was different 
for each component of the DAS28. Pregnancy influenced the VAS GH to a 
small extent. The mean VAS GH of the healthy women was almost equal during 
pregnancy and postpartum (Figure 2.2.1). Despite this result, the mean 
pregnancy-induced deviation of the 2 possible DAS28 with 4 variables due to 
VAS GH was 0.22 in healthy women, calculated between the third trimester and 
12 weeks postpartum. Pregnancy influenced ESR considerably. The mean ESR 
of the healthy women differed statistically significantly between pregnancy and 
postpartum period (p = 0.03); ESR increased statistically significantly between 
the first and third trimesters (p = 0.01) from 10 mm/hour to 33 mm/hour. The 
calculations of the mean ESR at the third trimester excluded 1 woman who had 
sinusitis (ESR 120 mm/hour). The mean ESR returned to normal (< 20 mm/ 
hour) directly postpartum (Figure 2.2.1). The mean pregnancy-induced 
deviations of the DAS28 using ESR with 4 variables (DAS28-ESR-4) and the 
DAS28-ESR with 3 variables (DAS28-ESR-3) due to ESR were 1.07 and 1.16, 
respectively, in healthy women, regarding the different ESR levels at the third 
trimester and 12 weeks postpartum. Pregnancy influenced CRP levels slightly. 
The mean CRP levels of the pregnant healthy women differed statistically 
 
Baseline characteristics 
Patient group 
(n = 30) 
Healthy women 
(n = 32) 
 
p 
Mean age at first trimester (years) (sd) 
Number of nulliparous women (%) 
Mean number of previous pregnancies (sd) 
Median disease duration in months (range) 
Erosions present (%) 
RF present (%) 
30 ± 3.7 
15 (50) 
0.9 ± 1.0 
46 (3 - 343) 
58 
65 
32 ± 4.4 
14 (44) 
1.0 ± 1.1 
-- 
-- 
-- 
NS
NS
NS
-- 
-- 
-- 
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significantly from those postpartum (p = 0.03). The mean CRP levels were 
equal between the first trimester (0.7 mg/dL) and the third trimester (1.0 mg/dL) 
(Figure 2.2.1). The calculations at the third trimester excluded 1 woman who 
had sinusitis (CRP level 7.6 mg/dL). The mean CRP level returned to normal 
(< 0.7 mg/dL) directly postpartum. The mean pregnancy-induced deviations of 
the DAS28 using CRP level with 4 variables (DAS28-CRP-4) and the DAS28-
CRP with 3 variables (DAS28-CRP-3) due to CRP were 0.25 and 0.27, 
respectively, in healthy women, calculated between the third trimester and 12 
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Figure 2.2.1: Values of visual analogue scale (VAS) global health (GH), erythrocyte
sedimentation rate (ESR) and C-reactive protein level (CRP) during pregnancy and postpartum
(PP) in 32 healthy women are presented in bars as mean r SE. Normal values (in non-pregnant
population) are represented by dotted lines. * p < 0.05. NS = not significant; trim = trimester. 
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weeks postpartum. The results of the sensitivity analysis of the 4 different 
DAS28 formulas differed considerably. The calculated mean pregnancy-induced 
deviations of the VAS GH, ESR, and CRP level for healthy women were added 
as in the 4 DAS28 formulas (see Appendix 2.2). The total pregnancy-induced 
deviations per DAS28 were +1.16 for the DAS28-ESR-3, +1.29 for the DAS28-
ESR-4, +0.27 for the DAS28-CRP-3, and +0.47 for the DAS28-CRP-4. Thus, 
healthy pregnancy influenced the DAS28-CRP-3 the least and the DAS28-ESR-
4 the most. 
 
RA patients. When, according to the 4 DAS28 variants, patients in their third 
trimester were categorized in high, intermediate, and low disease activity and 
remission, large differences were found in the percentages of patients per 
category (Table 2.2.2). The percentages of clinical remission ranged between 
0% and 23%. The highest total percentage (46%) of women with low disease 
activity or remission during the third trimester was identified by the DAS28-
CRP-3, whereas according to the DAS28-ESR-3 and DAS28-ESR-4 the 
percentage was only 25%. 
Pregnancy-induced deviations of the HAQ 
Healthy women. Because the healthy women answered more HAQ items “with 
some difficulty” or “with much difficulty,” they had difficulties in functioning 
during pregnancy. All items defined in the consensus meeting were marked with 
at least “some difficulty” in > 20% of healthy women (Table 2.2.3). Only 1 item, 
i.e., walking outdoors, was not defined, but was also marked in > 20% of 
healthy women in the third trimester. 
Table 2.2.2: Percentages of patients with rheumatoid arthritis expressing high, intermediate, and 
low disease activity or remission in the third trimester based on calculation of disease activity by 
4 different DAS28 formulas* 
 
 
DAS28 variant 
High 
disease activity 
DAS28 > 5.1 
Intermediate 
disease activity 
3.2 < DAS28 d 5.1 
Low 
disease activity 
2.6 < DAS28 d 3.2 
Remission 
 
DAS28 d 2.6 
DAS28-CRP-3 
n = 30 
 
10 
 
43 
 
23 
 
23 
DAS28-CRP-4 
n = 30 
 
13 
 
50 
 
20 
 
17 
DAS28-ESR-3 
n = 28 
 
11 
 
64 
 
25 
 
0 
DAS28-ESR-4 
n = 28 
 
18 
 
57 
 
14 
 
11 
* DAS28 = Disease Activity Score including 28-joint counts; DAS28-CRP-3 = DAS28 using C-
reactive protein with 3 variables; DAS28-CRP-4 = DAS28 using C-reactive protein with 4 
variables; DAS28-ESR-3 = DAS28 using erythrocyte sedimentation rate with 3 variables; 
DAS28-ESR-4 = DAS28 using erythrocyte sedimentation rate with 4 variables. 
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Table 2.2.3: Percentages per item of the Health Assessment Questionnaire (HAQ) categories 
scored by healthy women in the first, second, and third trimesters and 6 weeks postpartum, 
showing the items that were marked as at least “with some difficulty” by 20% of the women in 
the third trimester* 
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Among the categories marked most frequently during pregnancy were the 
categories as defined at the consensus meeting, i.e., arising (69%) and doing 
activities (59%). The category reaching, however, was also marked in 69% of 
healthy women in the third trimester. However, this third category could not be 
taken into account in a HAQ variant simultaneously with the other 2 categories, 
because calculating the HAQ score requires at least 6 categories. 
 
Box plots demonstrated the differences of the HAQ and the 2 HAQ variant 
scores (HAQv1 and HAQv2) during pregnancy and postpartum (Figure 2.2.2). A 
third HAQ variant (not shown) was calculated on the basis of omitting items with 
the highest number of marks, instead of only the items considered in the 
consensus meeting. The scoring of this third HAQ variant did not perform better 
than the HAQv2. The median pregnancy-induced deviation in HAQ score 
Figure 2.2.2: Box plots of the healthy women showing the distribution Health Assessment 
Questionnaire (HAQ) scores and the variants from the first trimester (trim) until 6 weeks 
postpartum (PP). The score at 12 weeks PP (not shown) resembled the 6-week score. 
Horizontal lines (from bottom) indicate the minimum, lower quartile, median, upper quartile, and 
maximum, with the exceptions of outliers. HAQv1 = 1st HAQ variant scored without 2 categories 
(arising and activities); HAQv2 = 2nd HAQ variant scored without items 1.1, 2.2, 4.2, 5.2, 6.2, 
and 8.2. * p = 0.001, Z = - 4.39 compared with HAQ score at 1st trimester (n = 31). † p = 0.001, 
Z = - 4.42 compared with HAQ score at 3rd trimester (n = 31). 
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measured with the HAQ score between the third trimester and 6 weeks 
postpartum was 0.5. This pregnancy-induced deviation in HAQ score was 
clinically relevant and statistically significant. Although the use of the HAQv1 
and HAQv2 reduced the pregnancy-induced deviation in HAQ scores between 
the third trimester and 6 weeks postpartum to 0.33 and 0.25, respectively, the 
influence of pregnancy on the scoring of the HAQ cannot totally be disregarded. 
 
RA patients. Median HAQ scores of the patients with RA increased statistically 
significantly by 0.31 from the first to the third trimester (p = 0.04) (Table 2.2.4). 
The median HAQv1 score also increased significantly by 0.42 (p = 0.04). 
Although the median HAQv2 score increased by 0.17 between the first and the 
second trimester, it decreased in the third trimester. The median HAQv2 scores 
between the first and third trimester, however, differed only 0.07 (p = 0.06). 
Table 2.2.4: HAQ score and the two HAQ variants of RA women during pregnancy are 
presented as median and quartile range.* 
 1st trimester 
n = 30 
2nd trimester 
n = 30 
3rd trimester 
n = 29 
6wk PP 
N = 29 
HAQ 
HAQv1 
HAQv2 
0.69 (0.4-1.3) 
0.58 (0.2-1.1) 
0.56 (0.3-1.0) 
0.88 (0.4-1.3) 
0.75 (0.2-1.3) 
0.75 (0.5-1.3) 
1.00† (0.4-1.3) 
1.00† (0.5-1.3) 
0.63‡ (0.3-1.0) 
0.75 (0.2-1.2) 
0.75 (0.2-1.2) 
0.50 (0.2-1.0) 
* Values are the median (interquartile range). HAQv1 = 1st HAQ variant scored without 2 
categories (arising and activities); HAQv2 = 2nd HAQ variant scored without items 1.1, 2.2, 4.2, 
5.2, 6.2, and 8.2. † p < 0.05 for HAQ score at 3rd trimester compared with HAQ score at 1st 
trimester. ‡ Not significant for HAQv2 score at 3rd trimester compared with HAQv2 score at 1st 
trimester. 
DISCUSSION 
Our study demonstrates not only that pregnancy influences the scoring of the 
DAS28 and HAQ, but also that the HAQ variants can be used to reduce the 
influence of pregnancy on scoring the HAQ. The study also shows that the 2 RA 
assessment tools that performed best during pregnancy were the DAS28-CRP 
calculated without GH and the HAQ variant calculated without 6 selected items, 
although this variant did not totally preclude the influence of pregnancy. 
 
Because the DAS28 had never previously been used in studies of RA in 
pregnancy, each component of the 4 different DAS28 formulas was first 
regarded separately in order to properly estimate the contribution pregnancy 
made to the formulas. 
 
First, we showed that in healthy women, the mean GH score hardly changed 
during pregnancy, but was higher than postpartum. Although this difference was 
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small, it still resulted in a mean pregnancy-induced deviation of 0.22 in both 
DAS28 formulas incorporating the GH. The GH during pregnancy in patients 
with RA had not been studied before; only patients’ global assessment of RA 
had been studied. In 2004, Ostensen et al (8) prospectively studied patients’ 
global assessments of RA in 10 pregnancies from preconception until 24 weeks 
postpartum. Patient assessment decreased by an average of 15 mm during 
pregnancy, and increased by 10 mm postpartum. The differences in GH 
measured in our 30 patients with RA during pregnancy and postpartum did not 
completely follow this pattern, because the mean GH of patients with RA 
decreased by only 1 mm during pregnancy and increased by 12 mm 
postpartum. During pregnancy, the GH and the patient’s global assessment of 
RA may not be interchangeable, because the former scored health and disease 
activity together, whereas the latter scored only disease activity. The mean 
increases postpartum in the GH (12 mm) and in patients’ global assessment of 
RA (10 mm) were comparable. This suggests that outside pregnancy both 
assessment tools solely scored the difference in disease activity of RA, which 
will have the greatest influence on the GH postpartum. Based on these findings, 
we suggest that, during pregnancy, DAS28 formulas can be better used without 
GH. 
 
Second, in line with previous studies (14), our study demonstrates that ESR 
increases substantially during pregnancy. On the basis of earlier studies, 30% 
of patients with RA should be in clinical remission during pregnancy (4-6). The 
percentages of our patients with RA in clinical remission as determined by the 
DAS28-ESR formulas with or without GH were only 11% and 0%, respectively, 
at the third trimester. The DAS28-ESR will therefore certainly be unreliable, and 
therefore it is not a useful tool for assessing RA during pregnancy. 
 
Third, during healthy pregnancy, a reference CRP level is lacking, especially 
because it is unknown whether CRP levels rise or fall. In our healthy women the 
levels measured were slightly higher during pregnancy, but the CRP levels did 
not increase as pregnancy proceeded. In gynaecologists’ daily practice, CRP 
level is already a useful marker of inflammation and infection, and is starting to 
be used in high-risk obstetrics such as gestational diabetes and pre-eclampsia 
(20). The higher CRP level we found during pregnancy agrees nicely with the 
slightly higher mean CRP levels (0.45 mg/dL) in early pregnancy (4 weeks of 
gestation) determined in women who became pregnant after in vitro fertilization 
procedure, and with the lower levels (0.13 mg/dL) in women in whom the 
procedure had failed (15). The higher CRP levels during pregnancy resulted in 
a pregnancy-induced deviation of the DAS28 of +0.25, which therefore performs 
better than that of the ESR (deviation of +1.1). The DAS28-CRP might therefore 
be a more reliable tool for assessing RA during pregnancy. 
83
2.2 Measuring disease activity & functionality during pregnancy 
77 
 
Last, although the joint scores of the DAS28 have never been designed for use 
in non-RA patients, it is conceivable that pregnancy potentially results in a joint 
score due to oedema or to pain. Therefore, we performed joint counts in an 
additional 34 healthy pregnant women in different stages of pregnancy (7 in the 
first trimester, 10 in the second trimester, 17 in the third trimester). None of the 
examined women had swollen joints, and only 2 of them had 1 painful joint 
each. There was neither a correlation between oedema and the presence of 
painful or swollen joints nor between the stage of pregnancy and the presence 
of painful or swollen joints. Therefore, we are convinced that the sensitivity 
analyses performed without joint scores but with ESR or CRP level, and with or 
without a GH are still valid. 
 
In total, of the 4 DAS28 formulas, the DAS28-CRP calculated without GH was 
shown by the sensitivity analysis to be the least influenced by pregnancy itself. 
Therefore, this might be the best tool for scoring disease activity during 
pregnancy. Patients in their third trimester of pregnancy were categorized into 
different disease activity groups according to their DAS28-CRP score. DAS28-
CRP calculated without GH showed the highest percentage of patients in 
clinical remission. The use of DAS28-CRP may still result in some 
overestimation of disease activity because CRP level is elevated during 
pregnancy compared with non-pregnancy, and therefore it may result in an 
underestimation of the percentage in clinical remission. Because a gold 
standard is not available to measure either the quantity of this underestimation 
or the percentage of misclassification that occurred, we suggest that pregnant 
patients with RA are best categorized according to their level of disease activity 
measured by DAS28-CRP without GH. This is important not only for research 
purposes but also for clinical practice in keeping an adequate control of disease 
activity. 
 
The median HAQ score of our pregnant patients with RA was 1.0 at the third 
trimester, and is comparable with the median HAQ score of 0.9 calculated at the 
third trimester of 140 pregnant patients with inflammatory arthritis prospectively 
studied by Barrett et al from late pregnancy to postpartum (5). At the third 
trimester, the patients in the study by Barrett et al. completed 2 HAQs, one 
pertaining to recalled disability before pregnancy and one to current disability. 
Their patients completed the HAQ at 4 and 26 weeks postpartum. However, 
their recalled disability before pregnancy was higher than all the HAQ scores 
prospectively measured. This pattern is very different from that of the HAQ we 
scored prospectively, which increased from the first trimester until the third 
trimester. The retrospective design of their study may have introduced recall 
bias. Postpartum, however, the median HAQ scores were again comparable: 
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our patients had a median score of 0.75 and their patients a median score of 
0.60 (5). 
 
In contrast to what we found, Ostensen et al noted no difference at all between 
HAQ scores measured during pregnancy in 10 prospectively studied 
pregnancies of patients with RA (8). However, in that study the disease activity 
of the patients decreased at the same time and therefore one should have 
expected an increase in functionality. Because this was not the case, an 
explanation may be that pregnancy had also contributed to stable instead of 
lower HAQ scores. 
 
Our results of the performance of the HAQ during pregnancy and results of 
former studies underline the arguments made by Nelson (16): the HAQ is not a 
good RA assessment tool during pregnancy. Therefore, we used different HAQ 
variants in an attempt to minimize the influence of healthy pregnancy on the 
HAQ. In healthy pregnant women, a pregnancy-induced increase in HAQ score 
was shown by all our variants that applied the HAQ scoring rules, such as the 2 
defined in the consensus meeting, and those made on the basis of items with a 
high number of marks (12,13). Despite this, the HAQ variants calculated without 
the 6 selected items generally performed best in this study. We have to 
conclude, however, that even this HAQ variant cannot preclude all influences of 
pregnancy on the assessment of functionality, and that each HAQ should 
therefore be used with great care during pregnancy. 
 
In conclusion, pregnancy has various degrees of influence when calculating 
disease activity by 4 different DAS28 formulas and scoring functionality with the 
HAQ and HAQ variants. During pregnancy, the DAS28-CRP may therefore be 
the best tool for calculating disease activity and the percentage of patients with 
RA in clinical remission. The best tool for measuring functionality may be the 
HAQ variant from which 6 selected items were omitted. 
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APPENDIX 2.2: 4 DAS28 FORMULAS 
DAS28 using ESR with 3 or 4 variables (10)  
DAS28-ESR-3 = [0.56xSQRT(t28) + 0.28xSQRT(sw28) + 0.70xLn(ESR)]x1.08 + 0.16 
DAS28-ESR-4 =  0.56xSQRT(t28) + 0.28xSQRT(sw28) + 0.70xLn(ESR) + 0.014xGH 
DAS28 using CRP with 3 or 4 variables (10) 
DAS28-CRP-3 = [0.56xSQRT(t28) + 0.28xSQRT(sw28) + 0.36xLn(CRP+1)] x 1.10 + 1.15 
DAS28-CRP-4 =  0.56xSQRT(t28) + 0.28xSQRT(sw28) + 0.36xLn(CRP+1)  + 0.014xGH + 0.96 
 
t28:  The number of tender joints of 28 joints examined for tenderness.  
sw28:  The number of swollen joints of the 28 joints examined for swollenness. 
28 joints: Twenty-eight tender and swollen joint scores include the same joints: shoulders, 
elbows, wrists, metacarpophalangeal joints, proximal interphalangeal joints and 
knees. 
ESR:  Westergren’s Erythrocyte Sedimentation Rate, entered in mm/hr. 
CRP:  C-reactive protein, entered in mg/L (instead of in mg/dL as shown in Figure 2.2.1). 
GH:   General Health rated on a 100mm Visual Analogue Scale. GH was rated on a line 
from 0 (very well) to 100 (very poor). 
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Objective. According to common knowledge and retrospective studies, 
approximately 75–90% of patients with rheumatoid arthritis (RA) will improve 
during pregnancy. Prospective data on disease activity during pregnancy are 
limited. Therefore, this study aimed to prospectively determine the disease 
activity during pregnancy in RA patients treated in an era of new treatment 
options. 
Methods. For 84 RA patients (American College of Rheumatology criteria), a 
Disease Activity Score in 28 joints (DAS28) and medication use were obtained, 
before conception if possible, at each trimester of pregnancy and at 6, 12, and 
26 weeks postpartum. Improvement and deterioration were determined by 
assessing changes in DAS28 and by applying the DAS28-derived European 
League Against Rheumatism (EULAR) response criteria. 
Results. Disease activity decreased with statistical significance (p = 0.035) 
during pregnancy and increased postpartum. In patients with at least moderate 
disease activity in the first trimester (n = 52), at least 48% had a moderate 
response during pregnancy according to EULAR-defined response criteria. In 
patients with low disease activity in the first trimester (n = 32), disease activity 
was stable during pregnancy. Thirty-nine percent of patients had at least a 
moderate flare postpartum according to reversed EULAR response criteria. 
Less medication was used during pregnancy compared with before conception 
and compared with postpartum. 
Conclusion. This study demonstrates that patients achieve remission during 
pregnancy and deteriorate postpartum, although less frequently than previously 
described. 
INTRODUCTION 
Disease activity in patients with rheumatoid arthritis (RA) decreases 
spontaneously during pregnancy and increases postpartum. These generalities 
concerning RA rely on previous retrospective studies, which have been largely 
based on women’s self-reports and doctors’ observations in an era of restricted 
treatment options. In the last 7 decades, a substantial number of pregnant 
patients with RA improved in those studies; however, this number declined over 
time from 90% to 53% (1). 
 
Until now, only 1 large, prospective study on this subject has been conducted 
from late pregnancy onward to 6 months postpartum (2). In retrospect, 63% of 
patients reported improvement in disease activity. At the third trimester, only 
16% were in total remission, which was defined as having no swollen joints and 
receiving no antirheumatic therapy at the time of measurement. That study had 
2 main disadvantages. First, objective information on disease activity was not 
available before conception or during early pregnancy. Second, no validated 
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scoring systems for disease activity and remission were used. In addition, new 
treatment options are now available to reduce disease activity before 
pregnancy, which was not the case with the previous study. 
 
For this reason, we conducted a prospective nationwide cohort study from 
preconception or early pregnancy onward. This study, the Pregnancy-induced 
Amelioration of Rheumatoid Arthritis (PARA) study, had 2 main aims. One aim 
was to measure disease activity in patients with RA using a validated instrument 
(Disease Activity Score in 28 joints (DAS28)). The second aim was to collect 
patients’ blood and urine samples to perform laboratory investigations into the 
underlying mechanisms of spontaneous improvement during pregnancy and 
relapse postpartum. 
 
Here we present the first data of this study regarding the following 3 objectives. 
The first objective was to calculate the percentages of women in remission 
during pregnancy and postpartum. The second objective was to prospectively 
measure whether disease activity decreases during pregnancy and increases 
postpartum. Disease activity and remission were defined according to the 
DAS28 with 3 variables: swollen joint count, tender joint count, and C-reactive 
protein (CRP) level (mg/liter) (DAS28-CRP-3). The third objective was to 
provide a clear description of what medication was used before, during, and 
after pregnancy. 
PATIENTS AND METHODS 
Patient population 
All rheumatologists working in The Netherlands were contacted by mail twice a 
year from the start of the study in May 2002 until November 2006. 
Rheumatologists were asked to recruit patients with RA who wanted to 
conceive or who were already pregnant (preferably in their first trimester). 
Patients were eligible for the study if they fulfilled the 1987 revised criteria of the 
American College of Rheumatology (ACR; formerly the American Rheumatism 
Association) for RA (3) and had a good understanding of the Dutch language. 
During the study, the patients’ own rheumatologists provided patient care. The 
present analysis used data from patients who had information available from 
prepregnancy or the first trimester to 26 weeks postpartum onward. Women 
who had a miscarriage in the first trimester or were pregnant with twins were not 
included. No woman was included twice. 
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Data collection 
Patients were visited 6 or 7 times at their home address. They were visited 
before conception (if possible), at each trimester (8–12 weeks of gestation, 18–
22 weeks, and 28–32 weeks), and 3 times postpartum (6 weeks, 12 weeks, and 
26 weeks). The visit before conception took place if the woman had a desire to 
conceive, i.e., she and her partner did not use any contraceptives. If a woman 
did not conceive within a year after the first visit, another visit took place. Data 
collected before conception were classed as “before pregnancy.” 
 
Medical and obstetric history were taken at the first visit by interview. Presence 
of rheumatoid factor (RF), antibodies to cyclic citrullinated peptide (anti-CCP), 
and erosions were ascertained from the patients’ medical records. The 
presence of anti-CCP, IgM-RF, IgG-RF, and IgA-RF in serum from the first visit 
was also determined. Presence of anti-CCP was determined with the EliA CCP 
test (Phadia AB, Uppsala, Sweden) and was defined as a serum level >10 
units/ml. Positivity for anti-CCP used in the analyses was defined as “ever 
recorded positive” in the medical records or “tested positive at first visit.” A 
positive IgM-RF, IgG-RF, or IgA-RF (Hycor Biomedical, Garden Grove, CA) was 
defined as a serum level higher than the level at which less than 5% of healthy 
controls tested positive in these tests. Presence of RF was defined as “ever 
recorded positive” in the medical records or “tested positive at first visit.” 
 
Current medication use was recorded and percentages of use and median daily 
doses of medication were calculated per time point. At each visit, women 
provided information about their current pregnancy, and postpartum they 
provided information on whether or not their newborn was breastfed. 
 
A research physician or research nurse performed a standardized 28-joint count 
for swelling and pain. Joint examinations were performed for pain and swelling 
as recommended by the European League Against Rheumatism (EULAR) 
Standing Committee for International Clinical Studies Including Therapeutic 
Trials (ESCISIT) (4).CRP levels were measured in serum by Tina-quant CRP 
(Roche Diagnostic, Mannheim, Germany). 
 
Disease activity was objectively scored using the DAS28-CRP-3 (5). In a 
previous study, we demonstrated that disease activity can be measured the 
most reliably during pregnancy with the DAS28-CRP-3 (6), because erythrocyte 
sedimentation rate increases physiologically during pregnancy. 
Data and statistical analysis. 
For all patients, the mean disease activity scores were calculated at the time 
points indicated. The mean individual difference between DAS28 at the first and 
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third trimesters was calculated. According to the EULAR criteria, remission was 
defined as a DAS28 < 2.6 (7). 
 
Improvement in disease activity between the first and third trimesters was 
defined, according to the EULAR response criteria, as good, moderate, or no 
responders as defined by ESCISIT (Appendix 3.1.A) (6). Because the baseline 
requirement for the EULAR response criteria is that patients have an initial 
DAS28 of at least 3.2, 2 subgroups of patients were created, 1 with patients 
with moderate to high disease activity (DAS28  3.2) and 1 with patients with 
low disease activity (DAS28 < 3.2) in the first trimester. The prerequisite of an 
initial DAS28  3.2 for application of the EULAR response criteria meant that 
only those patients with a DAS28  3.2 in the first trimester could be classified 
as good, moderate, or no responder (4,7). 
 
Because no classification for deterioration is available yet, we defined flares in 
disease activity between 6 weeks and 12 or 26 weeks postpartum as severe or 
moderate based upon “reversed” EULAR response criteria for disease activity 
(see Appendix 3.1.B). This classification was applied to all patients; there was 
no baseline DAS28 requirement. Finally, the mean individual difference 
between DAS28 at 6 weeks and 12 or 26 weeks postpartum was calculated. 
 
The proportions of women in clinical remission and the proportions with low, 
moderate, or high disease activity before pregnancy, during pregnancy, and 
postpartum were calculated. The proportions of women in remission were 
analyzed by generalized estimating equations with an exchangeable correlation 
structure. This takes into consideration whether patients are already in 
remission and stay in remission, or whether other patients go into remission. 
 
All time points during and after pregnancy were used to measure changes in 
DAS28 over time in a linear mixed model with unstructured covariance. This 
model considers random variation within individuals and random variation 
between individuals. In subgroup analyses, the disease course of patients with 
or without RF, anti-CCP, joint erosions, or biologic agent use prior to their desire 
to conceive was determined. A likelihood ratio test was used to test the 
differences in disease course between the different subgroups. A 2-sided p < 
0.05 was considered statistically significant. SPSS for Windows (SPSS, 
Chicago, IL) version 12.0 was used. 
Ethics 
This study is in compliance with the Declaration of Helsinki, and the ethical 
committee at the Erasmus MC, University Medical Center Rotterdam, 
Rotterdam, The Netherlands approved this study. 
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RESULTS 
Patient recruitment data 
Up to November 2006, 346 patients were recruited by rheumatologists. Of 
these, 276 were eligible; however, 111 were not yet pregnant. As shown in 
Figure 3.1.1, we obtained a complete disease activity data set of 84 
pregnancies from the first trimester to 26 weeks postpartum. A detailed 
description of disease activity, medication, and demographics of these patients 
is provided. Data from 41 pregnancies were available from before pregnancy. 
Demographics 
The cohort consisted of patients with RA with a median disease duration of 4.8 
years (range 0.1 - 28.6 years) at first visit. This range can be explained by 11 
women who had a desire to conceive within 1 year after diagnosis, and by 7 
women who had polyarthritis in childhood that developed into an RF-positive 
and erosive disease that could be classified as RA. RF was positive in 71% of 
patients and anti-CCP was positive in 68% (Table 3.1.1). Whether or not 
patients were erosive was documented in 74 pregnancies; of these, 53 (72%) 
were erosive. Almost half of the pregnancies were first-time pregnancies. Only 3 
pregnancies occurred in non-white women (2 Asian, 1 African). Postpartum, 
67% of the babies were breastfed, 49% for longer than 6 weeks. 
Table 3.1.1. Clinical and demographic features of 84 rheumatoid arthritis patients and their 
pregnancies (n = 84)* 
Baseline characteristics  
Age at delivery, mean ± SD years 
Disease duration at first visit, 
            median (range) years 
RF present 
Anti-CCP present 
Erosions present 
First-time pregnancies 
31.9 ± 3.3 
 
4.8 (0.1-28.6) 
60 (71) 
57 (68) 
53 (72)† 
41 (49) 
* Values are the number (percentage) unless otherwise indicated. RF = rheumatoid factor; anti-
CCP = anti-cyclic citrullinated peptide antibodies. † Only data for 74 patients were available for 
this analysis. 
Evaluation of disease activity 
Percentages in remission 
The total number of patients in remission (DAS28 < 2.6) increased during 
pregnancy from 17% in the first trimester to 27% in the third trimester  (p = 
0.16), and decreased to 18% in the 12th week postpartum (p = 0.07) (Figure 
3.1.2). The number of patients in remission increased, despite the remarkable 
changes in medication use that took place (Table 3.1.2). The percentage of 
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patients who received methotrexate < 1 year before conception (28%) was 
reduced to 0% during pregnancy, and the percentage of patients who received 
non-steroidal anti-inflammatory drugs (NSAIDs) before conception (32%) was 
reduced to 4% during pregnancy (data not shown in Table 3.1.2). The total 
number of patients with low disease activity (DAS28 2.6 - 3.2) remained stable  
 Women with RA recruited by 
rheumatologists between  
May 2002 and November 2006 
 
n = 346 
 
Invited to participate in study 
 
n = 276 
Not invited to participate (Total = 70) 
 
Missed invitation           n =  12 
Declined to be invited   n =  28 
Excluded for invitation *  n =  30 
 
Eligible for present analyses 
 
n = 100 
Invited to participate but not eligible 
for present analyses   (Total = 176) 
 
Did not become pregnant during 
follow-up period   n =  111 
Miscarriage    n =      24 
First visit > 12 wk of pregnancy  n =      26 
Lost to Follow up ( 1 visit) n =       12 
Participated twice   n =         2 
Twin pregnancy   n =          1 
Data available for analyses  
 
 
Disease activity (DAS28) n =    84 
Excluded for present analyses  
 
No DAS28 score at least at one visit † n = 16 
Figure 3.1.1. Flow diagram of the Pregnancy-induced Amelioration of Rheumatoid Arthritis
(PARA) study. Patients recruited and final number of patients eligible for the present analyses
are shown. * = Excluded for invitation: did not fulfill American College of Rheumatology criteria,
did not speak Dutch language. † = Disease Activity Score in 28 joints (DAS28) could not be
calculated because either C-reactive protein level or number of swollen or painful joints was
missing. RA = rheumatoid arthritis; wk = week. 
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Table 3.1.2: Disease-modifying antirheumatic drug and biologic agent use before pregnancy, 
during pregnancy, and postpartum* 
U
se
d 
at
 2
6 
w
k 
P
P
 a
nd
 u
se
d 
< 
1 
ye
ar
 b
ef
or
e 
co
nc
ep
tio
n 
n/
N
 (%
)‡
 
16
/2
4 
(6
6)
 
28
/4
1 
(6
8)
 
17
/2
2 
(7
7)
 
   
0/
1 
 (0
) 
   
1/
2 
 (5
0)
 
   
2/
6 
 (3
3)
 
   
N
/A
 
26
 w
k 
PP
 
n 
= 
84
 
n 
(%
) 
26
 (3
1)
 
31
 (3
7)
 
33
 (4
0)
  
  1
 ( 
1)
 
 3
 ( 
4)
 
 9
 (1
1)
 
13
 (1
5)
 
12
 w
k 
PP
 
n 
= 
84
 
n 
(%
) 
29
 (3
5)
 
31
 (3
7)
 
 2
8 
33
)  
 1
  (
 1
) 
  5
 (6
)  
  8
 (1
0)
 
17
 (2
0)
 
6 
w
k 
PP
  
n 
= 
84
 
n 
(%
) 
29
 (3
5)
 
27
 (3
2)
 
20
 (2
4)
  
  0
  (
 0
) 
  2
  (
 2
) 
  4
 ( 
 5
) 
27
 (3
2)
 
3r
d   
tri
m
 
n 
= 
84
 
n 
(%
) 
29
 (3
5)
 
28
 (3
3)
 
0 
   
( 0
) 
  0
  (
 0
)  
  2
  (
 2
) 
 0
  (
 0
)  
29
 (3
5)
 
2n
d   
tri
m
 
n 
= 
84
 
n 
(%
) 
30
 (3
6)
 
28
 (3
3)
 
  0
  (
 0
) 
  0
  (
 0
)  
  3
 ( 
 4
) 
 0
  (
 0
)  
29
 (3
5)
 
1s
t   
tri
m
 
n 
= 
84
 
n 
(%
) 
30
 (3
6)
 
26
 (3
1)
 
  0
  (
 0
) 
  0
  (
 0
)  
  2
  (
 2
) 
  0
  (
 0
)  
22
 (2
6)
 
B
ef
or
e 
pr
eg
na
nc
y 
n 
= 
41
 †
 
n 
(%
) 
16
 (3
9)
 
17
 (4
1)
 
  0
  (
 0
) 
  0
  (
 0
)  
  2
  (
 5
) 
  0
  (
 0
) 
  7
 (1
7)
 
U
se
d 
< 
1 
ye
ar
 b
ef
or
e 
co
nc
ep
tio
n 
n 
= 
84
 
n 
(%
) 
24
 (2
8)
 
41
 (4
9)
 
22
 (2
8)
 §
 
   
1 
(1
) 
   
9 
(1
1)
 
   
6 
(7
) 
N
/A
 
E
ve
r 
us
ed
 
n 
= 
84
 
n(
%
) 
33
 (3
9)
 
65
 (7
7)
 
46
 (5
5)
 
4 
  (
5)
 
31
 (3
7)
 
10
 (1
2)
 
N
/A
  
M
ed
ic
at
io
n 
pr
ed
ni
so
ne
 (o
ra
l) 
su
lfa
sa
la
zi
ne
 
m
et
ho
tre
xa
te
 
le
flu
no
m
id
e 
hy
dr
ox
yc
hl
or
oq
ui
ne
 
bi
ol
og
ic
al
s 
no
 m
ed
ic
at
io
n 
* 
V
al
ue
s 
ar
e 
th
e 
nu
m
be
r 
(p
er
ce
nt
ag
e)
 o
r 
nu
m
be
r/t
ot
al
 n
um
be
r 
(p
er
ce
nt
ag
e)
. 
Tr
im
. 
= 
tri
m
es
te
r; 
w
ks
 =
 w
ee
ks
; 
P
P
 =
 p
os
tp
ar
tu
m
; 
N
/A
 =
 n
ot
 
av
ai
la
bl
e.
 †
 T
hi
s 
gr
ou
p 
on
ly
 in
cl
ud
es
 p
at
ie
nt
s 
w
ho
 w
er
e 
vi
si
te
d 
be
fo
re
 c
on
ce
pt
io
n.
 ‡
 N
um
be
r 
(p
er
ce
nt
ag
e)
 o
f 
pa
tie
nt
s 
w
ho
 u
se
d 
th
e 
sa
m
e
m
ed
ic
at
io
n 
26
 w
ee
ks
 p
os
tp
ar
tu
m
 <
 1
 y
ea
r 
be
fo
re
 c
on
ce
pt
io
n.
 §
 I
n 
5 
pa
tie
nt
s,
 t
he
 e
xa
ct
 c
es
sa
tio
n 
da
te
 w
as
 m
is
si
ng
 (
n 
= 
79
). 
N
o 
de
ta
ile
d 
in
fo
rm
at
io
n 
w
as
 p
re
se
nt
 o
n 
w
he
th
er
 p
at
ie
nt
s 
w
er
e 
of
f m
ed
ic
at
io
n 
du
rin
g 
a 
ce
rta
in
 ti
m
e 
pe
rio
d.
 
 
99
3.1 Disease activity of RA during pregnancy  
93 
between the first and third trimesters, but decreased postpartum. Almost half of 
the patients had at least low disease activity in the third trimester (Figure 3.1.2).  
The total number of patients with moderate disease activity (DAS28 3.2 - 5.1) 
decreased during pregnancy, while the total number of patients (n = 10) with 
high disease activity (DAS28 > 5.1) remained stable during pregnancy. 
Changes in disease activity according to DAS28  
Altogether, mean disease activity scores decreased during pregnancy and 
increased postpartum (n = 84; p = 0.035) (Figure 3.1.3). The impact of 
pregnancy on disease activity in the third trimester was most pronounced in 
patients who had moderate to high disease activity in the first trimester (mean ± 
SD = 0.54 ± 0.92 (n = 52), DAS28 4.4 - 3.9; p < 0.001) compared with those 
with a low disease activity in the first trimester (mean ± SD = 0.23 ± 0.92 (n = 
32), DAS28 2.5 - 2.7; p = 0.21). The mean DAS28 increased from 6 weeks to 
12 weeks postpartum by 0.30 (95% confidence interval (CI) [0.07;0.48], p = 
0.01) from 3.5 to 3.8. In subgroup analyses, the presence of anti-CCP, RF, and 
erosions did not alter the course of disease activity during pregnancy and 
postpartum (likelihood ratio tests: p = 0.91, p = 0.98, and p = 0.98, respectively). 
Biologic agents were used in 6 patients < 1 year prior to conception. Because of 
the small number, no valid statistical analyses could be performed. 
 
The analysis of patients who were visited before pregnancy (n = 41) showed 
that the mean disease activity before pregnancy decreased in the third trimester 
by 0.4 (95% CI [-0.6;-0.03], p = 0.03) from 3.8 to 3.4. The change in DAS28 
from before pregnancy to first trimester was not statistically significant in these 
patients (mean -0.08 (95% CI [-0.3;0.2]; p = 0.61). The change in DAS28 from 
Figure 3.1.2. The percentages of patients grouped, according to Disease Activity Score in 28 
joints (DAS28) during pregnancy and postpartum, into remission (DAS28 < 2.6), low disease 
activity (DAS28 2.6 - 3.2), moderate disease activity (DAS28 3.2 - 5.1), and high disease activity 
(DAS28 > 5.1). RA = rheumatoid arthritis; trim = trimester; wk = weeks; PP = postpartum. 
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before pregnancy to 26 weeks postpartum was not statistically significant (mean 
-0.22 (95% CI [-0.5;0.1]; p = 0.13). 
Changes in disease activity according to DAS28-derived EULAR response 
criteria 
Patients who fulfilled the prerequisite for application of EULAR response 
criteria, namely, those with a DAS28 > 3.2 in the first trimester (n = 52), were 
classified as good, moderate, and no responders. This analysis showed that 
48% of these patients had at least a moderate response during pregnancy 
(Table 3.1.3). 
 
Of the 6 patients who received biologic agents < 1 year before conception, all 
had moderate to high disease activity in the first trimester. Similar to the total 
group (n = 52), 50% had at least a moderate response during pregnancy 
according to EULAR response criteria and 50% had no response. 
 
 
1.5 
2
2.5 
3
3.5 
4
4.5 
5 
5.5 
1st trim 2nd trim 3rd trim 6 wk PP 12 wk PP 26 wk PP
 T1 DAS28-CRP-3 > 3.2 (n=52)    T1 DAS28-CRP-3  3.2 (n=32) Total (n=84)
D
A
S2
8-
C
R
P-
3 
Figure 3.1.3 Disease Activity Score in 28 joints (DAS28) measured with swollen joint count, 
tender joint count, and C-reactive protein level (DAS28-CRP-3) during and after pregnancy 
presented as means and 95% confidence intervals. Trim = trimester; wk = weeks; PP = 
postpartum. 
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Table 3.1.3. Improvement during pregnancy according to the EULAR response criteria, and 
therefore restricted to patients with moderate disease activity (DAS28 > 3.2) in the first trimester 
(n = 52)* 
Classification (EULAR criteria) 
between first and third trimester 
DAS28 > 3.2 
at first trimester 
Good response 
Moderate response 
No response 
9 (17.3) 
16 (30.8) 
27 (51.9) 
* Values are the number (percentage). EULAR = European League Against Rheumatism; 
DAS28 = Disease Activity Score in 28 joints. 
Postpartum, RA deteriorated according to the “reversed” EULAR response 
criteria in 39.3% of all 84 patients (Table 3.1.4). Of the patients with moderate to 
high disease activity (DAS28 > 3.2) in the first trimester, 2 (3.8%) patients had a 
severe flare of RA postpartum, 17 (32.7%) patients had at least a moderate 
flare, and 33 (63.5%) patients had no flare. Of the patients with low disease 
activity (DAS28 > 3.2) in the first trimester, 1 (3.1%) patient had a severe flare 
of RA postpartum, 13 (40.6%) patients had at least a moderate flare, and 18 
(56.3%) patients had no flare. 
Table 3.1.4. Deterioration postpartum according to reversed EULAR response criteria between 
6 weeks postpartum and 12 or 26 weeks postpartum, shown for all patients (n = 84)* 
Classification (reversed EULAR criteria) All patients  
Severe flare 
Moderate flare 
No flare 
3 (3.6) 
30 (35.7) 
51 (60.7) 
* Values are the number (percentage). EULAR = European League Against Rheumatism. 
CRP levels during pregnancy 
During pregnancy, mean ± SD CRP levels decreased from 16.2 ± 15.1 mg/liter 
in the first trimester to 14.2 ± 15.1 mg/liter in the third trimester (not significant). 
Mean CRP levels increased from 11.3 ± 13.3 mg/liter at 6 weeks postpartum to 
14.8 ± 25.1 mg/liter at 12 weeks postpartum, and decreased to 11.5 ± 13.1 
mg/liter at 26 weeks postpartum. These differences were not statistically 
significant. 
Evaluation of medication use 
In Table 3.1.2, the percentages of disease-modifying antirheumatic drug 
(DMARD) use are categorized into ever used, used < 1 year before conception, 
before conception, during pregnancy, and postpartum. The medication used 
during conception is represented by the columns before pregnancy (n = 41) and 
first trimester (n = 84). The last column shows the percentage of women who 
were taking the same medication at 26 weeks postpartum as they were taking 
at < 1 year before conception. 
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Very few patients changed from one drug to another during pregnancy. The 
median daily dosage of prednisone was 7.5 mg (range 0.5 - 20 mg) before 
conception and did not change throughout pregnancy. The median daily dosage 
of prednisone increased to 10 mg (range 0.5 - 20 mg) at 6 weeks postpartum 
and decreased to 7.5 mg (range 0.5 - 20 mg) at 12 and 26 weeks postpartum. 
The median daily dosage of sulfasalazine was 2,000 mg (range 500 - 4,000 mg) 
at all time points. 
 
Biologic agents were prescribed before conception in 10 patients. Six patients 
received biologic agents < 1 year before conception; of these, 2 patients 
restarted biologic agents postpartum. None of the patients received a 
combination of biologic agents, prednisone, and methotrexate < 1 year before 
conception. 
 
Except for DMARDs and biologic agents, NSAIDs were used during pregnancy 
in 4% of patients, while up to 33% of patients needed them for pain relief 
postpartum. Acetaminophen was used in only 5 - 10% of patients for pain relief 
throughout pregnancy and postpartum. 
DISCUSSION 
The assumption of rheumatologists, based on previous studies, that almost all 
patients with RA will experience a remission of disease activity during 
pregnancy does not seem to be valid today. In this nationwide, prospective 
study, approximately one-quarter of women were in remission in the third 
trimester, despite the fact that medication use was remarkably reduced during 
pregnancy compared with before conception. The mean disease activity scores 
decreased during pregnancy and increased postpartum, and after applying 
EULAR-defined response criteria, almost half of the women had at least a 
moderate response during pregnancy and more than one-third had at least a 
moderate flare postpartum. The postpartum flare may be underestimated 
because medication use was remarkably increased after delivery. 
 
This is the first study to use the DAS28 as a validated disease activity score to 
measure disease activity during pregnancy. Therefore, any comparison with 
previous studies can only be made indirectly. In the present study, 48% of 
patients who had at least moderate disease activity (DAS28 > 3.2) in the first 
trimester had an improvement in disease activity during pregnancy. Only one 
large prospective study has been performed for comparison. In that study, 
performed by Barrett et al, 140 participants were scored for joint pain and 
swelling in the third trimester and 1 month and 6 months postpartum (2).  
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Improvement in RA during pregnancy, however, was recorded retrospectively 
by self-report. In that study, 65% of the patients retrospectively reported an 
improvement in pain and swelling compared with before pregnancy. In addition, 
a combination of smaller prospective studies (a total of 66 pregnancies) showed 
improvement in disease activity in approximately two-thirds of pregnancies (8-
12). That improvement was measured either by Camp index or by tender and 
swollen joint scores that were rated between 0 and 3 (8-12). Three of these 
studies selected patients with moderate to high levels of disease activity prior to 
pregnancy (9,10,12). In our study, changes in disease activity were also 
measured subjectively by means of a 3-point Likert scale (improved, stable, or 
deteriorated) between each visit (data not shown). A total of 77% of women 
reported an improvement at 1 visit, at least, during pregnancy. A difference in 
outcome between measuring disease activity by DAS28 or patient self-report 
might also be explained by the fact that in the latter method, patients may also 
take into consideration their decreased use of medication during pregnancy. 
 
In this study, 27% of patients were in remission in the third trimester according 
to the DAS28. This is comparable with the percentages of remission shown in 
previous studies in which other definitions were used. Barrett et al (2), in a 
manner quite similar to Nelson et al (9), defined remission as using no 
antirheumatic drugs and having no painful and no swollen joints. In these 2 
studies, 16% and 39% of patients, respectively, were in remission in the third 
trimester. In our study, women had no swollen and no painful joints in the third 
trimester in 14% of pregnancies, and in only 8% of all pregnancies, no 
antirheumatic drugs were used. 
 
In the present study, deterioration of RA postpartum was present in at least 
39% of all patients with at least a moderate flare according to reversed EULAR 
response criteria. At least 53% of our patients noted a deterioration on the Likert 
scale at 12 weeks postpartum compared with 6 weeks postpartum. Barrett et al 
demonstrated that 62% had more affected joints postpartum, and in ~70% of 
their patients, a deterioration in disease activity was self-reported at 1 and 6 
months postpartum (2). In addition, Barrett et al showed that the median 
number of affected joints significantly increased from 8 during pregnancy to 10 
joints at 6 months postpartum. At the same time, in 50% of those patients, 
treatment was increased postpartum. In our study, methotrexate and biologic 
agents were added to the prednisone or sulfasalazine therapy in 40% and 11% 
of patients, respectively, for adequate disease control postpartum. 
 
The differences in improvement rates during pregnancy and relapse rates 
postpartum can therefore be explained by various factors. First, subjective 
measurements seem to show higher percentages of improvement and 
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deterioration than the objective measurements of disease activity used in this 
study. Second, in many previous studies, only patients with active disease 
before pregnancy entered the study. In the present study, all women with RA 
entered, and a higher percentage of improvement was shown in women with 
RA with higher disease activity in the first trimester. Finally, as a consequence 
of better treatment options, the percentages of improvement and deterioration 
may also be lower today than previously described, because patients may have 
lower disease activity before pregnancy compared with previous studies and 
are treated more aggressively postpartum. 
 
Before conception, medication use in patients was remarkably reduced because 
most DMARDs are contraindicated during pregnancy. Despite this reduction, a 
decrease in disease activity was still observed, therefore the observed decrease 
in disease activity during pregnancy must be considered as a consequence of 
the beneficial effect of pregnancy itself. Another argument that supports the 
proposal that pregnancy itself has a beneficial effect on disease activity is that 
treatment of RA during pregnancy was almost completely restricted to 
sulfasalazine and low-dose prednisone, and it is known that this combination 
alone is insufficient to induce remission in patients with RA (13). 
 
For daily clinical practice in rheumatology, this study demonstrated that neither 
presence of RF, as in the study by Barrett et al (2), nor presence of erosions or 
anti-CCP was associated with improvement during pregnancy or postpartum 
flare. The levels of RF and anti-CCP in the PARA study were stable during 
pregnancy until 6 weeks postpartum; only IgM-RF decreased postpartum when 
treatment was resumed (14). It has previously been suggested that postpartum 
flare is associated with the cessation of nursing. This assumption, however, 
could not be tested in the present study because patients have to stop nursing 
in order to restart treatment when they flare. Furthermore, this study gives 
rheumatologists additional evidence that patients with low disease activity 
before pregnancy remain relatively stable, whereas patients with moderate to 
high disease activity will improve the most. 
 
Up until now, various studies have been undertaken to explain the beneficial 
effect of pregnancy in RA and many hypotheses have been formulated. 
Nevertheless, the exact reason is still unknown. Suppression of the immune 
system by HLA incompatibility between mother and child has been shown to be 
associated with a favourable disease course (9). In addition, biochemical 
changes such as elevation of Į2-glycoprotein levels during pregnancy (11) and 
an increase in IgG glycosylation (10) were related to the improvement of 
disease activity. Finally, as is still hypothesized, a shift in T cell function from a 
Th1 phenotype to a Th2 may be important (15). The PARA study will provide 
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excellent opportunities for future laboratory studies on autoantibodies and 
immune regulation during pregnancy and for epidemiologic investigations of 
pregnancy outcome related to disease activity during pregnancy. 
 
Finally, the PARA study has some limitations. First, the analyses were restricted 
to women (n = 84) with a complete data set, because medication use could not 
otherwise be clearly and correctly interpreted. The missing data were, however, 
completely random, and when the analyses were repeated including all eligible 
women (n = 100), similar results were obtained. Second, the present analysis 
was restricted to all data of singleton pregnancies because twin pregnancies 
result in more physical problems. Third, pregnancy outcome was self-reported; 
however, this method was verified with medical charts and was found to be 
valid and accurate for all data reported (16). 
 
In conclusion, this study demonstrates that during pregnancy, patients go into 
remission and deteriorate postpartum, although less frequently than previously 
described. 
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APPENDIX 3.1 
A. EULAR response criteria for the definition of improvement during pregnancy (6). 
 
Decrease of DAS28 1st trimester with 
DAS28 at 3rd trimester > 1.2 > 0.6 AND  1.2  0.6 
 3.2 Good response Moderate response No response 
> 3.2 AND  5.1 Moderate response Moderate response No response 
> 5.1 Moderate response No response No response 
B. ‘Reversed’ EULAR response criteria for the definition of deterioration postpartum. 
 
Increase of DAS28 6 weeks postpartum with DAS28 at 12 or 26 weeks 
postpartum > 1.2 > 0.6 AND  1.2  0.6 
> 5.1 Severe flare Moderate flare No flare 
> 3.2 AND  5.1 Moderate flare Moderate flare No flare 
 3.2 Moderate flare No flare No flare 
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AUTOANTIBODIES 
DURING 
PREGNANCY AND 
POSTPARTUM 
“Women with rheumatoid arthritis  
negative for anti-CCP and rheumatoid factor  
are more likely to improve during pregnancy, whereas 
in autoantibody positive women autoantibody levels  
are not influenced by pregnancy.” 
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Objectives. To determine whether changes in levels of anti-cyclic citrullinated 
peptide (anti-CCP) and rheumatoid factor (RF) are associated with the 
spontaneous improvement of rheumatoid arthritis (RA) during pregnancy and 
with the subsequent flare postpartum. 
Methods. Disease activity scores from the Pregnancy-induced Amelioration of 
Rheumatoid Arthritis (PARA)-study of 118 patients were available for analysis. 
Before conception (if applicable), at each trimester and at 6, 12 and 26 weeks 
postpartum levels of the autoantibodies anti-CCP, IgM-RF, IgG-RF and IgA-RF 
were determined. Responses in disease activity were classified according 
EULAR response criteria during pregnancy and postpartum, and associated 
with the presence or absence of autoantibodies. 
Results. The median levels of anti-CCP and all subclasses of RF during 
pregnancy were stable, whereas postpartum the levels of anti-CCP, IgM-RF 
and IgA-RF declined. A significantly higher percentage of women without 
autoantibodies (both anti-CCP and RF negative) improved compared with 
women positive for either or both autoantibodies (75% vs 39%, p = 0.01). The 
occurrence of a flare postpartum was comparable between these groups. 
Conclusions. Improvement of disease activity of RA during pregnancy was not 
associated with changes in levels of autoantibodies during pregnancy, however, 
improvement may occur more frequently in the absence of anti-CCP and RF. 
INTRODUCTION 
Pregnancy is the only natural situation where improvement of rheumatoid 
arthritis (RA) occurs and flares after delivery (1). However, the aetiology of this 
spontaneous improvement of RA during pregnancy and that of the flare 
postpartum is still unknown (1-5). Insight into this mechanism may enlarge our 
knowledge on pregnancy-induced remission and also contributes to a better 
understanding of pathogenic mechanism RA in general. 
 
Evidence for a role of the B cell and autoantibodies in the pathogenesis of RA is 
accumulating (6-7). Anti-cyclic citrullinated peptide autoantibodies (anti-CCP) 
and rheumatoid factor (RF) are not only important in diagnosing RA (8,9) and in 
the prediction of severity of the disease (10,11), but are also thought to play an 
important role in the pathophysiology of this disease (12). Other evidence in 
support of B cells is derived from clinical studies demonstrating improvement of 
disease activity upon treatment with B-cell targeted therapies (13). However, 
whether changes in B-cell function, as reflected in levels of anti-CCP and RF 
during pregnancy and postpartum, are associated with improvement of RA 
during pregnancy or with the flare after delivery is not known. 
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The two aims of the present study, therefore are (I) to determine whether 
changes in levels of anti-CCP and RF can be associated with the spontaneous 
improvement of rheumatoid arthritis (RA) during pregnancy, or with the 
subsequent flare postpartum, and (II) to determine whether presence or 
absence of autoantibodies is associated with the disease course of RA patients 
during pregnancy. 
PATIENTS AND METHODS 
Patient population 
The current study is embedded in the PARA-study, and has been described 
previously in detail (14). Briefly, all rheumatologists working in the Netherlands 
were asked to recruit patients with RA, according to the 1987 revised ACR 
criteria, who had a wish to conceive or who were already pregnant (preferably in 
their first trimester) (8). During the study the patient’s own rheumatologists 
provided patient care. For present analysis data were collected between May, 
2002, till November, 2006. Only data of women were used, that were available 
from before pregnancy or first trimester till 26 weeks postpartum onwards. 
Women who had a miscarriage in the first trimester were not included. No 
woman was included twice. 
Data collection 
Patients were visited at home, they were visited before conception 
(prepregnancy), at each trimester (8-12, 20, and 30 weeks of gestation) and 
three times postpartum (6, 12, and 26 weeks). The visit prepregnancy took 
place if a woman had a wish to conceive, when she did not conceive within a 
year after this visit, another visit prior to pregnancy took place. At each visit 
serum was stored for determination of autoantibodies and disease activity was 
measured. Presence of anti-CCP, RF, and erosions were ascertained from 
patient’s medical records. 
Determination of anti-CCP and RF (IgM, IgG and IgA) 
In all sera the levels of anti-CCP antibodies were measured with the 
ImmunoCAP EliATM CCP test (Phadia AB, Uppsala, Sweden) as routinely used 
in our diagnostic laboratory. The test was performed according to the 
manufacturer’s instructions. As defined by the manufacturer a positive anti-CCP 
antibody level was defined as a concentration of anti-CCP antibodies above 10 
U/ml. The levels of IgM-RF, IgG-RF and IgA-RF in the sera were all measured 
by ELISA (HYCOR Biomedical, Inc, California, USA). The cut-off levels were 
determined in our laboratory by using the sera of 100 healthy voluntary blood 
bank donors. For each subclass of RF, the level above which only 5% of 
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healthy controls were tested as positive was defined as the cut-off level. A 
positive RF was defined in present study as a level above the cut-off level: IgM-
RF > 24 IU/mL, IgG-RF > 40 IU/mL, and IgA-RF > 30 IU/mL. 
Determination of disease activity 
A research physician or research nurse performed a standardized joint count of 
28 joints for swelling and pain as recommended by the EULAR Standing 
Committee for International Clinical Studies Including Therapeutic Trials 
(ESCISIT) (15). C-reactive protein (CRP) levels were measured in serum by 
Tina-quant® CRP (Roche Diagnostic GmbH, Mannheim, Germany). 
As described previously, disease activity was calculated using a Disease 
Activity Score of 28 joints (DAS28) with three variables, consisting of a swollen 
joint count, a tender joint count and a CRP level (mg/L) (DAS28-CRP-3) 
(16,17). 
Data analysis  
Levels of autoantibodies during pregnancy and postpartum 
To determine whether autoantibody levels changed during pregnancy and after 
delivery only data of those women were used that were classified as positive for 
the presence of that autoantibody. Patients were classified as positive either 
when the presence of an autoantibody was reported in medical records, or 
when the autoantibody was tested positive at first visit. All other patients were 
classified as negative. Levels of autoantibodies are expressed as median ± 
interquartile range (IQR). 
 
To determine whether changes in autoantibody levels were associated with 
improvement of RA during pregnancy and with the flare after delivery, patients 
were classified for their clinical response during and after pregnancy. 
 
For classification during pregnancy, improvement of disease activity between 
the first and third trimesters was defined according to the EULAR response 
criteria as ‘good’, ‘moderate’ or ‘no’ responders as defined by the ESCISIT (see 
Appendix 3.2.A) (15,16). Since the baseline requirement for the EULAR 
response criteria is that patients have an initial DAS28 of at least 3.2, analyses 
could be performed on a subgroup of patients. Differences in anti-CCP, IgM-RF, 
IgG-RF, and IgA-RF levels were calculated between the first and third 
trimesters and compared between ‘responders’ (‘good’ and ‘moderate’ 
responders combined), and ‘no responders’. 
 
For classification postpartum, flare of disease activity between 6 weeks and 12 
weeks, as well as between 6 weeks and 26 weeks was defined according to the  
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‘reversed’ EULAR response criteria of disease activity of RA, as described 
previously (14). These reversed EULAR response criteria classify a flare as 
‘severe’, ‘moderate’ or ‘no’ flare. Also for this analysis patients were categorized 
as having a ‘flare’ (severe and moderate flare combined) or ‘no flare’ 
postpartum (see Appendix 3.2.B). This classification for flares postpartum was 
applied to all patients; there was no baseline DAS28 requirement. The 
differences in levels of anti-CCP, IgM-RF, IgG-RF and IgA-RF were calculated 
between 12 and 6 weeks postpartum and between 26 and 6 weeks postpartum. 
The largest change in each autoantibody level postpartum was associated with 
the disease course postpartum. 
Disease course during pregnancy and postpartum and presence of 
autoantibodies 
Changes in disease course during pregnancy and postpartum were determined 
in women who were classified according to the presence of autoantibodies: 
‘both negative’, ‘either anti-CCP or RF positive’, and ‘both positive’. 
Subsequently it was determined whether the percentages of women who 
improved during pregnancy and who flared postpartum, were different in these 
defined groups. 
Statistical analysis 
Changes in autoantibody levels within patients between different time points 
were tested for significance by Wilcoxon’s test. 
 
Mann-Whitney-U test was used to test for significance the differences in 
changes in autoantibody levels between different subgroups of patients. 
 
The significance of the association between achievement of clinical 
improvement, or the occurrence of a flare postpartum and the presence of one 
or other of the tested autoantibodies, was tested with a Fisher’s exact test or 
Chi-squared test, depending on the number of examined women in each group. 
A two-sided p<0.05 was considered statistically significant. SPSS for Windows 
(Chicago, IL) version 15.0 was used. 
Ethics 
This study complies with the Helsinki declaration and the ethical committee at 
the Erasmus MC, University Medical Center Rotterdam, Rotterdam, The 
Netherlands approved this study. 
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RESULTS 
Patients recruitment data and demographics 
From May 2002 until November, 2006, data of 118 pregnancies with a complete 
dataset from first trimester to 26 weeks postpartum were obtained. Data from 59 
pregnancies were also available from before conception. Demographics of 
patients are given in Table 3.2.1. According to the EULAR response criteria 
47% (34/72) of patients with an initial DAS28 3.2 in first trimester, were 
‘responders’ during pregnancy, and postpartum 36% (42/118) of patients had a 
‘flare’ according to the reversed EULAR response criteria. 
Table 3.2.1: Demographics and clinical features of 118 RA patients 
Baseline characteristics 118 RA patients 
Mean age at delivery in years (SD) 
Median disease duration at delivery in years (range) 
Patients with disease duration < 2 years, % (n)  
Anti-CCP present, % (n) 
RF* present, % (n) 
IgM-RF 
IgG-RF 
IgA-RF 
Erosions present, % (n) 
DAS28-CRP-3 > 3.2 in first trimester, % (n) 
Classification of disease activity during pregnancy  
Good response/ moderate response, % (n) 
no response, % (n) 
Classification of disease activity postpartum 
severe deterioration/ moderate deterioration, % (n) 
no deterioration, % (n) 
Use of methotrexate prior to wish to conceive, % (n) 
Use of (oral) prednisone use prior to pregnancy, % (n) 
Use of biologicals prior to wish to conceive, % (n) 
Mean number of DMARDs and biologicals ever used prior to wish to 
conceive, n (SD) 
32.3 (3.6) 
5.7 (0.7 - 29.7) 
16 (19) 
62 (73) 
74 (87) 
73 (86) 
33 (39) 
35 (41) 
70 (81)  
61 (72)  
 
47 (34)** 
53 (38)** 
 
36 (42) 
64 (76) 
58 (68) 
43 (50) 
10 (12) 
 
2.5 (1.5) 
* RF = rheumatoid factor ** of 72 patients with DAS28-CRP-3 > 3.2 in first trimester 
Course of autoantibody levels during pregnancy and postpartum 
In Figure 3.2.1(a-d) the courses of the median levels with IQR of autoantibodies 
during pregnancy are shown. Only levels of patients who were positive for a 
certain autoantibody are shown. Median levels at first trimester of anti-CCP 
(200 U/mL, IQR 782, n = 73), IgM-RF (133 IU/mL, IQR 200, n = 86), IgG-RF (48 
IU/mL, IQR 66, n = 39), and IgA-RF (61 IU/mL, IQR 49, n = 41) did not change 
with statistical significance during pregnancy. Postpartum, however, median 
levels of all autoantibodies, except IgG-RF, statistically significant decreased. 
Median levels of anti-CCP decreased from 229 U/mL (IQR 850) to 194 U/mL 
(IQR 497) (n = 73, p = 0.023), median levels of IgM-RF from 152 IU/mL (IQR 
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252) to 88 IU/mL (IQR 199) (n = 86, p < 0.001) and median levels of IgA-RF 
from 50 IU/mL (IQR 48) to 42 IU/mL (IQR 58) (n = 41, p = 0.015). 
 
Since autoantibody production might be influenced early in pregnancy, data of 
59 women visited before pregnancy were analyzed separately. No statistically 
significant changes were found between median autoantibody levels before 
pregnancy and at first trimester (see Table 3.2.2), or between disease activity at 
these time points (mean DAS28-CRP-3 3.8 and 3.7 respectively). 
Table 3.2.2: Median levels of autoantibodies in subgroup analysis of women visited 
prepregnancy and at first trimester (n = 59). Statistical analyses were performed with Wilcoxon’s 
tests. 
Autoantibody prepregnancy 1st trimester p 
Anti-CCP U/mL (IQR), n = 34 
IgM-RF    IU/mL (IQR), n = 43 
IgG-RF    IU/mL (IQR), n = 22 
IgA-RF    IU/mL (IQR), n = 20 
142 (299) 
164 (252) 
  44 (32) 
  53 (38) 
163 (308) 
112 (215) 
  47 (53) 
  51 (37) 
0.84 
0.12 
0.51 
0.78 
Course of autoantibody levels in responders versus no responders during 
pregnancy and postpartum 
During pregnancy the change in levels of anti-CCP at first and third trimester 
were not related to the clinical disease course, classified according to the 
EULAR response criteria in responders and no responders. Also the changes in 
serum levels of IgM-RF, IgG-RF or IgA-RF between the first and third trimester 
were not statistically significantly different between responders en no 
responders during pregnancy as shown in Table 3.2.3. Postpartum the largest 
difference in levels of anti-CCP was measured either between 12 and 6 weeks 
postpartum or between 26 and 6 weeks postpartum. The largest difference in 
levels of anti-CCP was not associated with a flare postpartum. The median 
differences in levels of anti-CCP, and median differences in levels of IgM-RF, 
IgG-RF and IgA-RF postpartum were not associated with a flare (Table 3.2.3). 
Disease course during pregnancy and postpartum and presence of 
autoantibodies 
Finally, patients (n = 118) were classified as being positive or negative for a 
certain autoantibody. In some women anti-CPP (n = 2) or RF (n = 10) was 
documented as positive in medical charts, although they tested negative at first 
visit. Neither the presence of anti-CCP, nor of any RF was more likely to be 
present in responders during pregnancy or in patients with a flare postpartum 
(all p > 0.05). However, in subsequent analysis on patients classified for 
autoantibodies as ‘both negative’ compared with patients classified as ‘either-or’ 
or ‘both positive’ (see Table 3.2.4), the percentage of responders during 
pregnancy of the first group was significantly higher (75% vs 39%, p = 0.01). 
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Comparable results were obtained when classification of the autoantibody 
status was made only by autoantibodies measured at first visit. Postpartum, 
presence of autoantibodies was not associated with flares (p = 0.42). 
c NS NS d NS p = 0.015 
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Figure 3.2.1: Boxplots of autoantibody levels in RA women during pregnancy and postpartum 
(n = 118). a) Levels of anti-CCP (n = 73); b) Levels of IgM-RF (n = 86); c) Levels of IgG-RF 
(n = 39); d) Levels of IgA-RF (n = 41). Each box represents the 25th-75th centiles; lines inside the 
boxes represent the medians. Lines outside the boxes represent the 10th and 90th centiles. 
Statistical analyses were performed by Wilcoxon’s tests. (NS = not significant) 
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Table 3.2.3: Median differences in levels of autoantibodies by different disease courses during 
(between first and third trimester) and after pregnancy (maximum between 6-12 or 6-26 weeks 
postpartum). 
 
Anti-CCP 
(U/mL) 
IgM-RF 
(IU/mL) 
IgG-RF 
(IU/mL) 
IgA-RF 
(IU/mL) 
Responders (n = 34) 
median (IQR; n) 
Non-responders (n = 38) 
median (IQR; n) 
 
+24 (323; 21) 
 
+ 7 (149; 28) 
 
-0.8 (96; 23) 
  
+0.1 (87; 32) 
 
+1.7 (42; 9) 
 
-3.5 (23; 20) 
 
-0.6 (27; 12) 
 
+3.2 (26; 18) 
Flare (n = 42) 
median (IQR; n) 
No flare (n = 76) 
median (IQR; n) 
 
+15 (124; 24) 
 
+4.3 (140; 46) 
 
+4.2 (97; 28) 
  
+5.2 (66; 54) 
 
+3.9 (37; 13) 
 
+8.8 (29; 24) 
 
-2.2 (19; 15) 
 
+4.8 (21; 25) 
Table 3.2.4: Patients characteristics and disease activity responses classified according to 
presence of anti-CCP and RF 
* Anti-CCP and RF ‘both negative’ versus combined groups of “either-or” and both positive 
(ANOVA, Chi-square or Fisher Exact test) ** moderate and good responders combined; 
analysis is restricted to patients with DAS28-CRP-3 > 3.2 in 1st trimester, n = 72 *** ‘moderate 
and severe’ flare postpartum combined # p d 0.05 
DISCUSSION 
In this large prospective study of pregnant RA patients, for the first time levels of 
anti-CCP and subclasses of RF were measured during pregnancy. Anti-CCP 
remained stable during pregnancy, even in women with spontaneously 
improved disease activity. As reported previously in smaller studies, similar 
results were obtained regarding RF (18). Postpartum however, when 
medication was resumed, levels of all autoantibodies, except IgG-RF, declined. 
The changes in the measured autoantibody levels, however, were not 
associated with the disease course during and after pregnancy. But, surprisingly, 
 Anti-CCP and 
RF both negative 
(n = 26 ) 
Either Anti-CCP 
or RF positive  
(n = 24) 
Anti-CCP and 
RF both positive 
(n = 68) 
 
p * 
Age mean (SD) 31.9 (3.6) 33.5 (4.1) 32.2 (3.5) 0.35 
Disease duration median 
(months) 
83 56 57 0.03# 
DAS28-CRP-3 > 3.2 at 
first trimester % (n/N) 
62 (16/26) 29 (7/24) 72 (49/68) 0.95 
prednisone use 
during pregnancy % (n/N) 
27 (7/26) 46 (11/24) 44 (29/66) 0.11 
sulfasalazine use  
during pregnancy % (n/N) 
35 (9/26) 25 (6/24) 36 (24/66) 0.90 
responders ** 
during pregnancy % (n/N) 
75 (12/16) 14 (1/7) 43 (21/49) 0.01# 
flare *** 
postpartum % (n/N) 
42 (11/26) 33 (8/24) 34 (23/68) 0.42 
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women who were negative for both autoantibodies were more likely to improve 
during pregnancy. 
 
The results of this study are in contrast with changes in autoantibody levels that 
were found in association with disease course outside pregnancy (19). Outside 
pregnancy, the levels of autoantibodies (anti-CCP and RF) in relation to clinical 
disease activity and treatment have been investigated more extensively. In RA 
patients who were only treated with traditional DMARDs, mainly IgM-RF has 
been found to correlate positively with clinical disease activity, while IgG-RF, 
IgA-RF and anti-CCP did not correlate with serum levels of C-reactive protein 
(CRP), erythrocyte sedimentation rate (ESR) or white blood cell counts (20-21). 
More recent literature describe a decline in the levels of anti-CCP and IgM-RF 
upon treatment with tumour necrosis factor (TNF) alpha blocking agents (22,23), 
while the presence of IgA-RF may only be related to a poor clinical response to 
these biologicals (24-27). 
 
The lack of association between levels of autoantibodies and disease course 
during pregnancy, brings the study design into question, however:  
1 the number of patients included seems sufficient, since postpartum a 
statistically significant decline in autoantibody levels (anti-CCP, IgM-RF and 
IgA-RF) was observed; 
2 in analogy with previous studies outside pregnancy (21), disease activity in 
the present cohort may be too well-established to demonstrate changes in 
autoantibody levels. However, subgroup analysis on only patients with recent 
(< 2 years, n = 19) RA also failed to demonstrate a decline in autoantibody 
levels during pregnancy; 
3 medication use hardly changed during pregnancy in our cohort, (reported 
previously(14)), so this is unlikely to have biased our results. Although 
dosages of medication were changed in 50% of patients during pregnancy, 
the actual medication remained the same; mainly sulfasalazine (35% of 
patients) and prednisone (30% of patients). Postpartum, however, the effect 
of medication use on autoantibody levels such as anti-CCP, IgM-RF and IgA-
RF, as in prior studies, might have been preserved since the levels of these 
antibodies declined in the postpartum period and the use of methotrexate 
and biologicals was started in over 40% of patients before 26 weeks after 
delivery. 
 
The finding that women who were negative for both autoantibodies are more 
likely to improve during pregnancy, supports the hypothesis that RA is a 
heterogeneous disease with different pathogenic mechanisms involved (28). In 
analogy with SLE, where presence of auto-antibodies together with increased 
Th2-mediated responses during pregnancy, may make that disease flare during 
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pregnancy (29), one can speculate that similar mechanisms are responsible for 
the observation that disease activity is less likely to improve during pregnancy in 
RA-patients with autoantibodies (anti-CCP and/or RF). 
 
Although a decrease in levels of autoantibodies during pregnancy was not 
found in the present study, this study does not rule out that other functions of B 
cells and autoantibodies might play a role in the improvement of RA during 
pregnancy. Other functions in the pathogenesis of RA that are attributed to B 
cells and might be influenced by pregnancy include the production of 
(inflammatory) cytokines and chemokines, antigen presentation and an 
important function in the formation of ectopic lymphoid tissue (6). Furthermore it 
has been shown that during pregnancy the pathogenecity of autoantibodies are 
modified by differences in glycosylation of IgG (30-32). Since the glycosylation 
of IgG determines its ability to bind to complement and to Fc receptors, a role 
for glycosylation of IgG in the pregnancy induced remission of RA has been 
suggested. 
 
In conclusion, in the world’s largest cohort of pregnant RA patients, no 
association was found between improvement of disease activity during 
pregnancy and changes in levels of autoantibodies. However, in the absence of 
autoantibodies (anti-CCP and RF), improvement of RA during pregnancy 
occurred more frequently. Further investigations will be needed to discover 
whether improvement during pregnancy is related to other roles of B cells 
beyond autoantibody production. 
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APPENDIX 3.2 
A. EULAR response criteria for the definition of improvement during pregnancy (15). 
 
Decrease of DAS28 1st trimester with 
DAS28 at 3rd trimester > 1.2 > 0.6 AND  1.2  0.6 
 3.2 Good response Moderate response No response 
> 3.2 AND  5.1 Moderate response Moderate response No response 
> 5.1 Moderate response No response No response 
B. ‘Reversed’ EULAR response criteria for the definition of deterioration postpartum (14). 
 
Increase of DAS28 6 weeks postpartum with DAS28 at 12 or 26 weeks 
postpartum > 1.2 > 0.6 AND  1.2  0.6 
> 5.1 Severe flare Moderate flare No flare 
> 3.2 AND  5.1 Moderate flare Moderate flare No flare 
 3.2 Moderate flare No flare No flare 
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Objective. To determine pregnancy outcome of rheumatoid arthritis (RA) 
patients in relation to disease activity and prednisone use. 
Methods. In a prospective study, pregnant women with RA were visited 
preconceptionally, if possible, and at each trimester and postpartum. Clinical 
characteristics, disease activity, medication use, and pregnancy outcome were 
analyzed. To examine the independent influence of prednisone use and disease 
activity on birth weight, regression analyses were performed adjusting for 
gestational age at delivery, sex of newborn, smoking, educational level, parity 
and assisted reproduction. Kaplan-Meier curve and Log-Rank-test were 
performed to examine the association between prednisone use and gestational 
age at delivery. 
Results. Data of 152 Caucasian RA patients with singleton pregnancies were 
available. Both mean birth weight (3379 g, SD 564) and mean birth weight 
standard deviation score (SDS) (+0.1, SD 1.1), i.e. birth weight adjusted for 
gestational age and sex of newborn, were comparable to the general population. 
In multiple linear regression on birth weight and birth weight SDS, adjusted for 
covariates, only disease activity was associated with lower birth weight            
(p = 0.025). Gestational age at delivery of patients using prednisone was 
significantly shorter (385 vs 396 weeks, p = 0.006), and their delivery more often 
premature (< 37 weeks, p = 0.004). 
Conclusion: Pregnancy outcome in women with well-controlled RA is 
comparable to the general population. The effect of prednisone on birth weight 
is mediated by shortening gestational age at delivery, whereas a higher disease 
activity independently influences birth weight negatively suggesting an immune-
mediated mechanism. 
INTRODUCTION 
Rheumatoid arthritis (RA) is a systemic auto-immune disease leading to a 
destructive arthropathy (1). In the last decades, the pharmacological treatment 
of RA has improved considerably (2). Irrespective of medical treatment, 
pregnancy is a special situation that is associated with a spontaneous decrease 
of disease activity in patients with RA (3-8). 
 
Conversely, pregnancy outcome might be negatively influenced by RA, since 
unfavourable pregnancy outcome has been demonstrated in several rheumatic 
diseases (9-13). However, only few studies examined pregnancy outcome in 
women with RA (5, 10, 11, 13-15). These studies were mostly retrospective, 
conflicting, and results were easily confounded by selection. Studies regarding 
the newborns of women with RA showed lower birth weight (11), especially in 
newborns of women who had high disease activity during pregnancy (15). 
However, this was done without concerning medication use as a covariate. Low 
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birth weight, but especially small for gestational age, is not only an important 
risk factor for perinatal complications, but is also associated with developmental 
delay (16), metabolic syndrome and cardiovascular disease in children, and in 
(late) adulthood (17-19). In contrast to the reports that mean birth weight was 
lower in RA patients compared with healthy controls, the risk of low birth weight 
defined as <2500 gram, does not seem to be elevated in women with RA (14, 
15). However higher rates of small for gestational age (SGA) have been 
reported as well (11, 13). Furthermore, prednisone use may be associated with 
both lower birth weight and shorter gestational age at delivery (20), but the only 
study thus far conducted lacked power to elucidate the influence of disease 
activity and prednisone use on birth weight separately (15). 
 
Our large prospective nationwide cohort of pregnant women with RA enables us 
to provide more insight into the influence of RA on pregnancy outcome (8). 
Measurements of standardized disease activity scores during pregnancy and 
well-documented medication use make it possible to discriminate the 
independent effect of these variants on pregnancy outcome, and elucidate their 
mechanisms. 
 
In addition to this, new insight into pregnancy outcome and birth weight has 
resulted into the development of birth weight standard deviation score (SDS), in 
which birth weight is adjusted for gestational age at delivery and sex of newborn 
(21, 22). This is the first time that birth weight of a cohort of RA patients is 
analyzed this way. 
 
The objectives of the present study are to determine 1) the pregnancy outcome 
in women with RA and 2) whether disease activity and prednisone use during 
pregnancy influences birth weight independently, or whether the effect on birth 
weight is mediated via gestational age at delivery. 
PATIENTS AND METHODS 
Current study is embedded in the PARA-study (Pregnancy-induced 
Amelioration of Rheumatoid Arthritis -study) which is a prospective nationwide 
study in the Netherlands including women with RA who are visited before 
pregnancy (if possible), at each trimester during pregnancy, and three times 
after delivery (6, 12 and 26 weeks postpartum). The PARA study was described 
in detail previously (8). Briefly, rheumatologists in the Netherlands asked 
patients with RA to be approached by our research team. Women were eligible 
if they met the 1987 ACR criteria for RA, had a pregnancy wish or were already 
pregnant, and had a good understanding of the Dutch language. Women not 
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already visited preconceptionally were visited from the applicable trimester and 
onwards. 
 
In the present analysis on pregnancy outcome in women with RA, only singleton 
pregnancies of Caucasian women who delivered a baby without congenital 
deformities were included. No women contributed twice, only results of a 
woman’s first application were included. These inclusion criteria were 
formulated as such, since birth weight is different in non-Caucasians (23), in 
twin pregnancies, and in newborns with congenital deformities. Finally, inclusion 
of a second, subsequent pregnancy might introduce bias, since it may be a 
selection of women with a previously good experience with the course of RA 
during and after pregnancy and/or with the pregnancy outcome. 
Disease activity 
Disease activity was measured with a disease activity score (DAS28-CRP-3) 
with three variables: the total numbers of swollen and tender joints of 28 
predefined joints, and C-reactive protein (CRP) level (24). It has previously 
been shown that disease activity during pregnancy can be measured most 
reliably with this variant of the DAS28 (25). Joint counts were performed at all 
visits by a research nurse or medical doctor, and blood samples were drawn for 
CRP measurements by Tina-QuantCRP (Roche Diagnostics, GmBH, 
Mannheim, Germany). 
Pregnancy outcome 
Clinical characteristics including maternal age at delivery, rheumatologic history, 
obstetric history, smoking habits, educational level and medication use were 
collected by interview. The rheumatologic history was ascertained by obtaining 
information from patient’s own rheumatologist on the duration of RA, erosion 
status, presence of rheumatoid factor (RF) and anti-cyclic citrullinated peptide 
(anti-CCP). Presence of these autoantibodies was determined in our laboratory 
as well. Smoking habits were obtained by interview before and at first trimester 
during pregnancy. Only if a patient smoked at first trimester she was defined as 
smoking during pregnancy. Educational level of a woman was collected, of most 
of them after the last visit, and was categorized according to the highest level 
attained; low ( 9 yrs: primary school, lower and intermediate secondary 
schooling or lower vocational training), intermediate (10-14 yrs: higher 
secondary schooling or intermediate vocational training), and high ( 15 years: 
higher vocational training or university). Medication use was monitored 
throughout all visits. 
 
Method of conception was obtained by interview and was categorized as 
spontaneous or assisted reproductive endocrinology techniques. Assisted 
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techniques included ovulation induction, Intra Uterine Insemination (IUI), In Vitro 
Fertilization (IVF), or Intracytoplasmic Sperm Injection (ICSI). 
 
Data on pregnancy outcome included spontaneous abortions, intrauterine foetal 
death, birth weight, gestational age at delivery, gender of child, mode of delivery 
and location of delivery. Collected pregnancy complications included the 
incidence of prematurity, small for gestational age, and hypertensive disorders 
(gestational hypertension and preeclampsia). The data were collected at 
various visits by interview and analysis of medical charts. Information on the 
mode of delivery was subdivided into spontaneous birth, instrumental vaginal 
birth, or caesarean section. Instrumental vaginal birth was defined as use of 
forceps or ventouse extractor during labour, and the reason was documented 
as ‘failure to progress’ or ‘foetal distress’. Caesarean sections were 
documented as either ‘elective’ or ‘emergency’. 
 
Birth weight was assessed in grams and also by birth weight SDS, the use of 
this reference standard facilitates evaluation of size deviation of the standard at 
birth (21). Birth weight SDS were calculated by means of following gender 
specific formulas: 
 
ᄝ 
Birth weight SDS = 
    
   32
32
ga60.00008522ga20.00936308ga40.3384874993.89636285
ga70.00022061ga40.02124330ga10.6008168616.05183658bweight
uuu
uuu  
ᄛ 
Birth weight SDS = 
    
   32
32
ga60.00003689ga00.00418448ga00.1556745101.77611391
ga50.00028677ga00.02826482ga60.8470209048.86733479bweight
uuu
uuu  
 
With: 
bweight  = birth weight (kilogram) 
ga   = gestational age at delivery (weeks) 
 
Small for gestational age (SGA) is defined as a birth weight SDS at least 2 SD 
below the mean ( -2 SD) (26). 
 
The pregnancy complications in present study were defined as follows: 
spontaneous miscarriage as gestational age of < 16 weeks; prematurity as a 
delivery < 37 weeks (259 days) of gestational age, gestational hypertension, 
according to the criteria described by the ‘International Society for the Study of 
Hypertension in Pregnancy’, as systolic blood pressure  140mmHg and/or 
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diastolic blood pressure  90mmHg without proteinuria after 20 weeks of 
gestation in previously normotensive women (27). Preeclampsia was defined as 
gestational hypertension with concurrent proteinuria (> 2 g/l or 2+) (27, 28). 
Statistical Analysis 
Descriptive statistics on pregnancy outcome were presented as numbers and 
percentages. 
 
To compare the pregnancy outcome of present cohort with the general 
population, two reference groups were used. The first reference group contains 
results of the general obstetric population registered in ‘The Netherlands 
Perinatal Registry’ (PRN). This registry covers almost all deliveries (about 
179,000) pregnancies in the Netherlands in 2004 by linking the database of 
midwifes and general practitioners with the database of obstetricians (29). The 
vast majority (82%) of the registry consists of the pregnancy outcome of 
Caucasian women. The second reference group contains results of ‘Generation 
R’, which is a population-based prospective cohort study from foetal life until 
young adulthood of 10,000 pregnancies, conducted in Rotterdam, an urban 
area in The Netherlands, with children born between 2002 and 2006 (30). No 
statistical analyses were performed between present cohort and both registries, 
since inclusion criteria were not exactly comparable, and therefore those 
registries cannot be used as formal control groups. 
 
To describe the association between disease activity at third trimester and birth 
weight or birth weight SDS, the following covariates were analyzed by 
regression analysis; maternal age, parity, smoking status during pregnancy, 
educational level, gestational age at delivery and sex of newborn (the latter two 
are not applicable for analyzing birth weight SDS, since these are incorporated 
in the score). First, simple linear regression was performed. Secondly, multiple 
regression analysis was performed with all possible explanatory variables that 
were associated with birth weight or birth weight SDS and those that had a p-
value < 0.2 in simple linear regression. Smoking was addressed because of its 
known negative correlation with birth weight (31). Analyses were performed by 
multiple linear regression along with disease activity and prednisone use. 
 
A Kaplan-Meier curve visualized the correlation between gestational age at 
delivery and prednisone use. Differences in gestational age at delivery between 
prednisone and non-prednisone users were assessed by the Log-rank (Mantel-
Cox) test. The difference between the number of prednisone and non-
prednisone using women with a gestational age at delivery < 37 weeks were 
addressed by Fisher’s Exact test. 
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Two sided p-values  0.05 were considered as statistically significant. All 
statistical analyses were performed using SPSS version 15.0 for Windows. 
Ethics 
The PARA-study was approved by the Medical Ethical Committee of the 
Erasmus MC, University Medical Center Rotterdam, Rotterdam, The 
Netherlands in June 2002. Written informed consent was obtained from all 
participants. 
RESULTS 
Patient recruitment 
From May 2002 until August 2007, 388 patients were recruited by 
rheumatologists. Figure 4.1.1 shows the flow sheet of inclusion. After applying 
the inclusion criteria, only one more woman was excluded, since she was 
diagnosed with breast cancer during pregnancy. Therefore, 152 Caucasian 
women with RA with singleton pregnancies were eligible for present analyses. 
Demographics 
As shown in Table 4.1.1, women had a mean age at delivery of 32.5 years, 
slightly older than the general population, and had a median disease duration of 
70 months (range 8-356 months) at delivery. Only 4.1% of RA patients smoked 
in the first trimester of pregnancy, this is much lower than documented in the 
general population reference groups. Artificial reproduction techniques were 
used in 18% of the patients, this is  much more frequent than documented in the 
PRN reference group (3%). 
 
Because some patients were included in the second or third trimester, DAS28-
CRP-3 scores are lacking in 27 patients in first trimester, and in 12 patients in 
second trimester. Median disease activity throughout pregnancy (DAS28-CRP-3) 
decreased  from 3.8 at the first trimester to 3.3 at the third trimester. These 
disease activity scores indicate that disease activity was well-controlled in this 
cohort during pregnancy. Correlation between DAS28-CRP-3 at first and 
second trimester was 0.715, and between first and third trimester 0.647 
(Spearman’s correlation coefficients, p < 0.001). 
 
Only 10 patients changed prednisone use and/or their dosage throughout 
pregnancy and at each trimester slightly more than one third of women used 
prednisone. Prednisone use during the first trimester was strongly correlated 
with prednisone use during the second and third trimester (r = 0.880 and r = 
0.969, respectively). 
130
4 Pregnancy Outcome 
124 
 
 
 
 
Women with RA recruited by 
rheumatologists between  
May 2002 and August 2007 
 
n = 388 
 
Invited to participate in study 
 
n = 300 
Not invited to participate (Total = 88) 
 
Missed invitation           n =  16 
Declined to be invited   n =  34 
Excluded for invitation *  n =  38 
 
* Excluded for invitation: not fulfilling ACR 
criteria, not speaking Dutch language. 
 
Eligible for present analyses 
 
n = 155 
Invited to participate but not eligible ** 
for present analyses   (Total = 145) 
 
Did not become pregnant during 
follow-up period   n =     54 
Miscarriage   n =      31 
Lost to Follow up   n =         4 
Participated twice (39 women, 3 three times)       
              n =       45 
Twin pregnancy   n =          5 
Non-Caucasian   n =       19 
 
 
** A woman could have one or more reasons 
not to be eligible 
Data available for analyses 
 
Birth weight and disease activity  
 
n =    152 
Excluded for present analyses  
 
Congenital abnormalities  n =        2 
Other    n =       1 
Figure 4.1.1 Flowsheet PARA-study 
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Table 4.1.1 – Descriptive characteristics of RA patients and reference groups * 
 Present cohort Reference groups 
 RA patients 
(n = 152) 
PRN b 
(n = 175,498) 
Generation R c 
(n = 3,659) 
Mean age (SD) at delivery, yrs 32.5 (3.7) 30.5 (4.9) 31.2 (4.5) 
Median duration (range) of RA at 
delivery, months 
 
70 (8-356) 
  
RF status %(n) 75 (114)   
Anti-CCP %(n) 60 (91)   
Erosions %(n) 66 (101)   
Educational level %(n) 
- low 
- intermediate 
- high 
- missing 
 
  7.2 (11) 
38.2 (58) 
36.1 (55) 
18.4 (28) 
 
 
  5.2a 
37.2 
56.7 
  0.8 
Parity %(n) 
-nulliparae 
-multiparae 
 
57.2 (87) 
42.8 (65) 
 
47 
53 
 
58.6 
39.4 
Smoking %(n) 4.1 (5) -- 17.0 
Conception %(n) 
- Spontaneous 
- Assisted reproduction technique 
  - ovulation induction 
  - ovulation induction + Intra Uterine 
      Insemination (IUI) 
  - In Vitro Fertilisation (IVF) 
  - IntraCytoplasmic Sperm Injection 
      (ICSI) 
 
82.2 (125) 
17.8 (27) 
- 6.0 (9) 
 
- 3.3 (5) 
- 5.2 (8) 
 
- 3.3 (5) 
 
97 
  3 
 
 
 
 
 
DAS28-CRP-3 third trimester 
    (N = 148) 
- d 3.2 (low) 
- 3.2-5.1 (intermediate) 
- > 5.1 (high) 
 
 
47 (69) 
44 (66) 
9 (13) 
  
DAS28-CRP-3, mean (IQR) 
-trimester 1 (N = 125) 
-trimester 2 (N = 140) 
-trimester 3 (N = 148) 
 
3.8 (1.0) 
3.6 (1.1) 
3.3 (1.0) 
  
Prednisone use %(n) 
-trimester 1 % (N = 127) 
-trimester 2 % (N = 140) 
-trimester 3 % (N = 150) 
 
36 (46) 
36 (50) 
35 (52) 
  
* Values are the percentage (number) unless otherwise indicated. a Different defined as: low: 
primary school, intermediate: secondary school, high: higher education (23). PRN = The 
Netherlands Perinatal Registry, RA = rheumatoid arthritis, IQR = interquartile range.b (29); c (23) 
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Pregnancy outcome in women with RA 
Pregnancy outcome is shown in Table 4.1.2. The mean birth weight of women 
with RA is within the normal birth weight range and the mean birth weight SDS 
was +0.1 (SD 1.1), which is comparable with the standard population. 
Twenty-five patients required a caesarean section for delivery. About half of 
these patients required an elective caesarean section, due to foetal (n = 10 
(breech presentation)), maternal (n = 1), or combined reasons (n = 1). The 
remaining half required an emergency caesarean section due to failure of 
progress during labor (n = 7), foetal distress (n = 4), or combined reasons (n = 
2). Another twenty-five patients (18%) required an instrumental vaginal delivery, 
this is more frequent than documented in the PRN reference group (10.5%). 
When RA patients were categorized according to their disease activity at third 
trimester (‘low’ versus ‘intermediate or high’), caesarean sections were 
performed significantly more often in the intermediate or high disease activity 
group (10% versus 22%, Chi-square p = 0.04), while instrumental vaginal births 
were equally performed in both disease activity groups (25% versus 19%, Chi-
square p = 0.43). 
 
The incidence of prematurity was 8.6%, and 3% was born as small for 
gestational age. The incidences of the hypertensive disorders in women with 
RA were 7.2% for gestational hypertension (n = 11) and 0.7% for preeclampsia 
with admission (n =1). Though the number of patients in present cohort is too 
small to properly study the incidence of these fairly rare complications, it does 
not seem to differ largely from the general population. 
The influence of disease activity and prednisone use on birth weight 
Univariate analysis 
The association between birth weight and disease activity or prednisone use is 
shown in Table 4.1.3. We already showed that disease activity at third trimester 
is highly correlated with disease activity at first and second trimester. Disease 
activity at third trimester (DAS28-CRP-3) was significantly negatively associated 
with birth weight expressed in grams, as well as with birth weight SDS (p < 
0.001 and p = 0.025 respectively). Similar data were obtained for disease 
activity at second and first trimester. Furthermore, prednisone use during 
pregnancy is significantly associated only with birth weight expressed in grams, 
but not with birth weight SDS (p = 0.002 and p = 0.256 respectively). This 
indicates that prednisone indirectly influences birth weight via gestational age at 
delivery. 
133
4.1 Pregnancy Outcome in RA 
127 
Table 4.1.2 – Pregnancy outcome in RA patients and in reference groups * 
 Present cohort Reference groups 
 
RA patients 
(n = 152) 
PRNa  
(n = 179,457) 
Generation Rb 
(n = 3,659) 
Mean birth weight, gram (SD) 3379 (564) 3363 3485 (555) 
Mean gestational age at delivery, 
days (SD) 
 
276 (11.2) 
 
275 (15.7) 
 
278 (11.9) 
Mean birth weight SDS (SD) +0.1 (1.1)   
Gender of child: 
   Male 
 
58 (88) 
 
51.3 
 
50.4 
Mode of delivery: (n = 147) 
   Spontaneous vaginal birth 
   Instrumental vaginal birth 
         -  failure to progress 
         -  foetal distress 
         -  combined reason 
   Caesarean section 
         -  elective CS  
         -  emergency CS 
 
65 (96) 
17 (25) 
     - 56 (14) 
     - 36 (9) 
     -   8 (2) 
17 (25) 
     -  48 (12)   
     -  52 (13)  
 
75.3 
10.5 
 
 
 
14.2 
  -  6.5 
  -  7.7 
 
Location of delivery child: 
   At home 
   Hospital 
 
18 (27) 
82 (125) 
 
29.4 
70.6 
 
Pregnancy complications: 
   Prematurity (<37 weeks )  
   Intruterine foetal death 
   Birth weight SDS < -2 (SGA) 
   Hypertensive disorders (verified) 
    - Gestational hypertension 
   -  Preeclampsia with admission 
 
  8.6 (13)  
     0 (0) 
  3.3 (5) 
  7.2 (11) 
  -  6.6 (10) 
  -  0.7 (1) 
 
6.2 
 
 
8.5 
  -  7.9 
  -  0.4 
 
* Values are the percentage (number) unless otherwise indicated. PRN = Netherlands Perinatal 
Registry, RA = rheumatoid arthritis, SDS = Standard Deviation Score a(29);b(23) 
To detect potential confounders on the association between birth weight or birth 
weight SDS and disease activity and prednisone use, simple linear regression 
analyses was carried out with several factors as independent variables as 
shown in table 4.1.3. 
 
In simple linear regression on birth weight, parity and gestational age at delivery 
were most predictive (Table 4.1.3, left column). Multiparae gave birth to heavier 
newborns, and smoking was not associated with lower birth weight in this cohort. 
In simple linear regression on birth weight SDS (Table 4.1.3, right column), only 
parity and maternal age were both statistically significantly associated with birth 
weight SDS. While all other potential confounders were not significantly 
associated with birth weight SDS. 
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Table 4.1.3: Simple linear regression on birth weight and birth weight SDS 
 
Birth weight  Birth weight SDS  
Simple linear 
regression 
Standardized coefficient 
(n = 152)a 
p Standardized coefficient 
(n = 152)a 
p 
DAS28-CRP-3 3rd trim 
Prednisone use (yes) 
Gestational age at 
delivery (days) 
Parity (multi) 
Age of mother (years) 
Smoking (yes) 
Gender (male)  
Education level 
(low vs high) 
Conception 
(assisted reproduction) 
-108.9
-296.5
+187.7
+383.1
+18.5
-15.0
+99.3
-171.0
-5.8
[-190.6;-27.2] 
[-479.3;-113.7] 
 
[142.6;232.7] 
[210.44;555.8] 
[-6.0;43.1] 
[-522.5;494.6] 
[-83.8;282.3] 
 
[-512.5;169.3] 
 
[-243.1;234.6] 
0.009
0.002
<0.001
<0.001
0.137
0.954
0.286
0.321
0.831
-0.18
-0.21
--
+0.77
+0.05
+0.41
--
-0.39
+0.05
[-0.340;-0.023] 
[-0.574;0.154] 
 
 
[0.438;1.104] 
[0.002;0.096] 
[-0.570;1.389] 
 
 
[-1.073;0.292] 
 
[-0.409;0.509] 
0.025
0.256
--
<0.001
0.041
0.410
--
0.260
0.831
a n = 117 for education level 
Multivariate analyses 
In the multivariate analyses, higher disease activity at third trimester is 
significantly associated with lower birth weight and birth weight SDS after 
adjustment for all covariates (Table 4.1.4). 
Table 4.1.4 - Regression analyses of birth weight and birth weight SDS with disease activity 
(DAS28-CRP-3 in third trimester) as dependent variable 
 Crude Adjusted 
 n           B [95% CI]               p  n              B [95% CI]                  p  
DAS28-CRP-3  
 Birth weight 
 
 
 
Birth weight SDS 
 
148 a 
 
 
 
148 
 
-111.9  
[-193.6;-30.2] 
 
 
-0.181  
[-0.34 ; -0.023] 
 
0.008 
 
 
 
0.025 
 
 
117 b 
 
141 c 
 
117 d 
 
141 e 
 
-82.6 
[-154.5;-10.6]  
-74.9 
[-141.7; -8.0] 
-0.193 
[-0.362;-0.037] 
-0.174 
[-0.331;-0.016] 
 
0.025 
 
0.029 
 
0.025 
 
0.031 
a: adjusted for sex newborn b: adjusted for sex newborn, gestational age at delivery (in days), 
level of education (low, intermediate, high), smoking (yes/no), age of mother (in years at 
delivery), parity (0 or > 0), use of assisted reproduction technique (yes/no) , and prednisone use 
during pregnancy (yes/no) (R Squared = .391 (Adjusted R Squared = .334)) c: adjusted for sex 
newborn, gestational age at delivery (in days), smoking (yes/no), age of mother (in years at 
delivery), parity (0 or > 0), use of assisted reproduction technique (yes/no), and prednisone use 
during pregnancy (yes/no) (R Squared = .462 (Adjusted R Squared = .429)) d: adjusted for level 
of education (low, intermediate, high), smoking (yes/no), age of mother (in years at delivery), 
parity (0 or > 0), use of assisted reproduction technique (yes/no), and prednisone use during 
pregnancy (yes/no) (R Squared = .161 (Adjusted R Squared = .099)) e: adjusted for smoking 
(yes/no), age of mother (in years at delivery), parity (0 or > 0), use of assisted reproduction 
technique (yes/no), and prednisone use during pregnancy (yes/no) (R Squared = .179 (Adjusted 
R Squared = .143)) 
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Prednisone use and gestational age at delivery 
Prednisone use is associated with birth weight in grams, but not with birth 
weight SDS, in the linear regression analyses (Table 4.1.3). Also in multivariate 
analysis prednisone use during pregnancy was significantly associated with 
shorter gestational age (p < 0.001) after correction for potential confounders as 
disease activity at third trimester (DAS28-CRP-3), way of delivery (spontaneous 
versus caesarean section), parity (1 versus > 1), and age of mother. This shows 
that prednisone is independently associated with lower birth weight via shorter 
gestational age. 
 
A statistically significant association between prednisone use and gestational 
age at delivery was also confirmed with a Kaplan Meier curve (Figure 4.1.2).  
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Gestational age (weeks) 
p = 0.006 
Prednisone use 
Figure 4.1.2 Kaplan-Meier survival curve showing gestational age at delivery in weeks between 
the women using prednisone (dotted, n = 56) and no prednisone (black, n = 95). Log-Rank test, 
Chi-square 7.31, p = 0.006. 
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Women using prednisone during pregnancy delivered on average one week 
earlier compared with non-prednisone using women (38.8 weeks, 95% CI 
[38.2;39.3] versus 39.9 weeks 95% CI [39.6;40.1]). This could not be explained 
by differences in frequency of induction of labor (14% in both groups) or elective 
caesarean sections. Patients using prednisone delivered more often < 37 
weeks of gestational age, compared with non-prednisone using women (Fisher 
Exact, p = 0.004). 
DISCUSSION 
In present prospective study on pregnancy and RA we showed that women with 
good rheumatology care have a pregnancy outcome comparable to the general 
obstetric population, and we demonstrated that disease activity and prednisone 
use during pregnancy were both negatively associated with birth weight. 
Though, only higher disease activity was associated with lower birth weight 
SDS, whereas the effect of prednisone on birth weight was mediated by 
shortening gestational age at delivery. This resulted in significantly more women 
with prednisone delivering < 37 weeks of gestation. 
 
In this study, we addressed for the first time birth weight of newborns of RA 
patients with birth weight SDS, in which birth weight was adjusted for 
gestational age at delivery and sex of newborn (21, 22). Because of this method, 
we could certify that newborns in present cohort are on average appropriate for 
gestational age at birth, since the mean birth weight SDS is +0.1SD. 
Furthermore birth weight SDS enabled us to determine that the effect of disease 
activity on birth weight was a direct effect (both birth weight SDS as well as birth 
weight  were affected) and that the effect of prednisone was mediated through 
gestational age (only birth weight but not birth weight SDS was affected). 
 
Almost all studies so far conducted in pregnant women with RA, reported lower 
birth weight, but still within the normal range, in newborns of RA patients. 
Almost all studies reported birth weight without correction for gestational age 
and without prospectively measured disease activity during pregnancy (11, 13, 
14, 32). In the present cohort however, we showed that mean birth weight and 
mean birth weight SDS are in general comparable to the general obstetric 
population. The discrepancy with previous literature can be explained by 
several factors. First, RA is treated more aggressively nowadays, which may 
have resulted in low disease activity in our cohort. Second, in our cohort only 
few patients smoked and a higher percentage of patients had a higher 
educational level than the general population; both are associated with higher 
birth weight. The low percentage of smoking women and the high educational 
level suggest a healthy cohort effect in this study. On the other hand, in our 
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cohort women had a higher age and there was a higher percentage of nulliparity, 
both associated with a lower birth weight. 
 
In present study disease activity of RA during pregnancy is associated with 
lower birth weight and birth weight SDS. We demonstrated that disease activity 
at third trimester influenced birth weight negatively and independently of many 
covariates as prednisone use, parity, smoking, gender of the child, pregnancy 
duration, maternal age, educational level, and assisted reproduction. In present 
multiple linear regression analysis, we focused on the role of disease activity 
and prednisone use during the third trimester, since at that time point our cohort 
included the most patients.  Since disease activity in first, second and third 
trimester are highly correlated, our data are not suitable for determining whether 
a certain critical period exists for the effect of disease activity on birth weight. 
 
In general, as a rule of thumb, only a difference in SDS score of 0.5 SDS is 
considered to be of clinical relevance. Since the estimated mean decrease in 
SDS score was 0.18 for 1.0 increase in DAS28, our findings may only be 
clinically relevant for women with high disease activity during pregnancy. 
Although this small difference in birth weight is unlikely to result in more 
perinatal complications, a small decrease in birth weight, even within the normal 
range, has been associated with future developmental delay (16,33), metabolic 
syndrome and cardiovascular disease (17-19). Whether this holds true for the 
children born in this study will be subject of further research. 
 
Furthermore, we showed for the first time that prednisone use in women with 
RA has an indirect negative influence on birth weight by independently 
influencing gestational age at delivery. This influence of prednisone has already 
been shown in a study of women using prednisone for a wide spectrum of 
indications (20). Here we confirm this effect, but now in solely RA patients. This 
is of clinical importance for obstetricians, since women with RA and prednisone 
use did more frequently deliver < 37 weeks of gestational age compared with 
non-prednisone using women, regardless of induction of labor or elective 
caesarean sections. 
 
There were four more observations in present cohort that need some further 
discussion. The first is the relatively high number of pregnancies accomplished 
with assisted reproduction techniques in present cohort. This may be explained 
by several arguments. The time to conceive in women with RA may be longer, 
as previously suggested (34), but also women with RA may be more easily 
referred for artificial reproduction techniques, and lastly, it may be explained by 
referral bias, because rheumatologists will be more aware of a pregnancy wish 
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of the patient when it takes longer to conceive, as well as patients with 
difficulties to conceive may be more interested to participate. 
 
The second observation to discuss is the high rate of instrumental vaginal 
delivery compared with the general population. However, this should be 
interpreted against the higher number of nulliparity, since nulliparous women in 
general need in about 20% instrumental help at vaginal delivery. We could not 
explain this by a higher disease activity at third trimester. 
 
The third observation to discuss is about caesarean sections. It has been 
previously documented that caesarean sections are more prevalent among RA 
patients compared with healthy controls (11, 13, 14). In present study, however, 
the number of caesarean sections conducted, and the subdivision in elective 
and emergency seem to be comparable with the general population. The higher 
number of caesarean sections reported in previous studies may be explained by 
the fact that women may have had higher disease activity in previous studies. 
As we showed in our cohort, caesarean sections were significantly more 
frequent in women with high disease activity. 
 
About the fourth observation on pregnancy complications we can be short. 
Women with RA have been reported as having an increased risk on premature 
labor (10, 12, 14), however in present cohort the risk was comparable with the 
PRN reference group. In our RA patients, only 5 newborns were born (3%) 
small for gestational age, which is in accordance with the general population. 
Higher risks on hypertensive disorders (gestational hypertension and 
preeclampsia) have been described (11, 13), while in other studies this was not 
(14, 15, 32). We compared our data with the percentage of hypertensive 
disorders during pregnancy that could be obtained from PRN (all hypertensive 
disorders combined) and from literature 6-10% (27, 28, 35, 36). The incidence 
of hypertensive disorders in women with RA in present study seemed to be 
comparable with the reference groups, however this should be interpreted with 
caution because of the low number of patients. 
 
The present study has some limitations. Beforehand we showed that patient-
reported pregnancy characteristics are generally of good validity and high 
reliability compared with obstetric records (data not shown). Since the study 
was not designed as a case control study, comparison with healthy controls can 
only be made indirectly and should therefore be interpreted cautiously. One of 
the important limitations is the lack of valid control data for all pregnancy 
outcomes. Finally a healthy cohort effect may have influenced the results which 
may even underestimate the results we found. In our opinion, the results of 
present study can be generalized to Caucasian RA patients with singleton 
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pregnancies, seen in rheumatology clinics and treated with current available 
therapies resulting in well-controlled disease. The ‘opinion’ of rheumatologists 
that disease activity should be low before pregnancy to have a better pregnancy 
outcome, seems to hold true. 
 
The mechanism of high disease activity leading to lower birth weight has yet to 
be elucidated, however some pathophysiological hypotheses might explain this. 
First, vasculopathy resulting from endothelial dysfunction may contribute to 
maldevelopment of the placenta. Endothelial dysfunction is a common 
complication of active RA and is thought to be the initial stage of atherosclerosis. 
Maldevelopment of the placenta is associated with unfavourable pregnancy 
outcome (e.g. lower birth weight, hypertension) (37,38, 39). Secondly, a proper 
fetal development requires lower foetal than maternal cortisol levels. In the 
placenta the enzyme 11beta-hydroxysteroid dehydrogenase type II (11bHSD2) 
inactivates the maternal cortisol. High maternal cortisol levels (chronic stress) or 
low 11beta-hydroxysteroid dehydrogenase type II (11bHSD2) in the placenta 
(famine), are both associated with decreased birth weight as shown previously 
(40). Additionally, presence of high pro-inflammatory cytokines as TNF, IL-1 and 
IL-6, all associated with active RA, can down regulate 11bHSD2 in the placenta 
(41), and may thus result in lower birth weight. This will be the subject of future 
studies. 
 
In conclusion, this is the first prospective study in RA women describing 
pregnancy outcome and extensively linking disease activity and medication use 
throughout pregnancy to birth weight and birth weight SDS. Although the 
incidence of pregnancy complications is comparable with the Dutch general 
obstetric population, among patients with high disease activity more caesarean 
sections were performed. Furthermore, we showed that newborns of women 
with higher disease activity and prednisone use had lower birth weight. The 
effect of prednisone on birth weight is mediated indirectly by shortened 
gestational age at delivery, whereas disease activity directly influences birth 
weight. For obstetricians, this study might implicate that they should be aware of 
a higher incidence of caesarean sections in RA patients with high disease 
activity, and of an increased risk of preterm delivery by use of prednisone in RA 
patients. For rheumatologists, it might implicate that they should strive to low 
disease activity in their patients before and during pregnancy for a better 
pregnancy outcome. 
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Background. Rheumatoid arthritis (RA) may affect women’s ability to fulfill 
parenting tasks postpartum. 
Objective. To describe parenting disability (PD) of women with RA postpartum 
and its correlations with disease activity and HAQ scores, define factors 
influencing PD postpartum, and examine responsiveness of PD scores. 
Methods. This study is embedded in the nationwide prospective study on 
pregnancy and RA, the PARA-study. At 6, 12 and 26 weeks postpartum HAQ-
scores and Parenting Disability Index scores (PDI and modified-PDI) were 
calculated, medication use was registered and disease activity was scored with 
DAS28-CRP-3. Correlations between PDIs, HAQ, and DAS28 were calculated. 
GEE was performed with PDIs as dependent variables and covariates DAS28, 
medication use, duration of RA, and family size. Responsiveness of the PDI to 
RA flare was assessed. 
Results. Data from 100 women with RA were available. Sixty-eight percent was 
erosive. Mean (SD) PDI scores at three visits postpartum were stable: PDI 
0.51(0.42), mPDI 0.64(0.56). PDI scores were significantly correlated with both 
HAQ and DAS28. Higher disease activity and erosive disease were associated 
with higher PDI scores postpartum. Activities in which women most frequently 
encountered difficulty were carrying and bathing the baby and household 
chores. PDI scores rose significantly in women with a flare postpartum, 
suggesting responsiveness of PDI scores. 
Conclusion. PDI scores postpartum are significantly influenced by disease 
activity and erosive disease. Health professionals could be advised to lower 
disease activity to preserve parenting functions. Patients may benefit from joint 
protective instructions directed toward most affected domains. 
INTRODUCTION 
Many women with rheumatoid arthritis (RA) are concerned about their parenting 
capacities after giving birth, since RA tends to flare postpartum in a substantial 
number of women (1, 2). Perceived inability to fulfill parenting roles, as 
previously studied, may result in feelings of frustration, guilt, anger and 
depression (3). The influence of the functionality of women with RA postpartum 
on parenting, however, has rarely been addressed. 
 
Functionality in RA is measured worldwide with the Health Assessment 
Questionnaire (HAQ) and is numerically expressed in a HAQ score (4, 5). The 
HAQ score, however, may not be specific enough to rate functionality of women 
with RA postpartum, since it concerns only regular daily activities, while women 
face many unique tasks in caring for their babies. 
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The Parenting Disability Index (PDI) was developed to measure parenting 
function and disability and was validated in a sample of women with RA living in 
northern California, USA (6). In the validation study, only 9 women who had 
young children (ages 0-5 years) at the time of the study, and 79 women who 
had young children at the time of their RA diagnosis but answered the 
questionnaire retrospectively, were included. It appeared that even in that small 
sample, a substantial proportion of women with RA experienced disability in 
parenting activities. In the nine women with currently young children, 52% of the 
activity domains of the PDI were affected. Therefore, the PDI may identify 
difficulties in care and functionality women with RA are facing postpartum. 
Furthermore the, PDI may provide information for health professionals to focus 
care for patients more precisely, and results from larger studies may provide 
information for women that will help them prepare for potential parenting 
challenges postpartum. 
 
To study the effects of parenting disability among women with infants in a larger 
study, the present study was embedded in the PARA-study (Pregnancy-induced 
Amelioration of Rheumatoid Arthritis study), which provides up to now the 
largest prospective national cohort of RA patients examined before, during and 
after pregnancy in the world (2). 
 
The goals of our study were to describe the parenting disability indices (PDIs) 
over 6 months postpartum, to identify how PDIs are correlated with DAS28 and 
HAQ, to define (modifiable) factors influencing PDIs postpartum, and to 
examine the responsiveness of PDI scores to RA flares. 
PATIENTS AND METHODS 
Patient population 
Data for the current study are from the PARA-study, which has been described 
previously in detail (2). Briefly, all rheumatologists working in the Netherlands 
were asked to recruit patients with RA, according to the 1987 revised ACR 
criteria, who wished to conceive or who were already pregnant (preferably in 
their first trimester). During the study the patient’s own rheumatologists provided 
patient care. For the present analysis, data were collected between August, 
2004, and August, 2007. Only data of women who had miscarriages in the first 
trimester were excluded. Two women were included twice. 
Data collection 
Patients were visited at home before conception (prepregnancy), at each 
trimester, and three times postpartum (6 weeks, 12 weeks and 26 weeks). At 
148
5 Parenting 
142 
each visit women completed questionnaires containing the HAQ, current 
medications, and, after delivery, the PDI for women with children between 0-5 
years. A clinical examination of joints was performed according to the EULAR 
defined joint count (DAS28) (7) and finally serum was stored for determination 
of C-reactive protein (CRP) levels, by Tina-quant® CRP (Roche Diagnostic 
GmbH, Mannheim, Germany). 
Parenting Disability Index 
The original Parenting Disability questionnaire for women with children between 
0 to 5 (including an additional 5 questions) was translated into Dutch by two 
native Dutch-speaking English translators and was retranslated into English by 
two native English-speaking translators in order to come to consensus after two 
versions. All questions could be retained as in the American version. We 
performed a pilot among 10 women with RA and this revealed adequate 
responses. Since August 2004 all participants of the PARA-study completed the 
PDI at each visit. In Appendix 5.1.A-C, all questions of the questionnaire are 
shown. For this questionnaire a response scale similar to that of the HAQ was 
used (0 = no difficulty,1 = some difficulty, 2 = a lot of difficulty, 3 = unable to 
perform), with an additional category “did not perform for reasons other than 
arthritis”. For all except two function domains, namely “safety” and “getting 
down to and up from the floor” domains, patients were also asked whether they 
“did less of the activity because of their arthritis”. Two summary scores were 
calculated. The first was the “parenting disability index” (PDI), which represents 
the mean difficulty level across the domains. To calculate the PDI, responses 
were scored from 0 to 3, and a mean score of all items was calculated. As with 
the HAQ score, the PDI score could range from 0 to 3, with 0 reflecting no 
disability, and 3 representing the inability to perform parenting tasks. The 
second summary score was the “modified PDI” (mPDI) that took also into 
account responses to the “did less” question. If a patient responded that she did 
less of an activity, that domain score was increased to a “2,” regardless of the 
subject’s initial difficulty rating. This is similar to the protocol for scoring the 
HAQ, in which use of assistive devices or help from other people in a particular 
functional area increases the score in that area to a “2.” 
Covariates 
To assess associations with parenting disability, sociodemographic and health 
characteristics, function, and disease activity were assessed. 
Sociodemographic and health characteristics included subject age, duration of 
RA, number of children, and medication use. Functionality with RA was also 
assessed with the HAQ score (range 0-3), as described previously (4), and 
disease activity was calculated using a Disease Activity Score of 28 joints 
(DAS28) with three variables, consisting of a swollen joint count, a tender joint 
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count and a CRP level (mg/L) (DAS28-CRP-3, range 0-10). Response criteria 
for improvement, as recommended by the EULAR Standing Committee for 
International Clinical Studies Including Therapeutic Trials (ESCISIT), and the 
reverse classification criteria for a postpartum flare, as previously described, 
were applied (7-9). 
Statistical analysis 
Descriptive statistics were presented as numbers and percentages. 
 
When comparing PDI scores as new method of measuring functionality 
postpartum compared with the HAQ, the standard functionality score in RA, 
correlation coefficients were calculated, as well as whether the differences 
between the measurements by the two methods (HAQ and PDI) were related to 
the magnitude of the measurement as defined by Bland and Altman (10). 
 
To determine if parenting disability was associated with disease activity, 
Pearson’s correlation coefficients between PDI and DAS28-CRP-3 at each visit 
postpartum were calculated and tested for significance.  
 
Data were analyzed with longitudinal regression analysis (generalized 
estimating equations (GEE)), to adjust for within-patient dependence of the 
outcome variable (PDIs), using autoregression (AR) with lag one structure. To 
determine which patient characteristics were associated with postpartum 
parenting disability, the GEE analyses included the following covariates: 
disease activity (continuous DAS28 scores), disease duration at partus (< 2 or 
> 2 years), family size (1 or > 1 children), medication use postpartum (yes/no), 
erosive disease (Yes/No), and the interaction between medication use and 
disease activity. If correlation coefficients were > 0.7 between two covariates, 
one covariate was removed because of possible colinearity. 
 
Responsiveness of PDI scores to RA flares was addressed by comparing PDI 
scores of two visits (6 and 12 or 6 and 26 weeks postpartum) between women 
with and without a flare postpartum. The postpartum flare was defined 
according to reversed EULAR response criteria, as previously described (2). 
Mean differences in PDI scores between flare and non flare women were 
compared with ANOVA. The responsiveness of PDI scores to flares were 
compared with the responsiveness of HAQ scores to flares in present cohort. 
The Minimal Clinically Important Difference (MCID) of the PDI scores were 
determined as 0.5 of the SD as a good estimate (11-13), and compared with the 
MCID of the HAQ in present study.  
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Two sided p-values  0.05 were considered as statistically significant. All 
statistical analyses were performed using SPSS version 15.0 for Windows. 
Ethics 
The PARA-study complies with the Helsinki declaration and the Medical Ethical 
Committee of the Erasmus MC, University Medical Center Rotterdam, 
Rotterdam, The Netherlands approved this study in 2002. Written informed 
consent was obtained from all participants. 
RESULTS 
Demographics 
As shown in Table 5.1.1, the current cohort consists of 100 postpartum periods 
of 98 women with RA with a mean age of 33 years, 73% were rheumatoid factor 
positive and 65% anti-CCP positive. Thirty (27/92) percent of patients had a 
postpartum flare of RA. 
Parenting disability indices postpartum 
Responses on all questions of the PDI, at 6, 12, and 26 weeks postpartum are 
shown in the appendices. The five domains in which respondents had the most 
difficulty at 6 weeks postpartum were: doing other household chores or 
shopping (63% reported some level of difficulty), picking up or carrying your 
child (61%), taking your child out in the car (59%), taking care of your child’s 
hygiene needs (53%), and taking care of your child while out of the house 
(53%). The first four of these domains were consistently rated as the most 
difficult at all three visits postpartum. The five domains in which women “did less 
because of arthritis” were consistent over the three visits, with the highest rates 
at 12 weeks postpartum: Doing other household chores or shopping (50%), 
picking up or carrying your child (35%), taking your child out in the car (23%), 
taking care of your child’s hygiene needs (34%), and going for walks with your 
child (32%). 
PDI scores 
Table 5.1.2 shows the mean PDI and mPDI scores at each postpartum 
assessment. There was very little change in the mean scores over time. There 
were no consistent significant correlations between the PDI scores and 
sociodemographic variables in this cohort: age of mother at delivery (r = 0.06), 
years of education (r = 0.01), number of children (r = 0.003), and duration of RA 
at delivery (r = 0.04). 
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Table 5.1.1: Demographics of study population 
 
100 postpartum periods of 
98 RA patients 
Age, mean ± SD years 
Caucasian, n (%)  
Education, mean ± SD years  
Disease duration, mean ± SD years 
Rheumatoid Factor, n (%) 
Anti-CCP, n (%) 
Erosions, n (%) 
HAQ scores: mean ± SD 
        before pregnancy (n = 57) 
        6wk PP 
      12wk PP 
      26wk PP 
No. of children, 
      1 child, n (%) 
      2 children, n (%) 
   > 2 children, n (%) 
DAS28-CRP-3 Mean ± SD (scale 0-10) 
       third trimester 
       6 wk postpartum 
     12 wk postpartum 
     26 wk postpartum 
Methotrexate (re)start, n (%) 
       6 wk postpartum 
     12 wk postpartum 
     26 wk postpartum 
Biologicals (re)start, n (%) 
       6 wk postpartum 
     12 wk postpartum 
     26 wk postpartum 
Postpartum disease course:  
     Flare (severe/moderate), n (%) 
     No flare, n (%) 
     Missing, n (%) 
33.2 ± 3.6 
96 (96) 
15 ± 2.7 
7.9 ± 6.2 
73 (73) 
65 (65) 
68 (68) 
 
0.74 ± 0.54 
0.67 ± 0.5 
0.83 ± 0.6 
0.74 ± 0.6 
 
55 (55) 
39 (39) 
6 (6) 
 
3.4 ± 1.1 
3.5 ± 1.1 
3.6 ± 1.3 
3.4 ± 1.2 
 
19 (19) 
30 (30) 
39 (39) 
 
5 (5) 
9 (9) 
12(12) 
 
27 (27) 
65 (65) 
8 (8) 
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Table 5.1.2: Parenting Disability indices postpartum * 
 6wk PP 12wk PP 26 wk PP 
95% - CI 
of the difference 
6wk – 12 wk 
PP ‡ 
95% - CI 
of the difference 
6wk – 26 wk 
PP ‡ 
N: 
PDI:  
   Mean ± SD 
   Range 
mPDI:†  
   Mean ± SD 
   Range 
97 
 
0.51 ± 0.42 
0.00 - 1.50 
 
0.64 ± 0.56 
0.00 - 2.00 
97 
 
0.57 ± 0.50 
0.00 - 2.00 
 
0.71 ± 0.58 
0.00 - 2.06 
96 
 
0.52 ± 0.48 
0.00 - 2.30 
 
0.65 ± 0.58 
0.00 - 2.30 
 
 
[-0.13;0.01], NS 
 
 
[-0.14;0.02], NS  
 
 
[-0.08;0.05], NS 
 
 
[-0.09;0.07], NS 
* Disability score, without accounting for “doing less” † Disability score, with accounting for 
“doing less” ‡ Paired T-test of the difference between given time points, NS = Not significant; CI 
= Confidence Interval; PP = postpartum; wk = weeks. 
 
Associations of parenting disability with functionality and disease activity 
scores 
There was a strong correlation between PDI scores and HAQ scores. The 
Pearson correlation coefficient at 6 weeks postpartum was 0.78 between PDI 
and HAQ and 0.72 between mPDI and HAQ. The difference measured between 
the HAQ and mPDI was not related to the magnitude of the measurements (see 
Figure 5.1.1). 
 
There was a moderate correlation between HAQ and the DAS28 (r = 0.54). 
There were also a moderate correlations between PDI scores and the DAS28. 
Pearson correlation coefficients were on average 0.48 between PDI and DAS28 
and 0.46 between mPDI and DAS28. 
Factors influencing PDI/mPDI scores postpartum 
Evaluating (modifiable) factors contributing to functionality postpartum, the GEE 
analyses (see Table 5.1.3) revealed that PDI and mPDI were significantly 
higher when disease activity was higher and when patients had erosive 
disease. The PDI rose on average 0.15 when DAS28 was 1 point higher, and 
0.24 when patients had erosive disease. Results were comparable with mPDI in 
which mPDI rose 0.16 for each DAS28 point and 0.35 when patients had 
erosive disease. In the present study, longer disease duration, a higher number 
of children and the use of medication postpartum did not significantly contribute 
to PDI scores. 
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The interaction of DAS28 and medication postpartum did not significantly 
contribute in the GEE analysis, and therefore results are shown without the 
interaction variable. 
Table 5.1.3: Generalized estimating equations (GEE) with PDI or mPDI as dependent variables 
and following covariates: disease duration at delivery, family size, medication use and erosive 
disease. An autoregressive with lag one structure was chosen. 
 PDI 
 B 95% Wald CI p 
Intercept 
DAS28 (continuous) 
Disease duration (> 2 year) 
Family size (> 1 child) 
Medication postpartum (yes) 
Erosive disease (yes) 
-0.119 
 0.152 
-0.007 
 0.002 
-0.006 
 0.243 
[-0.301; 0.062] 
[ 0.106; 0.199] 
[-0.018; 0.005] 
[-0.151; 0.156] 
[-0.107; 0.096] 
[ 0.083; 0.403] 
0.196 
<0.001 * 
0.274 
0.986 
0.910 
0.003 * 
* p  0.05 
 
 
Figure 5.1.1: Plot of the difference between HAQ and mPDI at 6 weeks postpartum against the 
mean of HAQ and mPDI in each patient. This shows that differences in PDI scores are not 
related to the magnitude of the mPDI. 
0.00 0.50 1.00 1.50
mean of HAQ and mPDI 6 wk PP
-1.00
-0.50
0.00
0.50
1.00
di
ffe
re
nc
e 
in
 H
A
Q
 a
nd
 m
PD
I 6
 w
k 
PP
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
33
3
3
3
3
3
3
3
3
3
3
33
3
33
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
D
iff
er
en
ce
 in
 H
A
Q
 a
nd
 m
PD
I a
t 6
 w
k 
Mean of HAQ and mPDI at 6 wk 
154
5 Parenting 
148 
Table 5.1.3 (continued) 
 mPDI 
 B 95% Wald CI p 
Intercept 
DAS28 (continuous) 
Disease duration (> 2 year) 
Family size (> 1 child) 
Medication postpartum (yes) 
Erosive disease (yes) 
-0.126 
 0.158 
-0.006 
 0.063 
 0.036 
 0.347 
[-0.333; 0.081] 
[ 0.111; 0.206] 
[-0.022; 0.009] 
[-0.133; 0.259] 
[-0.100; 0.172] 
[ 0.151; 0.544] 
0.234 
<0.001 * 
0.432 
0.526 
0.602 
0.001 * 
* p  0.05 
Responsiveness of PDI postpartum 
PDI scores in women with a postpartum flare rose significantly, while in women 
without a flare, PDI scores stayed stable (see Table 5.1.4). ANOVA analyses 
revealed that women with a flare had a significant change in PDI and mPDI 
scores compared to women without a flare (between 6 and 12 or 6 and 26 
weeks postpartum PDI [F 7.8,df91,p < 0.01]; [F 7.9,df90,p < 0.01], mPDI 
[F5.5,df91,p = 0.02]; [F8.5,df90,p < 0.01] respectively). This is also true for the 
HAQ score: in patients with a flare HAQ scores changed significantly (see Table 
5.1.4), while they remained stable in non flare patients (ANOVA between 6 and 
12 or 6 and 26 weeks postpartum [F 10.56,df 90,p < 0.01] and [F 7.4,df 91,p < 
0.01] respectively). 
 
Another way to approach responsiveness is by use of a Minimal Clinically 
Important Difference (MCID) of the PDI scores. As previously defined, 0.5 of the 
SD of the measurement is a good estimate of the MCID (11, 12). However this 
was mostly used for quantification of improvement, here we used it to quantify 
deterioration in functionality during a flare. The maximum MCIDs of 
deterioration of PDI and HAQ postpartum was defined as the maximum of all 
halves of the SD of (m)PDI and HAQ scores at all time points (see Table 5.1.2). 
This resulted in a MCID of 0.25 for PDI score, a MCID of 0.29 for mPDI score, 
and a MCID of 0.31 for HAQ score. The proportions of women that met the 
MCID criterion for PDI scores were 40.7% in the flare group and 23.1% in the 
non-flare group, for mPDI scores these proportions were 37.0% and 27.7%, 
respectively. The proportions of women that met the MCID criterion for the HAQ 
scores were 52.9% in flare women and 18.5% in non-flare women. Another way 
to give insight into the responsiveness, is by comparing the MCIDs and mean 
differences of (m)PDI and HAQ scores between the flare and non-flare groups 
(Table 5.1.4). None of the mean differences in the flare groups was larger than 
the MCID of the corresponding score. 
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Table 5.1.4: Mean differences of PDI and HAQ postpartum in women with and without a flare. 
(paired t-test, CI: confidence interval, NS not significant; ANOVA between non-flare and flare 
patients, in all subgroups p < 0.01) 
Postpartum Mean difference 95% CI of the difference p 
No flare (n = 65) 
PDI 6wk - 12wk 
PDI 6wk - 26wk 
mPDI 6wk - 12wk 
mPDI 6wk - 26wk 
HAQ 6wk - 12wk 
HAQ 6wk - 26wk 
Flare (moderate/severe) (n = 27) 
PDI 6wk - 12wk 
PDI 6wk - 26wk 
mPDI 6wk -12wk 
mPDI 6wk -26wk 
HAQ 6wk - 12wk 
HAQ 6wk - 26wk 
 
 0.00 
-0.05 
 0.01 
-0.06 
-0.01 
-0.07 
 
 0.23 
 0.16 
 0.22 
 0.18 
 0.29 
 0.16 
 
[-0.29;0.16] 
[-0.12;0.03] 
[-0.09;0.10] 
[-0.15;0.03] 
[-0.11;0.08] 
[-0.16;0.15] 
 
[ 0.06;0.40] 
[ 0.02;0.30] 
[ 0.06;0.38] 
[ 0.03;0.33] 
[ 0.11;0.48] 
[ 0.01;0.33] 
 
NS 
NS 
NS 
NS 
NS 
NS 
 
0.01 
0.03 
0.01 
0.02 
0.01 
0.04 
DISCUSSION 
The present study, embedded in the PARA-study, shows for the first time 
prospectively measured parenting disability in a large cohort of women with RA 
postpartum. This study therefore gives detailed information for patients and 
health professionals about how RA patients function postpartum. Although the 
overall mean PDI scores of the group did not significantly change between each 
postpartum visit, in a subgroup of patients with a documented flare, PDI did 
change significantly. Furthermore, we identified two covariates, a higher 
disease activity and having erosive disease, that were both associated with 
higher PDI scores postpartum. 
 
For the first time we were able to show the responsiveness of PDI scores, since 
we measured the score over time and we were able to compare it with disease 
course (flare/no flare). Changes in PDI between 0.25-0.29 may be of clinical 
significance, based on estimates of the MCID from this study. The MCID, 
however, will have to be confirmed in future longitudinal studies. In the present 
study also a considerable amount of women without a flare had a clinical 
significant change in parenting function, this may point to other causes than 
changes in disease activity contributing to lower parenting function postpartum. 
 
In comparison with the only available results of PDI scores of 9 women with RA 
and young children (6), PDI scores in present study were lower. Compared to 
the previous study, our cohort contains younger patients, with a lower HAQ 
score and  also the erosive status might have been lower, which all may have 
accounted for lower PDI scores. There was also a difference regarding the 
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number of domains used in the Parenting Disability questionnaire; in previous 
study 20 questions and in the current study 25 questions. A higher number of 
domains asked in the latter may have accounted for lower PDI scores. PDI 
scores calculated with 20 questions in our cohort resulted indeed in slightly 
higher mean PDI scores postpartum than with 25 questions: at 6wk 0.55, 12 wk 
0.61 and 26 wk 0.58. However, as in the previous study, all questions have 
been answered at least once with some degree of difficulty in current cohort, 
and the range of scores were identical. Comparable results with the previous 
conducted study were found regarding HAQ and PDI scores; in both studies, 
these were highly correlated. An additional study to elucidate the most optimal 
set of questions from the Parenting Disability questionnaire that correlates even 
more strongly, might be subject of future research. 
 
In the present study we highlighted the domains that were influenced the most 
postpartum. These domains were centered on carrying, hygiene needs, using 
car safety seats, taking care of the child outside the house and doing household 
chores and shopping. Three of the five domains were also in the top five of 
domains affected the most in the previous study. Differences could be explained 
by the fact that women with older children were involved in the previous study. 
For example, in those women the domain ‘taking care of your child’s hygiene 
needs’ was less often rated, since this is less difficult with toddlers than with 
babies. In another study these same items were thought to be of significance in 
parenting function of RA patients (3). 
 
Although it seems obvious, this is the first study showing that higher disease 
activity and erosive disease are associated with higher parenting disability of 
the mother postpartum. Other covariates such as a larger family size, which 
were previously associated with less parenting disability, were not of 
significance in the present study (14). Asking for help in child care is often 
needed, which may indirectly be reflected in the number of domains in present 
study on which women answered ‘less due to arthritis’. Many women with RA 
find requesting help very difficult to do, but necessary for completion of daily 
tasks (3). Further research will be conducted among patients with and without 
substantial additional help postpartum, in order to determine whether additional 
household help results in better parenting function. Other strategies, such as 
adjusting expectations and adaptive approaches to completing tasks, may be 
applicable rehabilitation and public health interventions targeting mothers living 
with a chronic illness as RA (14). 
 
Because HAQ and PDI scores are highly correlated and both have comparable 
responsiveness during a flare postpartum, one could say that there is no need 
for a PDI. However, in our opinion the Parenting Disability questionnaire 
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provides much more information of the functioning of a patient just after delivery 
because of assesses specific tasks related to parenting, which may direct 
health professionals to give adequate joint protective advices to the tasks with 
which patients have difficulties. Further research will be focused on women with 
and without joint protective instructions before delivery and PDI scores after 
delivery to assess the effectiveness of such instructions on parenting disability. 
 
The present study has some limitations. The PDI was used for the first time in 
The Netherlands, therefore cultural differences between California and The 
Netherlands may have influenced the final scores, and another reference group 
was not available. However, our careful translation and back-translation in 
addition to pilot testing did not suggest any significant cultural differences. 
Second, PDI scores were very strongly correlated with disease activity, but 
were measured in a country with the possibilities for high disease control (mean 
DAS28 3.4 6 weeks postpartum). Therefore, one should be aware of that if 
disease is or cannot be maximally controlled, help in parenting may be of 
greater importance than showed here. 
 
In conclusion, difficulties in the parenting function of women with RA postpartum 
can be measured with PDI scores. Postpartum parenting disability of patients 
with RA was significantly influenced by having higher disease activity and 
erosive disease. Therefore, the treatment goal postpartum should be focussed 
on modifiable factors such as lowering disease activity and giving joint 
protective advices before delivery, to preserve the parenting tasks of RA 
patients. 
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INTRODUCTION 
The objectives of this thesis were (I) to prospectively study disease activity of 
rheumatoid arthritis (RA) before, during and after pregnancy, (II) to explore 
causal relations of the pregnancy-induced amelioration of RA between the 
clinical characteristics and immunological changes in autoantibodies, (III) to 
determine the influence of disease activity and medication use on pregnancy 
outcome, and, finally, (IV) to address clinical aspects in parenting function 
postpartum. 
 
Previous, mostly retrospective, studies reported that about 55-85% of women 
with RA experienced a spontaneous improvement of the disease activity during 
pregnancy (1-3). Whether this still holds true in a large prospective cohort study 
from prepregnancy onwards, in an era of new treatment options, is one of the 
principal research questions addressed in this thesis. Therefore, first, objective 
disease activity scores and functionality scores were defined for use during 
pregnancy, secondly, disease activity was measured before conception, during 
pregnancy and postpartum, and thirdly, associations between disease course 
during pregnancy and patients’ characteristics, with autoantibodies in particular, 
were addressed. 
 
Another important research question addressed in the present study is about 
pregnancy outcome in women with RA. In previously performed case-control 
studies in rheumatic diseases pregnancy outcome was often described as being 
unfavourable (4-8). Having RA was especially associated with delivering babies 
of lower birth weight compared with controls, and with higher rates of maternal 
complications, especially gestational hypertension, (pre)eclampsia, and 
caesarean sections (4-8). Also higher disease activity during pregnancy was 
previously suggested as being unfavourable for birth weight, which, however, 
could not be proven in a statistically significant manner (8). Previous studies 
had difficulties in distinguishing the effect on disease activity of pregnancy or of 
medication use, and several studies showed pregnancy outcomes without 
appropriate corrections for gestational age (4, 6-8). In the present prospective 
cohort only prevalences of pregnancy-related maternal and child complications 
could be described. The exclusiveness of the present prospective cohort of 
pregnant women with RA is that disease activity scores were measured 
objectively. This, in particular, made it possible to determine the influence of 
prednisone use and disease activity during pregnancy on birth weight, and on 
the occurrence of maternal complications. 
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Finally, our last research question is of great interest to health professionals and 
patients, and addressed impairments in parenting function postpartum. Detailed 
information on this special situation postpartum has not been reported in 
women with RA up to now. The present prospective cohort study addressed this 
issue by using an objective functionality scoring method of parenting function, 
‘the parenting disability index (PDI)’ (9). Examining the detailed questions on 
difficulties in parenting function and the association of PDI scores with patients’ 
characteristics will provide information for health professionals and patients and 
may contribute to the provision of more appropriate care in order to preserve 
parenting function postpartum. 
 
In this chapter, first the main findings are summarized per objective. Next 
methodological considerations related to our study design are addressed. The 
new insights achieved with studies in this thesis are presented subsequently. 
Then the possible implications for clinical practice are discussed. Finally, 
directions for future research are discussed. 
MAIN FINDINGS 
Objective 1: Measuring disease activity during pregnancy 
The aim was threefold: First, to assess how pregnancy influences the scoring of 
the Disease Activity Score in 28 joints (DAS28) (10, 11) and the Health 
Assessment Questionnaire (HAQ) (12), and how both scores perform in 
pregnant patients with RA. Second, to prospectively determine the disease 
activity during pregnancy in RA patients treated in an era of new treatment 
options. Third, the levels of anti-cyclic citrullinated peptide (anti-CCP) and 
rheumatoid factor (RF) were determined during pregnancy and postpartum to 
correlate with disease activity, and the chance to improve during pregnancy in 
the presence or absence of autoantibodies was additionally addressed. 
Measuring disease activity during pregnancy: Validated instruments 
Pregnancy has a favourable effect on the course of rheumatoid arthritis (RA), 
although we cannot be certain about the magnitude of this effect, because RA 
assessment tools have never been validated in pregnancy and were mainly 
subjective (1, 2, 13, 14). 
 
In chapter two it was demonstrated that being pregnant influences the scoring 
of disease activity and functionality. Disease activity was measured with the 
DAS28 and functionality with the HAQ. Certain HAQ variants, made within the 
rules of scoring the HAQ (12, 15), could reduce the influence of pregnancy on 
functionality scores. The two RA assessment tools for use during pregnancy 
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which perform best were found to be: for disease activity the DAS28-CRP-3 
(calculated with C-reactive protein (CRP in mg/L) but without visual analogue 
scale (VAS) of global health (GH)), and for functionality the HAQ variant 
calculated without 6 selected items, although even this variant of the HAQ did 
not totally preclude the influence of pregnancy. These two well-defined objective 
assessment tools are indispensable for the present prospective cohort study, 
and will probably also have their merits in future research. 
Measuring disease activity during pregnancy: Disease course during pregnancy 
and postpartum 
As stated before, according to previously conducted retrospective studies, 
approximately 55–85% of patients with rheumatoid arthritis (RA) will improve 
during pregnancy (1,13,14). Prospective data on disease activity during 
pregnancy, however, are limited (2, 6, 16). The assumption of rheumatologists 
that almost all patients with RA will experience a remission of disease activity 
during pregnancy does not seem to be valid today, and must be viewed in the 
context of new treatment options. In this nationwide prospective study disease 
activity was documented with validated objective instruments and showed that 
disease activity significantly declines during pregnancy and significantly rises 
postpartum. Furthermore, it showed that approximately 25% of women were in 
remission (DAS28-CRP-3 < 2.6) in the third trimester, despite the fact that 
medication use was remarkably reduced during pregnancy compared with 
before conception. The difference in reported frequencies of improvement 
compared with results in the present study may be explained by three 
arguments: (I) measuring with an objective measurement tool instead of 
subjective recording of decrease of disease activity, (II) a prospectively 
conducted study versus retrospectively conducted studies (no recall bias), (III) 
patients with low and high disease activity participated in the present study, 
while in previous studies mainly women with high disease activity were selected 
(selection bias). We found that in women with at least a moderate disease 
activity (DAS28-CRP-3 > 3.2) at first trimester (62% of participants), almost 50% 
of them had at least a moderate improvement during pregnancy. Postpartum, 
we found that more than 33% of all participants had at least a moderate flare. 
The postpartum flare in the present study, however, may be underestimated 
because medication use was considerably increased after delivery. 
 
This study demonstrated that neither presence of anti-CCP or RF separately, 
nor presence of erosions, were associated with improvement during pregnancy 
or postpartum flare. Finally, this study showed that during pregnancy patients 
with low disease activity before pregnancy remained relatively stable, and 
patients with moderate to high disease activity frequently improved. 
 
167
General discussion 
161 
Measuring disease activity during pregnancy: Associations with autoantibodies 
The mechanism underlying the spontaneous clinical improvement of RA during 
pregnancy and the subsequent flare after delivery is still unexplained. Anti-CCP 
and RF are thought to play an important role in the pathophysiology of RA (17). 
Furthermore there is increasing evidence in support of the role of B cells, 
derived from clinical studies that demonstrate improvement of disease activity 
upon treatment with B-cell targeted therapies (18). However, whether changes 
in B-cell function, as reflected in levels of anti-CCP and RF during pregnancy 
and postpartum, are associated with improvement of RA during pregnancy or 
with a flare after delivery, was not known. In the present thesis we showed that 
autoantibody levels were stable during pregnancy, and not related to the 
improvement of disease activity during pregnancy. Postpartum, all levels of 
autoantibodies, except of IgG-RF, decreased when medication was resumed, 
as reported previously (19-21). However, surprisingly, in the absence of both 
autoantibodies (negative for both anti-CCP and RF) women had significantly 
more frequently an improvement according to EULAR response criteria during 
pregnancy, than women positive for one or both of the autoantibodies. This 
finding may support the hypothesis that RA is a heterogeneous disease with 
different pathogenic mechanisms involved (22). In analogy with SLE, where the 
presence of autoantibodies together with increased Th2-mediated responses 
during pregnancy (23), may result in a disease flare during pregnancy, one can 
speculate that similar mechanisms are responsible for the observation that 
disease activity is less likely to improve during pregnancy in RA patients with 
autoantibodies (anti-CCP and/or RF). 
Objective 2: Determining pregnancy outcome in RA 
The aim of this study was twofold: firstly to determine the pregnancy outcome of 
rheumatoid arthritis (RA) patients in relation to disease activity, and secondly in 
relation to prednisone use. Furthermore, pregnancy outcome might be 
negatively influenced by RA, since unfavourable pregnancy outcome has been 
demonstrated in mostly case-control studies in several rheumatic diseases (3, 4, 
7, 8, 24). Case definitions in previous studies have always been difficult, and 
prospective studies are still warranted to find (clinical) associations between 
adverse pregnancy outcome and, for example, disease activity. 
 
The PARA-study is the world’s largest prospective study in women with RA up 
to now, describing pregnancy outcome and extensively linking disease activity 
and medication use throughout pregnancy to birth weight and birth weight SDS 
(standard deviation score), i.e. birth weight adjusted for gestational age and sex 
of newborn. Although the incidence of pregnancy complications in our cohort 
was comparable with the Dutch general obstetric population (25), among 
patients with high disease activity caesarean sections were performed more 
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frequently. Furthermore, we showed that newborns of women with higher 
disease activity and prednisone use had a lower birth weight compared to 
newborns of women with low disease activity and without prednisone use. We 
described for the first time that the effect of prednisone on a lower birth weight 
was mediated indirectly by shortened gestational age at delivery, whereas 
higher disease activity directly negatively influenced birth weight. Both results 
were strongly suggested in previous studies, however, in those studies the 
influence on disease activity could not be ascribed with statistical significance to 
pregnancy or medication use separately (8, 26). 
Objective 3: Parental function postpartum 
This thesis addresses for the first time an observational study on parenting 
disability postpartum to describe correlations between PDI scores and disease 
activity, and other functionality scores (HAQ), so that (modifiable) factors 
associated with PDI scores postpartum could be defined. Only a few studies 
have addressed the difficulties parents with RA encounter in parenting up to 
now (27-29). When modifiable factors are defined, patients can be better 
prepared for their parenting task postpartum. 
 
Results of this study showed that difficulties in the parenting function of women 
with RA postpartum can easily be measured with PDI scores, and showed that 
PDI scores are responsive to changes in time. PDI scores were, as expected, 
highly correlated with HAQ scores. Two (modifiable) factors influencing 
parenting disability postpartum could be defined: having higher disease activity 
postpartum and erosive disease. So lowering disease activity of RA postpartum 
and providing joint protective advice during pregnancy may be useful for 
reducing parenting disability postpartum. 
METHODOLOGICAL ISSUES 
One of the strengths of the studies in this thesis is that all studies were 
performed in the same study population. This facilitates direct comparison 
across the studies, though differences in the exact number of persons existed 
due to the fact that the cohort was still ongoing at the time of analyses, and 
depended on the outcome measures studied. Each study showed the time 
frame in which patients enrolled the specific study. 
 
Another strength of the study is that the compliance of the patients, even up to 
seven visits after inclusion, was over 95%. This was mainly due to visiting 
participants at home. However, for the interpretation of the findings, some 
methodological issues should be taken into account. Below, the internal and 
external validity of the studies described in chapters two to five are discussed. 
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Internal validity 
Internal validity refers to the extent to which results are valid for the study 
population itself; more specifically the extent to which the results might be 
distorted by systematic errors. In the following, selection bias and information 
bias are discussed. 
Selection bias 
In chapters two to five, data of women participating in a nationwide 
observational prospective cohort study (PARA-study) were used. Selection bias 
may have occurred as a result of (I) selective referral of patients by 
rheumatologists and self-referral of patients to this cohort study, (II) selective 
non-response, and (III) selective loss to follow-up. 
 
In order to reduce selective referral, all rheumatologists in The Netherlands 
were informed twice a year about the study and asked to recruit patients. The 
recruitment may have been selective at two points: women with a long 
persistent wish to conceive and women with higher disease activity may have 
been referred more easily. Those women will get more attention because they 
visited their rheumatologist more frequently. Only a few applications were self-
referrals; these were checked with the patient’s own rheumatologist to ascertain 
the presence of RA according to the ACR 1987 criteria (30). 
 
The number of non-responding women for application of the study was very low, 
since the major selection was already made by rheumatologists. Participating 
women were highly motivated to enrol the study, and resulted in a follow-up rate 
of over 95%. Selective loss to follow-up might have been introduced in women 
with an adverse pregnancy outcome, however, the pregnancy outcome was still 
recorded by telephone interview, and only a few women preferred not to be 
visited anymore postpartum or after a miscarriage. 
Information bias 
One important source of information bias in our study may be the self-report of 
all clinical and non-clinical risk factors and outcome measures. Self-reports 
could have biased the results if there had been systematic differences in the 
answering of questions on risk factors by the outcome measure. In chapter 
three, we addressed the problem of possible information bias on reported 
pregnancy outcome separately. We conducted a small study on patient reports 
and clinical data from obstetricians of 40 participants of the PARA-study. The 
agreement between patient-reported and obstetric record-based pregnancy 
outcome and obstetric history, as used in this thesis, was reliable. In those 40 
patients, the patient-reported and obstetric record-based results on birth weight 
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and gestational age were correlated with an intraclass correlation coefficient 
(ICC) of at least 0.98. Also reports on the frequency of adverse pregnancy 
outcomes were reliable as reflected in kappas of 1. Of the rare adverse 
pregnancy outcome, the lowest kappa was 0.65 for eclampsia, 0.78 for 
gestational hypertension and 0.90 of premature birth. Another issue to address 
was that self-reports on induction of labour were unreliable, since women often 
confused this with stimulation of contractions during labour. In conclusion, in the 
present thesis patient-reported data were likely to be reliable, except for 
eclampsia and induction of labour. Therefore data of severe pregnancy 
complications were all verified with obstetric records, as well as for induction of 
labour. 
External validity 
The external validity refers to the generalizability of the study findings to 
persons outside of the study population, e.g. other women with RA and a wish 
to conceive, or who are already pregnant. 
 
The results of the present cohort study can be generalized to those RA patients 
under control of rheumatology care in a country with possibilities for high 
disease control; in the present cohort median DAS28-CRP-3 before pregnancy 
was 3.9. 
 
In chapter two the objective measurement tools available to describe 
functionality and disease activity in RA during pregnancy were studied. Since a 
“gold standard” test is not available during pregnancy we had to make 
assumptions. For functionality, we were able to perform HAQ scores in 30 
healthy pregnant women to measure the influence of pregnancy on the HAQ 
score. Furthermore rules were already stated by the developers of the HAQ, so 
the HAQ score could be adapted accordingly (12, 15), in order to obtain still 
valid functionality scores. However for disease activity this was more 
complicated. Results of previous literature showed that about 66% of patients 
reported an improvement during pregnancy, but only 16% of patients had a 
clinical remission of disease activity defined as no swollen or painful joints at 
third trimester (2). We decided to choose a variant of the objective disease 
activity score DAS28.(11) We defined the best performing disease activity score 
as that DAS28 variant that is most sensitive for recording remission and as the 
one less influenced by differences in inflammatory parameters (erythrocyte 
sedimentation rate (ESR) or CRP), and differences in VAS-GH introduced by 
pregnancy in healthy women. The DAS28-CRP-3 score showed to be 
influenced the least by pregnancy in that sensitivity analyses, and recorded the 
most (23%) of women with RA in clinical remission during pregnancy. 
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It is important to know that this is the first (observational) study that used 
DAS28-CRP calculated with 3 variables as disease activity score. Furthermore, 
we used the European League Against Rheumatism (EULAR) response criteria 
(31), however those were initially designed on the basis of the DAS or DAS28 
with ESR (32). Up to now several researchers have shown that DAS28-CRP 
and DAS28-ESR are not fully comparable in special situations (33, 34). 
Especially with higher age and with longer disease duration, although these 
were unlikely to interfere in the present study with the measurements, DAS28-
ESR would definitely underestimate the remission rate in RA patients. One 
should thus be aware of the restrictions of the DAS28-CRP-3, because it has 
been used as objective measurement tool throughout this thesis. 
 
In chapter three more restrictions concerning measuring disease activity were 
encountered, first, postpartum a good definition of a flare was absent. Therefore 
we defined ‘reversed’ EULAR response criteria, on the basis of the EULAR 
response criteria (based on DAS28-ESR) (31). These flare criteria need to be 
confirmed in other cohorts as well, and preferably correlated with patients and 
rheumatologist’s global assessment of disease activity. 
 
A second restriction in chapter three concerns the definition of EULAR-
response criteria during pregnancy. Only women with an initial DAS28-CRP-3 
> 3.2 at first trimester could be classified for their responses (31). Because of 
this requirement up to 38% of studied women with RA were excluded from 
classification of disease response during pregnancy. Also the association 
between improvement of RA during pregnancy and autoantibodies was only 
made for women fulfilling that requirement. However, only with good 
classification of an objectively measured disease activity during pregnancy, can 
one study clinical associations between pregnancy-induced amelioration and 
laboratory investigations, that was lacking in previously described studies. 
Therefore, we chose to make those restrictions for the present analyses. 
 
Another general issue to address here are the concerns of how to interpret 
medication use during pregnancy. As reported in this study, women were 
consistent in their kind of medication used during pregnancy, only dosages 
were adapted in half of them. Interpretation of laboratory findings and disease 
activity scores should therefore always be interpreted with care. In the present 
study an underestimation of the effect of pregnancy on disease activity of RA 
was still likely; women rather decreased than increased their dosage of 
medication. 
 
Postpartum the interpretation of data regarding medication use may be difficult, 
since women who decided to breastfeed their child were restricted in medication 
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use, while other women restarted their medication to prevent a relapse and 
started using disease-modifying antirheumatic drugs (DMARDs) and/or 
biologicals soon after delivery. In general, the flare rate postpartum is lower 
than expected in the present cohort, mainly due to restart of medication soon 
after delivery, however flares as the natural course of RA postpartum were still 
observed. 
 
Also in chapter four, where pregnancy outcome is addressed, some issues 
should be discussed regarding the study design. Since the PARA-study is an 
observational study, results are restricted to reports of prevalences of adverse 
pregnancy outcome, without the possibility for statistical analyses with results of 
healthy controls. This observational study however is the first large 
observational study of women with RA that can adequately study causal 
relations between (subgroups of) disease activity or medication use during 
pregnancy, and pregnancy outcome. 
 
Finally, for chapter five, where parenting disability postpartum is addressed, 
some minor issues should be discussed on study design. The most important 
issues are (I) that this was the first time that a Dutch translated version of the 
parenting questionnaires was used, and (II) that this was the first time that PDI 
scores were calculated at several time points as an objective score for 
parenting function postpartum. Another issue to address is the way 
questionnaires are used. In the present study questionnaires were filled out by 
women themselves, comparable to the HAQ, whereas the questionnaires were 
originally developed to collect data of women by telephone interview. 
NEW INSIGHTS 
The new insights acquired from this thesis are: 
I Disease activity and functionality during pregnancy should be measured 
with (adapted) objective measurement tools only. 
II Improvement of disease activity during pregnancy and flares postpartum 
are still present in women with RA, however in lower percentages (in 
patients with at least moderate disease activity 48% response during 
pregnancy, and of all patients 39% flare postpartum), even in an era of 
more treatment options. Furthermore, women with low disease activity 
remain stable during pregnancy. 
III RA patients without both autoantibodies (anti-CCP and RF) have a 
higher chance to improve during pregnancy than RA patients with one or 
both autoantibodies. 
IV Higher disease activity is directly associated with lower birth weight, 
while prednisone use reduces birth weight indirectly via gestational age. 
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Higher disease activity is also associated with a higher frequency of 
caesarean sections. 
V Postpartum a higher parenting disability is associated with erosive 
disease and higher disease activity. 
IMPLICATIONS FOR CLINICAL PRACTICE 
The new insights from this thesis were translated into seven implications for 
clinical practice: 
I During pregnancy in women with RA, disease activity could be measured 
with DAS28-CRP-3 and functionality can preferably be calculated by 
means of a HAQ without 6 selected questions to obtain objective data for 
research, and both scores can possibly be used for monitoring disease 
activity and functionality in an individual patient. 
II Women with RA and a wish to conceive can be informed that if the 
disease activity of RA can be adequately controlled, currently up to one-
half of the women with moderate or high disease activity at first trimester 
will improve during pregnancy, and of all patients at least one-third of all 
patients will flare postpartum. 
III Women may be informed that in the case of low disease activity before 
pregnancy, disease activity will remain stable during pregnancy, while 
women with at least moderate disease activity may have a considerable 
chance of improving. 
IV Women with RA without autoantibodies (anti-CCP and RF) at any time 
measured during disease course, may have a higher chance of 
improving during pregnancy. 
V Birth weight of the newborn may benefit from good control of disease 
activity before and during pregnancy, which might implicate that 
rheumatologists should strive to low disease activity in their patients for a 
better pregnancy outcome. 
VI Obstetricians should be aware of a higher incidence of caesarean 
sections in RA patients with high disease activity, and of an increased 
risk of preterm delivery (< 37 weeks) in RA patients using prednisone. 
VII Treatment goals postpartum should be focussed on modifiable factors to 
preserve parenting function of RA patients by giving joint protective 
advice before delivery and lowering disease activity postpartum. 
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RECOMMENDATIONS FOR FUTURE RESEARCH 
To state new research questions, one must first be aware that performing 
randomised controlled trials during pregnancy is in general difficult, because of 
unknown influences on unborn life and for ethical reasons. In these situations 
an observational study, as the PARA-study, thus provides the highest level of 
evidence possible to investigate causal relations. In the present thesis we 
described that RA patients can be properly classified into women with or without 
improvement during pregnancy, and with or without deterioration postpartum. 
This facilitates future comparisons between clinical responses and laboratory 
findings. 
 
A first suggestion for future research is directed towards the question why the 
disease activity of RA patients improves during pregnancy. Immunological 
research guided by the clinical observation that the presence of autoantibodies 
seems to play a role in the persistence of disease activity during pregnancy can 
be important. Regarding this, biochemical research on glycosylation might be 
important (35), since this mechanism may change the functional properties of 
autoantibodies and may result during pregnancy in autoantibodies that are less 
pathogenic. But also changes in the immune system in general, like the more 
Th2-guided responses during pregnancy (23), probably as a result of more 
changes in hormonal status (36) or due to the influence of placental (37) or child 
characteristics (13, 38, 39), are still of interest for future research. 
 
A second suggestion for future research regarding pregnancy outcome in 
women with RA is directed towards the pregnancy outcome per DMARD used 
in the present cohort in order to provide additional information for 
rheumatologists, when therapy options are restricted and disease activity 
should be better controlled for the pregnant women (40). Furthermore, ideally a 
randomised-clinical trial should be conducted, in order to show the effect of 
DAS28-mediated intensified disease control during pregnancy versus regular 
care. However, performing this will need an impossibly high number of 
participants. Another way to support the suggestion that low disease activity 
during pregnancy is better than moderate to high disease activity, is to perform 
a study on their children. Lower birth weight of babies of women with high 
disease activity may influence children’s development in growth or health 
negatively compared with that of children born with a higher birth weight in 
women with low disease activity. It has been suggested that children with lower 
birth weight are more susceptible to perform less in school, and to develop 
already risk factors in their childhood for metabolic diseases for diabetes and/or 
cardiovascular diseases in adult life (41-44). These indicators for increased risk 
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are already present at young age, and therefore this could be topic of new 
research in children born in the PARA-study. 
 
A third suggestion for future research is defining characteristics of women with 
RA (I) that have not become pregnant yet, and (II) determining associations 
between the time to conceive and (modifiable) disease characteristics. 
Elucidating this is of great importance, since many women are treated, because 
of their wish to conceive, with less medication than needed for adequate 
disease control. To avoid irreversible loss of functionality due to high disease 
activity, referral to assisted reproduction techniques may be considered in 
women with RA. Finally, (III) less fecundity in RA has been described, however 
the cause has not yet been elucidated (3). 
 
The fourth and final suggestion for future research concerns the measuring of 
the effect of joint protective advice given to women with RA and erosive disease 
during pregnancy, and the effect of standardized lowering of disease activity 
with medication postpartum. Both may independently increase the ability of 
women to take care of their children. Future research can be conducted with 
already collected data, and will address the magnitude of the effect of joint 
protective advice during pregnancy on parenting disability postpartum, in order 
to generate evidence for adding this into the guidelines for standard care of RA 
patients during pregnancy. 
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The work presented in this thesis aimed to determine the course of disease 
activity of rheumatoid arthritis (RA) from before, during, till 6 months after 
pregnancy, and to define its associations with patients’ characteristics and 
pregnancy outcomes. All in order to elucidate the mechanism of immunological, 
biochemical, and/or hormonal changes that might explain this favourable effect 
of pregnancy in RA eventually. Previously mostly retrospectively conducted 
studies reported up to 90% of women with RA experiencing a spontaneous 
improvement of the disease activity during pregnancy. Whether this still holds 
true in a large prospective cohort study from prepregnancy onwards, in an era 
of new treatment options, is one of the principal research questions addressed 
in this thesis. Therefore, we conducted a nationwide prospective cohort study 
on pregnancy and RA (the PARA-study acronym for Pregnancy-induced 
Amelioration of Rheumatoid Arthritis) in the Netherlands, which was conducted 
between 2002 and 2009 (chapter two). 
MEASURING DISEASE ACTIVITY DURING PREGNANCY 
The aim was threefold. First, to assess how pregnancy influences the scoring of 
the Disease Activity Score in 28 joints (DAS28) and the Health Assessment 
Questionnaire (HAQ) (chapter two), and how both scores perform in pregnant 
patients with RA. Second, to prospectively determine the disease activity during 
pregnancy in RA patients treated in an era of new treatment options. Third, to 
determine whether changes in levels of anti-cyclic citrullinated peptide (anti-
CCP) and rheumatoid factor (RF), were associated with the spontaneous 
improvement of rheumatoid arthritis (RA) during pregnancy and with the 
subsequent flare postpartum (chapter three). 
Validated instruments 
In chapter two we demonstrated that being pregnant influences the scoring of 
disease activity and functionality. Disease activity was measured with the 
DAS28 and functionality with the HAQ. Certain HAQ variants, made within the 
rules of scoring the HAQ, could reduce the influence of pregnancy on 
functionality scores. The two RA assessment tools for use during pregnancy 
which perform best were found to be: for disease activity the DAS28-CRP-3 
(calculated without visual analogue scale (VAS) of global health (GH)), and for 
functionality the HAQ variant calculated without 6 selected items, although even 
this variant of the HAQ did not totally preclude the influence of pregnancy. 
These two well-defined objective assessment tools are indispensable for the 
present prospective cohort study, and will probably also have their merits in 
future research. 
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Disease course during pregnancy and postpartum 
In chapter three section one we showed that the assumption of rheumatologists 
that almost all patients with RA will experience a remission of disease activity 
during pregnancy does not seem to be valid today, and must be viewed in the 
context of new treatment options. In this nationwide prospective study disease 
activity was documented with validated objective instruments and showed that 
approximately one-quarter of women were in remission in the third trimester, 
despite the fact that medication use was remarkably reduced during pregnancy 
compared with before conception. Almost half of the women had at least a 
moderate response in disease activity during pregnancy and more than one-
third had at least a moderate flare postpartum. The postpartum flare, however, 
may be underestimated because medication use was remarkably increased 
after delivery. In this chapter we demonstrated that neither the presence of RF, 
or anti-CCP separately, nor the presence of erosions, were associated with 
improvement during pregnancy or postpartum flare. Finally, this study showed 
that during pregnancy patients with low disease activity before pregnancy 
remained relatively stable. 
Associations with autoantibodies 
In chapter three section two the mechanism underlying the spontaneous clinical 
improvement of RA during pregnancy and the subsequent flare after delivery 
was addressed by since RF and anti-CCP are thought to play an important role 
in the pathophysiology of RA. In the present study we showed that autoantibody 
levels were stable during pregnancy, and not related to improvement of disease 
activity during pregnancy. Postpartum, all levels of autoantibodies, except of 
IgG-RF, decreased when medication was resumed. However, surprisingly, in 
the absence of both autoantibodies (negative for both anti-CCP and RF) women 
had statistically significantly more frequently an improvement according to 
EULAR response criteria, than women positive for one or both of the 
autoantibodies. This finding may support the hypothesis that RA is a 
heterogeneous disease with different pathogenic mechanisms involved. 
DETERMINING PREGNANCY OUTCOME IN RA 
We described the results of this study in chapter four. The aim was twofold, first 
to determine pregnancy outcome of rheumatoid arthritis (RA) patients in relation 
to disease activity, and second in relation to prednisone use. 
 
We performed the world’s largest prospective study in RA women up to now, 
describing pregnancy outcome, and extensively linking disease activity and 
medication use throughout pregnancy to birth weight and birth weight SDS 
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(standard deviation score). Although the incidence of pregnancy complications 
in our cohort was comparable with the Dutch general obstetric population, 
among patients with high disease activity caesarean sections were performed 
more frequently. Furthermore, we showed that newborns of women with higher 
disease activity and prednisone use had a lower birth weight compared with 
newborns of women with low disease activity and without prednisone use. We 
described for the first time that the effect of prednisone on a lower birth weight 
was mediated indirectly by shortened gestational age at delivery, whereas 
higher disease activity directly negatively influenced birth weight. 
PARENTING FUNCTION POSTPARTUM 
In chapter five we performed for the first time an observational study on 
parenting disability postpartum to describe correlations between PDI scores and 
disease activity, and other functionality scores (HAQ), so (modifiable) factors 
associated with PDI scores postpartum could be defined. Results of this study 
showed that difficulties in the parenting function of women with RA postpartum 
can easily be measured with PDI scores, and showed that PDI scores are 
responsive for changes in time. PDI scores were, as expected, highly correlated 
with HAQ scores. Two (modifiable) factors influencing parenting disability 
postpartum could be defined: having higher disease activity postpartum and 
erosive disease. The three activities in which women most frequently 
encountered difficulty were carrying and bathing the baby and household 
chores. 
FUTURE RESEARCH 
The studies described in this thesis have identified several new insights and 
recommendations for future research (chapter six); both clinical and laboratory 
subjects are suggested. 
Clinical research 
The first hypothesis of future research may be to follow-up the children born 
from women with high disease activity during pregnancy, to discover whether 
they have already more risk factors for developing metabolic diseases than 
children born to women with low disease activity of RA, which may lead to an 
additional argument for good disease control during pregnancy. 
 
The second hypothesis to address is defining characteristics of women whose 
pregnancy wish is not fulfilled, and determining associations between the time 
to conceive and (modifiable) disease characteristics. 
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Finally a third hypothesis can be tested with already collected data that 
addresses the magnitude of the effect of joint protective advice during 
pregnancy on parenting disability postpartum. When there is a significant 
contribution of given joint protective advice, this will generate evidence for 
adding this into the guidelines for standard care of RA patients during 
pregnancy. 
Laboratory research 
Since we described in the present thesis validated measurement tools to 
classify disease course during pregnancy, it will facilitate future comparisons 
between clinical responses and laboratory findings. Immunological research 
guided by the clinical observation that presence of autoantibodies seems to play 
a role in the persistence of disease activity during pregnancy could be important. 
Also biochemical research on glycosylation might be important, since this 
mechanism may change the sensibility of autoantibodies and may account for 
different pathogenic effects of autoantibodies during pregnancy. Changed 
immunological responses, in general, as a switch to more Th2-guided 
responses during pregnancy, probably due to changes in hormonal status or 
due to the influence of placental or child characteristics, are still of interest for 
future research. 
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Al in de dertiger jaren van de twintigste eeuw werd beschreven dat tijdens 
zwangerschap de ziekteactiviteit van reumatoïde artritis (RA) spontaan kon 
verbeteren. Er waren in die tijd geen adequate behandelmogelijkheden voor RA. 
Er werden percentages tot 90% gerapporteerd van vrouwen die spontaan 
verbeterden tijdens de zwangerschap. Echter na de bevalling (postpartum) 
keerde de ziekteactiviteit in een even zo groot percentage vrouwen weer terug. 
Het fenomeen van de spontane verbetering en verslechtering van RA spreekt 
tot de verbeelding van vele onderzoekers. Tot nu toe ontbrak het echter aan 
een studie waarin een groot aantal vrouwen vóór, tijdens en na de 
zwangerschap is gevolgd. Een dergelijke studie is nodig om goed onderzoek te 
kunnen doen naar de oorzaak van de verbetering, en naar factoren die hiermee 
geassocieerd zouden kunnen zijn. Deze factoren zouden op immunologisch, 
biochemisch en/of hormonaal gebied kunnen liggen. Of het eerder 
gerapporteerde hoge percentage vrouwen dat verbetert tijdens de 
zwangerschap nog reëel is, in een tijdperk met veel meer therapeutische 
mogelijkheden voor RA, is één van de belangrijkste onderzoeksvragen die als 
eerste beantwoord moet worden alvorens dieper op de oorzaak (etiologie) van 
de verbetering in te kunnen gaan. De PARA-studie (acroniem voor Pregnancy-
induced Amelioration of Rheumatoid Arthritis) werd derhalve in 2002 gestart, en 
kan het beste omschreven worden als een landelijke observationele 
prospectieve cohort studie. (hoofdstuk twee) 
 
Dit proefschrift is gebaseerd op de PARA-studie en beschrijft: 
 
I A) het beloop van ziekteactiviteit van RA vóór, tijdens een zwangerschap 
en tot zes maanden postpartum. 
B) welke kenmerken van de RA patiënte verband houden met het beloop 
van de ziekteactiviteit tijdens en na de zwangerschap. 
II wat de invloed van ziekteactiviteit van RA en medicijngebruik (prednison) 
tijdens de zwangerschap is op de zwangerschapsuitkomst; in het 
bijzonder de invloed op zwangerschapsduur en geboortegewicht. 
III welke problemen vrouwen met RA ervaren tijdens de zorg voor hun 
kind(eren) na de geboorte, als de ziekteactiviteit van RA meestal weer 
toeneemt. 
METEN VAN ZIEKTEACTIVITEIT TIJDENS DE ZWANGERSCHAP  
De ziekteactiviteit van RA kan alleen goed vastgelegd worden als er objectieve 
maten voor het meten van ziekteactiviteit tijdens de zwangerschap gedefinieerd 
zijn. Daarna kunnen ziekteactiviteit en functionaliteit in de tijd gemeten worden 
en kan er gezocht worden naar associaties met kenmerken van de patiënten 
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met RA. In het eerste deel van dit proefschrift worden hiertoe drie 
vraagstellingen beantwoord:  
 
I a Hoe beïnvloedt een zwangerschap de score voor ziekteactiviteit 
gemeten met een ‘disease activity score voor 28 gewrichten’ (DAS28), 
en hoe de score voor functionaliteit gemeten met de ‘health assessment 
questionnaire’ (HAQ)? 
b Hoe betrouwbaar kunnen deze scores de veranderingen in 
ziekteactiviteit en functionaliteit tijdens de zwangerschap vastleggen? 
(hoofdstuk twee) 
II Verbetert de ziekteactiviteit van RA tijdens de zwangerschap, en 
verslechtert deze postpartum, ook in een tijd dat er meer therapeutische 
mogelijkheden zijn om RA te behandelen? (hoofdstuk drie sectie één)  
III a Veranderen de concentraties autoantistoffen (anti-cyclisch citrulline 
peptide antistoffen (anti-CCP) en subklassen reumafactoren (RF; IgM-RF, 
IgG-RF en IgA-RF)) tijdens de zwangerschap en postpartum?  
b Is een verandering in concentraties geassocieerd met de spontane 
verbetering in ziekteactiviteit van RA tijdens de zwangerschap en met de 
verslechtering postpartum? (hoofdstuk drie sectie twee) 
Objectieve en gevalideerde meetmethoden 
In hoofdstuk twee werd vastgesteld dat een zwangerschap zowel de 
meetmethode om ziekteactiviteit te meten (DAS28), als die om de functionaliteit 
te meten (HAQ) beïnvloedt. De invloed op de DAS28 was het meest 
uitgesproken als die berekend werd met de bezinking (BSE) en visuele analoge 
schaal voor algemene gezondheid (VAS-GH). De invloed op de DAS28 was het 
minst uitgesproken als die berekend werd met C-reactive protein (CRP) en 
zonder VAS-GH. Deze DAS28 kan kortweg worden aangegeven als DAS28-
CRP-3. De invloed van zwangerschap op de HAQ was in het algemeen groot. 
Door het opstellen van zogenaamde HAQ-varianten, allemaal gedefinieerd 
binnen de regels om een valide HAQ te berekenen, verminderde de invloed van 
zwangerschap op de functionaliteitscore aanzienlijk. Het resultaat van dit 
onderzoek was dan ook dat de twee meest valide maten om ziekteactiviteit en 
functionaliteit tijdens de zwangerschap te meten zijn: de DAS28-CRP-3 en de 
HAQ-variant berekend zonder de 6 specifieke vragen, die het meest door een 
zwangerschap worden beïnvloed. Hoewel daardoor de invloed van 
zwangerschap op deze HAQ-score aanzienlijk werd gereduceerd, bleef enige 
invloed op de score aanwezig. Zodra de meetmethoden voor ziekteactiviteit en 
functionaliteit tijdens de zwangerschap en postpartum goed beschreven waren, 
konden ze gebruikt worden in de PARA-studie en zullen mogelijk ook hun 
meerwaarde bewijzen in toekomstig onderzoek. 
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Ziekteactiviteit tijdens en na de zwangerschap 
In hoofdstuk drie sectie één werd de veronderstelling van reumatologen dat 
bijna alle vrouwen met RA een verbetering van ziekteactiviteit zullen ervaren 
tijdens de zwangerschap ontkracht. Dat lagere percentages gevonden werden 
dan in eerder onderzoek werd vermeld, moet geplaatst worden in de context dat 
er vele (nieuwe) therapeutische mogelijkheden voor RA zijn gekomen sinds de 
voorgaande studies. In de PARA-studie was een percentage van 25% van 
vrouwen in remissie (DAS28 <2.6) in het derde trimester van de zwangerschap. 
Dit percentage moet wel gezien worden in het licht dat medicatiegebruik tijdens 
zwangerschap reeds aanzienlijk was gereduceerd vergeleken met het gebruik 
vóór de zwangerschap, omdat het gebruik van de meeste medicatie tijdens de 
zwangerschap en het geven van borstvoeding (lactatie) wordt ontraden. Het 
percentage vrouwen dat verbeterde tijdens de zwangerschap werd berekend 
aan de hand van de vrouwen die in het eerste trimester tenminste matige 
ziekteactiviteit (DAS28 > 3.2) hadden. Alleen op deze vrouwen konden de 
gestandaardiseerde criteria voor verbetering, als gedefinieerd door de 
European League Against Rheumatism (EULAR), toegepast worden. Van deze 
vrouwen verbeterde 50% spontaan en zij werden geclassificeerd als hebbende 
tenminste een matige verbetering tijdens de zwangerschap. Postpartum konden 
alle vrouwen geclassificeerd worden naar de in dit proefschrift nieuw opgestelde 
criteria voor verslechtering (‘reversed’ EULAR criteria voor verbetering). In 
totaal verslechterde ruim één derde van alle vrouwen met RA postpartum, 
geclassificeerd als tenminste een matige verslechtering. Dit aantal zal een 
onderschatting zijn omdat de hoeveelheid medicatie die vrouwen postpartum 
gebruikten, aanzienlijk was toegenomen. In dit hoofdstuk konden geen 
kenmerken gedefinieerd worden die geassocieerd waren met een verbetering 
tijdens de zwangerschap of met een verslechtering postpartum (bijv. aan- of 
afwezigheid van alleen anti-CCP, of alleen RF, of erosies). Tenslotte was het 
opvallend dat vrouwen met een lage ziekteactiviteit vóór de zwangerschap, de 
zwangerschap met relatief gelijkblijvende ziekteactiviteit doorstonden. 
Associatie met autoantistoffen 
In hoofdstuk drie sectie twee werd een eerste poging gedaan om de spontane 
verbetering van RA tijdens de zwangerschap en de verslechtering postpartum 
te associëren met autoantistoffen. Het is bekend dat anti-CCP en RF een 
belangrijke rol spelen in de pathofysiologie van RA. In huidig onderzoek 
veranderden de concentraties autoantistoffen (anti-CCP en subklassen RF 
(IgM-RF, IgG-RF, IgA-RF)) tijdens de zwangerschap statistisch niet significant. 
Er werd zowel tussen de verandering in concentraties van een specifieke 
autoantistof en de spontane verbetering van de RA tijdens zwangerschap, als 
tussen verandering in concentraties en de verslechtering postpartum geen 
associatie gevonden. Postpartum lijkt meest waarschijnlijk dat het starten van 
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medicatie verantwoordelijk is voor de daling van alle concentraties 
autoantistoffen, behalve van IgG-RF. Uiteindelijk is er nog een opvallende 
conclusie uit dit onderzoek te trekken, namelijk dat vrouwen zonder beide 
autoantistoffen (afwezigheid van anti-CCP en RF) significant vaker een 
verbetering van de RA tijdens zwangerschap hadden, dan vrouwen met één of 
beide autoantistoffen in het bloed. Deze bevinding zou de hypothese kunnen 
onderschrijven dat RA een heterogene ziekte is waarbij verschillende 
pathogenetische mechanismen betrokken zijn. 
BEPALEN VAN DE ZWANGERSCHAPSUITKOMST IN PATIËNTEN MET RA 
In hoofdstuk vier worden de resultaten beschreven van het onderzoek naar de 
zwangerschapsuitkomsten van het cohort. Het doel van dit deelonderzoek was 
tweeledig: 
 
I  het bepalen van de invloed van ziekteactiviteit van RA tijdens de 
zwangerschap op de zwangerschapsuitkomst van de vrouwen in de 
PARA-studie (met name geboortegewicht en zwangerschapsduur) 
II het bepalen van de relatie tussen prednisongebruik en 
zwangerschapsuitkomst. 
 
De PARA-studie is ’s werelds grootste cohort van zwangere vrouwen met RA 
dat prospectief gevolgd is. Nooit tevoren kon de relatie tussen ziekteactiviteit en 
zwangerschapsuitkomsten in dit onderzoek gelegd worden. Het gebruik van 
geboortegewichten en geboortegewicht SDS (standaarddeviatie score), waarin 
gecorrigeerd wordt voor zwangerschapsduur en sekse van het kind, leverden 
nieuwe inzichten op. Het gemiddelde geboortegewicht van kinderen van 
vrouwen met RA is vergelijkbaar met de algemene Nederlandse obstetrische 
populatie. Ook het optreden van het aantal zwangerschapscomplicaties in de 
PARA-studie zijn grotendeels vergelijkbaar met die optreden in de Nederlandse 
obstetrische populatie.  
 
Twee opvallende conclusies ten aanzien van ziekteactiviteit en 
zwangerschapsuitkomst zijn:  
 
I vrouwen met hoge ziekteactiviteit in het derde trimester bevielen 
frequenter met een keizersnede 
II zowel de kinderen van vrouwen met hoge ziekteactiviteit als van 
vrouwen met prednisongebruik hadden een lager geboortegewicht 
vergeleken met de kinderen van vrouwen met een lage ziekteactiviteit en 
zonder prednisongebruik.  
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III Met aanvullende analyses is in dit onderzoek aannemelijk gemaakt dat 
hogere ziekteactiviteit een direct negatief effect heeft op het 
geboortegewicht, terwijl prednisongebruik het geboortegewicht verlaagt 
door het verkorten van de zwangerschapsduur. 
OUDERSCHAP POSTPARTUM 
In hoofdstuk vijf worden resultaten getoond van een observationele studie naar 
de functionele moeilijkheden die vrouwen met RA in het ouderschap postpartum 
ervaren. Dit kon in kaart worden gebracht middels het uitdrukken van het 
functioneren met betrekking tot het ouderschap in ‘Parenting Disability Indices’ 
(PDI-scores). Tegelijkertijd werd de functionaliteit ook met standaard HAQ-
scores gemeten en de ziekteactiviteit met DAS28-CRP-3. Op basis van 
veranderingen in PDI-scores tussen twee meetmomenten postpartum werden 
associaties gezocht met (veranderbare) factoren. PDI-scores bleken geschikt 
om de veranderingen met betrekking tot het functioneren in het ouderschap te 
registreren, en de score was sterk gecorreleerd aan de HAQ. 
 
Twee (veranderbare) factoren konden worden aangewezen:  
I erosieve schade 
II hogere ziekteactiviteit 
 
Het ligt in de lijn der verwachting dat met goede gewrichtsbeschermende 
instructies met betrekking tot de zorg voor baby’s aan vrouwen met reeds 
beschadigde gewrichten, als mede met het verlagen van ziekteactiviteit 
postpartum, het functioneren in het ouderschap postpartum verlicht kan worden. 
De drie activiteiten waarmee de meeste problemen werden ervaren zijn: het 
dragen van de baby, de lichamelijke verzorging van de baby en het doen van 
het huishouden. 
TOEKOMSTIG ONDERZOEK 
De studies die in dit proefschrift werden beschreven leverden diverse nieuwe 
inzichten en aanbevelingen op voor toekomstige projecten op het gebied van 
klinisch en laboratoriumonderzoek met gegevens van de PARA-studie. 
(hoofdstuk zes) 
Klinisch onderzoek 
Een eerste voorstel voor toekomstig onderzoek zou kunnen zijn de ontwikkeling 
van kinderen van vrouwen met RA te volgen, met als doel het effect van de 
ziekteactiviteit van de moeder tijdens zwangerschap te relateren aan het bij 
kinderen optreden van risicofactoren voor metabool syndroom (o.a. verhoogde 
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aanleg voor hart- en vaatziekten). Het vinden van een toegenomen frequentie 
van deze risicofactoren onder de kinderen van vrouwen met hoge 
ziekteactiviteit tijdens de zwangerschap, zou een extra argument kunnen 
vormen om ook tijdens de zwangerschap ziekteactiviteit van RA zo optimaal 
mogelijk te controleren. 
 
Een tweede voorstel zou gericht kunnen zijn op de specifieke karakteristieken 
van vrouwen die een niet-vervulde kinderwens hielden tijdens de PARA-studie. 
Associatiestudies naar (veranderbare) ziektekenmerken tussen vrouwen met 
RA die wel en niet zwanger geworden zijn, maar ook tussen ziektekenmerken 
en de tijd tot conceptie in de groep vrouwen die wel zwanger zijn geworden, 
zouden hier een antwoord op kunnen geven. 
 
Een derde voorstel kan zijn het toetsen van de hypothese of het geven van 
gewrichtsbeschermende adviezen tot behoud van het functioneren postpartum 
als ouder, zinvol is bij patiënten met reeds schade aan de gewrichten en of dit 
leidt tot lagere PDI-scores. Wanneer dit inderdaad bijdraagt aan beter 
functioneren als ouder, kan dit aanleiding zijn om gewrichtsbeschermende 
adviezen op te nemen in de standaardzorg voor vrouwen met RA tijdens de 
zwangerschap, ter voorbereiding op de fysieke zorg voor een baby postpartum. 
Laboratorium onderzoek 
Dit proefschrift beschrijft de gevalideerde meetmethoden om ziekteactiviteit en 
het beloop ervan tijdens zwangerschap en postpartum vast te leggen. Hiermee 
kunnen toekomstige vergelijkingen tussen klinische gegevens en laboratorium 
bevindingen eenvoudig worden gemaakt. Niet alleen immunologisch onderzoek 
naar de reden waarom de aanwezigheid van autoantistoffen de kans op een 
spontane verbetering van RA tijdens de zwangerschap vermindert, maar ook 
biochemisch onderzoek naar glycosylering van deze autoantistoffen kan in dit 
verband zinvol zijn. Dit mechanisme kan bijdragen aan een verandering in de 
gevoeligheid van autoantistoffen voor antigenen, en zo het pathogene effect 
van autoantistoffen tijdens de zwangerschap moduleren. Een volgende te 
toetsen hypothese is of de verandering van het immuunsysteem naar een meer 
Th2 gestuurde respons op antigenen tijdens de zwangerschap een belangrijke 
bijdrage aan de spontane verbetering kan leveren. Of deze tijdelijke 
verandering in het functioneren van het immuunsysteem hormonaal, placentair, 
danwel door foetale kenmerken gestuurd is, levert vele mogelijkheden voor 
toekomstig laboratorium onderzoek. 
192
 
 
 
193
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
DANKWOORD 
 
 
 
 
 
194
Dankwoord 
188 
Achter de realisatie van dit proefschrift gaat een groep enthousiaste en 
aimabele personen schuil, aan wie ik zonder meer veel dank verschuldigd ben. 
Iedereen heeft op zijn manier voor mij veel betekend; slechts een aantal van 
hen zal ik hier persoonlijk kunnen bedanken. 
 
Als eerste mijn promotor, mw. Prof. dr. J.M.W. Hazes. Beste Mieke, onze eerste 
ontmoeting, louter toeval, in Philadelphia in 2000 was een bijzondere. Ik ben 
Joan Bathon nog altijd dankbaar dat ze me aan je heeft voorgesteld, hoewel jij 
de kans klein achtte dat ik echt uit Rotterdam kwam. Om voor reumatologie te 
kiezen in een ziekenhuis waar reumatologie in die tijd slechts enkele vierkante 
meters terrein had was een uitdaging, maar de mogelijkheden die het bood 
waren aantrekkelijk. De keus om zwangerschap en RA te onderzoeken was 
snel gemaakt. Het promotiepad was echter bochtig en hobbelig, en we moesten 
af en toe een andere afslag nemen om het doel te bereiken. Ik ben blij dat je me 
al die jaren de kans, steun en het enthousiasme om onderzoek te doen hebt 
gegeven. En dat je me nu opleidt tot reumatoloog. 
 
Dan mijn co-promotor, dr. R.J.E.M. Dolhain. Beste Radboud, je eerste 
promovenda is klaar! Wij ontmoetten elkaar toen je in Leiden zelf nog assistent 
was en mij mocht gaan begeleiden. Ik ben je dankbaar voor je inzet, tijd, 
suggesties voor verbeteringen en het bijsturen van mijn soms al te ambitieuze 
plannen in de afgelopen jaren. Laten we nu feesten en het serieuze verlaten! 
 
De overige commissieleden, als eerste Prof. dr. P.L.C.M. van Riel. Ik vind het 
bijzonder fijn dat u als hoogleraar uit Nijmegen en deskundige op het gebied 
van meten van ziekteactiviteit van reumatoïde artritis wilt plaats nemen in de 
promotiecommissie waarvoor mijn dank. Prof. dr. H. Hooijkaas, u wil ik graag 
bedanken voor het enthousiasme dat u en uw team had om bij te dragen aan 
één van de artikelen in dit proefschrift. Prof. dr. E.A.P. Steegers, u wil ik graag 
bedanken voor de kritische overleggen over hoe met geboortegegevens om te 
gaan. Ik heb het als erg leerzaam ervaren, en dank dat ook u wilt opponeren. 
 
Ms. Prof. dr. P.P. Katz, dear Patti, thank you so much for your enthusiasm in 
research on parenting in women with rheumatoid arthritis. I felt very privileged 
while working with you on the last paper of my thesis. 
 
Prof. dr. J.L.C.M. van Saase, dank dat u mij in de gelegenheid stelde het  
promotietraject tijdens de opleiding tot internist te volbrengen. De competentie 
wetenschap is hiermee voldoende onder de aandacht geweest. Ik vind het fijn 
dat u plaats neemt in de promotiecommissie. 
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Mw. Prof. dr. A.C.S. Hokken-Koelega, graag wil ik u danken dat ook u in de 
commissie heeft plaatsgenomen met uw deskundigheid op het gebied van 
groeicurven van (ongeboren) kinderen. 
 
De deelneemsters aan de PARA-studie en hun partners, dank voor al het 
vertrouwen dat jullie in mij stelden. Vaak was ik één van de eersten in jullie 
omgeving die wist dat er een kinderwens en/of een prille zwangerschap was. 
Velen van jullie heb ik zelf thuis bezocht, hetgeen goed was voor mijn 
topografische kennis van NL, en garant stond voor vele gastvrije ontvangsten 
variërend van koffie, thee, of zelfs een warme maaltijd. Nogmaals dank, dankzij 
jullie bereidheid is er nu voor patiënten met RA met een zwangerschapswens 
meer kennis beschikbaar, dan er tot nu toe was. 
 
De reumatologen in den lande, dank voor uw betrokkenheid om patiënten te 
vragen te participeren in de PARA-studie. Tevens veel dank voor de vaak zeer 
enthousiaste reacties die ik van u mocht ontvangen over de studie(resultaten) 
en voor uw persoonlijke steun. 
 
De verloskundigen van Verloskundige Praktijk Voorburg (VPV) destijds, Katinka 
Huender, Corrie Toet en Karin in ’t Hout, wil ik graag bedanken voor hun inzet 
en bijdrage aan de PARA-studie. Lieve Katinka, ik ben je dankbaar, dat, hoewel 
je nu aan de andere kant van de wereldbol woont met je gezin, we elkaar nog 
altijd tot steun kunnen zijn. 
 
Mw. dr. C.G. de Groot, beste Christianne, graag wil ik je bedanken voor je 
bijdrage bij het opzetten en je begeleiding tijdens de analyses van de 
zwangerschapsuitkomsten van het PARA-cohort. Als geen ander was je altijd 
enthousiast betrokken bij het project, want hoe lang mijn resultaten ook op zich 
lieten wachten, je beantwoordde mijn e-mails altijd binnen 24 uur. 
 
De PARA-studie is in de gelukkige positie geweest dat het van een, logistiek 
gezien, eenmansbedrijfje is uitgegroeid tot een afdelingsbrede studie waarvoor 
ik een ieder die er sinds 2002 tot heden mee bezig is geweest enorm wil 
bedanken. Een bijzondere plek in de rij om te bedanken verdient Fleur van de 
Geijn: ik had me geen betere opvolger als PARA-studie promovenda kunnen 
wensen, dank voor al je inzet al de jaren. Jouw feestje zal snel volgen, ik kijk er 
naar uit! 
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In this PhD thesis, embedded 
in the PARA-study, several 
clinical aspects of the 
spontaneously occurring 
pregnancy-induced 
improvement of rheumatoid 
arthritis (RA) are addressed. 
An overview is given of all 
rheumatic diseases and the 
current knowledge about 
their disease courses and 
treatment options during 
pregnancy and postpartum. 
This thesis focuses fi rstly on 
the description of tools to 
objectively measure the 
disease activity and function-
ality of RA before, during, and 
after pregnancy. Associations 
with the disease course and 
patient’s characteristics are 
subsequently made. 
The infl uence on the 
pregnancy outcome of both 
disease activity and treatment 
of RA with prednisone, are 
assessed regarding pregnancy 
duration and birth weight. 
Postpartum however RA tends 
to fl are again. The problems 
which patients with RA will 
encounter in parental 
function, while nursing their 
babies, are addressed.
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